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ABSTRACT 
Preparations of Echinacea as a dietary supplement are most commonly used to treat 
or lessen the severity of symptoms associated with the common cold or other upper 
respiratory tract infections, although the use Echinacea as a medicinal herb dates back 
hundreds of years when Native American peoples used it to treat various ailments ranging 
from snake bite antidotes to venereal diseases to rheumatism.  With the popularity of this 
botanical growing throughout the United States, and the world, studies have been ongoing to 
understand how Echinacea and its constituents modulate the immune system. 
The purpose of this study was to identify Echinacea species, fractions, and 
constituents responsible for the anti-inflammatory properties associated with Echinacea, as 
well as establish a mechanistic basis for these properties.  The model system chosen to carry 
out these studies was the RAW264.7 mouse macrophage cell line which is a strongly 
established model used to mimic the inflammatory response when induced with 
lipopolysaccharide (LPS).  Inhibition of the production of the pro-inflammatory lipid 
mediator, prostaglandin E2 (PGE2), along with parallel cytotoxicity studies were used to 
identify Echinacea species with the greatest anti-inflammatory potential.  From the screening 
of Soxhlet ethanol root extractions (prepared in Dr. Patricia A. Murphy’s laboratory) from 
six of the nine Echinacea species, it was determined that Echinacea angustifolia, Echinacea 
pallida, Echinacea simulata, and Echinacea sanguinea were the strongest inhibitors of LPS 
induced PGE2 production, showing no cytotoxic effects.  Common alkylamides of Echinacea 
were also chemically synthesized in Dr. George A. Kraus’s laboratory and examined for their 
ability to inhibit PGE2 production, identifying 13 alkylamides capable of significant 
inhibition of the lipid mediator at 50 µM, five alkylamides capable of significant inhibition at 
25 µM, and only one alkylamide, Bauer alkylamide 14, capable of significant inhibition at 10 
µM.  Again, these constituents of Echinacea did not show cytotoxic effects at concentrations 
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at or below 50 µM.  Alkylamides present in the Echinacea species extracts were present at 
concentrations much lower than those screened in the PGE2 assay, implying that although 
alkylamides are anti-inflammatory as synthetic constituents, other constituents present in the 
plant, either previously identified or not, or interactions among these constituents are 
important for the anti-inflammatory properties of Echinacea preparations. 
In order to unravel the complex mixture of Echinacea constituents to identify key 
contributors to the anti-inflammatory activity, bioactivity guided semi-preparative reverse 
phased HPLC was used to fractionate four species of Echinacea in Dr. Patricia A. Murphy’s 
laboratory.  From the fractionation of an Echinacea pallida extract, it was determined that 
Bauer ketones 23 and 24 were important for the identified PGE2 inhibitory capabilities of a 
ketone rich first round fraction, necessitating further study of this group of compounds for 
their anti-inflammatory potential.  Following the inhibition of PGE2 production through three 
rounds of fractionation with an Echinacea angustifolia extract led to the identification of 
Bauer alkylamide 11 and Bauer ketone 23 at concentrations present in their respective third 
round fractions capable of partially explaining the PGE2 inhibition observed prior with their 
corresponding fraction.  Synthetic Bauer alkylamide 11 was also capable of significant 
inhibition of nitric oxide production.  The knowledge that Bauer alkylamide 11 and Bauer 
ketone 23 were key contributors to the anti-inflammatory properties of Echinacea at 
endogenous concentrations led to the hypothesis that through the enrichment of a first round 
alkylamide rich fraction of E. angustifolia with synthetic Bauer alkylamide 11 and Bauer 
ketone 23 an enhanced anti-inflammatory potential could be achievable.  By enriching the 
fraction with synthetic Bauer alkylamide 11 and Bauer ketone 23 to concentrations 
determined to be important from the third round fractions, a greater inhibition of PGE2 
production was identified than that observed with the fraction alone. 
 In order to identify key gene targets for the Echinacea angustifolia fraction, enriched 
fraction, the combination of Bauer alkylamide 11 and Bauer ketone 23, and these 
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constituents individually, microarray and time course qRT-PCR studies were conducted.  
These studies indicated from the microarray study that the selected Echinacea treatments to 
LPS induced RAW264.7 cells did not alter gene expression after eight hours, with only eight 
differentially expressed (DE) genes being identified with false discovery rates (FDR) ranging 
from 50% to 75% in the microarray.  Although, 3,257 DE genes were identified between the 
media + DMSO and the media + DMSO + LPS controls with a FDR of 0.0001%, 
establishing the expected LPS effect.  The qRT-PCR data showed a decrease in TNF-α gene 
expression after treatment with all samples and an increase in iNOS expression after 
treatment with enriched fraction.  Although PGE2 production had been decreased by these 
treatments, COX-2 mRNA levels were not significantly different between treatments 
compared the media + DMSO + LPS at any time point analyzed (0.5 hr, 1 hr, 2hr, 4 hr, 8 hr, 
and 24 hr).  COX-2 protein levels were increased after an 8 hour treatment of E. angustifolia 
fraction 3, and Bauer ketone 23.  Furthermore the activity of COX-2 was inhibited by all 
treatments.  Combined these studies suggest that Echinacea extracts, fractions and certain 
classes of constituents have anti-inflammatory potential through the direct modulation of a 
key enzyme in the eicosanoid pathway and that the noted inhibition of NO production and 
TNF-α gene expression may be due to the effect these treatments have on divergent signal 
transduction pathways.
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CHAPTER 1: GENERAL INTRODUCTION 
Echinacea (purple cone flower) is a member of the Asteraceae family that includes 
other species such as Ambrosia (ragweed), Artemisia (mugwort, sagebrush, and wormwood), 
Parthenium (feverfew), sunflowers, safflower, dahlias, chrysanthemums, marigolds, and 
daisies (1).  It is a perennial flower native to the central United States and commonly found 
as an ornamental flower in gardens of this region, although cultivation of this botanical has 
now spread worldwide (2).  The nine species of Echinacea that have been characterized are 
E. purpurea, E. angustifolia, E. pallida, E. sanguinea, E. simulata, E. tennesseensis, E. 
laevigata, E. atrorubens, and E. paradoxa, with each consisting of its own unique 
phytochemical make-up (3).  The diversity, or in some cases similarity, of the constituents 
present in these Echinacea species not only aid in the identification of each species, but also 
contributes to the diverse bioactivities associated with the botanical Echinacea.  Three 
species, E. purpurea, E. angustifolia, and E. pallida, are commonly classified as the 
medicinal species due to their early use by American Indians hundreds of years prior and 
because of their current presence in commercial preparations worldwide (4, 5).   
Approximately 400 years ago American Indian tribes, such as the Cheyenne, 
Choctaw, Dakota, Delaware, Fox Kiowa, Montana, Omaha Pawnee, Ponca, Sioux, and 
Winnebago, discovered the medicinal properties of the Echinacea plant (5).  Information 
regarding the uses of Echinacea and other botanicals by Native Americans has been made 
available through an Internet database (http://herb.umd.umich.edu/) that has taken years to 
compile (6).  Echinacea roots and aerial parts were used to treat a wide range of ailments, 
such as toothaches, sore throat, pain reliever, headache, antidote for poisons, and to relieve 
swelling, just to name a few (5). 
Today Echinacea preparations are most commonly used for the treatment or 
prevention of common cold symptoms or other respiratory tract infections (3).  Extracts of 
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the whole Echinacea plant, root, and/or aerial parts are available in a variety of different 
forms, including but not limited to pills, tablets, liquids, teas, tinctures, and toothpastes (7).  
Echinacea products are quite popular in the United States with this botanical remaining in the 
top 10 selling herbal dietary supplements (8). 
Echinacea extracts have been studied for several bioactivities and have yielded 
encouraging results as anti-inflammatory, anti-viral, immunomodulatory, and anti-oxidant 
agents (9-12).  Five classes of constituents found in the Echinacea species are presumed to be 
responsible for much of the bioactivity of this botanical, those being, alkylamides, caffeic 
acid derivatives, polysaccharides, glycoproteins, and more recently ketones (9).  Alkylamides 
have been hotly followed due to their reported immunomodulatory and anti-inflammatory 
properties (13) and caffeic acid derivatives are better known for their anti-oxidant capabilities 
(14).  Polysaccharides were shown to have macrophage activating properties (15) and 
glycoproteins have been studied for their immunostimulatory effects, such as the activation 
of the complement system (16).  Finally, ketones have shown promising results as cytotoxic 
agents toward certain tumor cells (17).  The reality is that researchers continue to discover 
diverse bioactivities that are in some way modulated by the constituents present in Echinacea 
products and further research is certainly warranted in order to clearly understand the 
complex mixture of these compounds making up this botanical and how they may act alone 
or synergistically. 
An interesting topic that somewhat plagues researchers studying botanicals such as 
Echinacea is that of synergy and how to uncover the details of which constituents act in 
concert to produce a certain bioactivity (18).  In several studies it has been shown that certain 
constituents are capable of eliciting a desired response, but unfortunately when comparing 
the concentration of the compound with that present in an extract or other natural 
preparation, more often than not the endogenous concentration of that compound is much 
lower than that required for the bioactivity (19).  This adds to the complexity of the studies 
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by leaving open the possibility for synergistic effects between the different constituents, 
whereby perhaps adding together the correct combination of compounds at the concentration 
attainable by the plant in nature, the bioactivity could be explained.  Researchers have been 
using bioactivity guided fractionations to probe this idea of synergy between compounds.  
Part of this dissertation also used the method of bioactivity guided fractionation to delve into 
the complex mixture of constituents that makes up the Echinacea root extracts and will be 
further described in chapter 3.  
Bioavailability has been of major concern in studies on Echinacea as well as other 
botanicals, with the question of “how much of the active compounds actually enter the body 
or cell and are able to elicit their effect?”  Studies performed within the past decade utilizing 
the Caco-2 monolayer model and clinical trials, which will be described in detail in chapter 
2, have started to build convincing evidence that alkylamides and polyacytelenes are 
bioavailable, whereas caffeic acid derivatives are to a lesser extent (19-21). 
Due to the fact that Echinacea species have been identified as immune modulators 
and people are utilizing this herb most prevalently to prevent or treat common cold 
symptoms (22), an appropriate effect to examine would be that of inflammation, which was 
the main focus of this dissertation.  Chapter 2 in this dissertation provides the necessary 
background to understanding the mounting of an inflammatory response, important cell types 
and cytokines involved in the inflammatory response, as well as what inflammatory 
mediators and signaling pathways may be of importance when studying the effects 
Echinacea products have on inflammation. 
The RAW264.7 mouse macrophage cell line is a strongly established cell model for 
the study of inflammatory endpoints and was therefore chosen as a relevant system to explore 
the anti-inflammatory effects of Echinacea preparations (11, 12).  RAW264.7 cells are 
macrophage-like cells that were Abelson murine leukemia virus transformed from BALB/c 
mice.  The macrophage cell was a logical choice for studying the innate immune response 
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and has been proven to induce prostaglandin E2 production via lipopolysaccharide ligand 
binding.   
The studies described in this dissertation were based on the hypothesis that Echinacea 
extracts, fractions, and pure constituents, such as alkylamides and ketones, are capable of 
inhibiting prostaglandin E2 production through the inhibition of the NF-kB signal 
transduction pathway, which therefore inhibits the expression of COX-2 in a RAW264.7 
mouse macrophage model. 
Thesis Organization 
The arrangement of this thesis begins with a general introduction on Echinacea’s 
history and common uses and the general ideas driving the research for this dissertation, 
followed by chapter 2, a literature review that delves into an explanation of the inflammatory 
response and provides a thorough evaluation of the research conducted thus far to understand 
the bioactivities associated with Echinacea extracts, fractions, and constituents.  Chapter 3 
consists of a manuscript published in the Journal of Agricultural and Food Chemistry 
entitled “Echinacea species and alkylamides inhibit prostaglandin E2 production in 
RAW264.7 mouse macrophage cells.” Co-authors on this manuscript include: Kimberly D. 
P. Hammer, determined which solvents were appropriate for the extracts of the Echinacea 
species and aided in conducting PGE2 experiments; Lankun Wu, conducted all HPLC 
experiments to identify constituents; Jaehoon Bae, synthesized all synthetic alkylamides; 
Norma Leyva, provided statistical consultation; Yi Liu and Avery K. S. Solco, prepared the 
extracts of the Echinacea species; George A. Kraus, mentored Jahoon Bae and guided the 
chemical synthesis of the alkylamides; Patricia A. Murphy mentored and consulted Yi Liu 
and Avery K. S. Solco on the extraction process for the Echinacea species extracts; Eve S. 
Wurtele, mentored Lankun Wu on the HPLC analyses; Ok-Kyung Kim, measured 
cytotoxicity on three species extracts; Kwon II Seo, conducted the cytotoxicity studies with 
the NIH/3T3 cells, SW480 cells, and HaCaT cells; Mark P. Widrlechner, provided all 
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Echinacea plant material; and Diane F. Birt, mentored Carlie A. LaLone and provided 
guidance and edits to all research conducted and manuscript drafts.  Chapter 4 contains a 
manuscript published in the Journal of Agricultural and Food Chemistry entitled 
“Endogenous Levels of Echinacea Alkylamides and Ketones are Important Contributors to 
the Inhibition of Prostaglandin E2 and Nitric Oxide Production in Cultured Macrophages.”  
Co-authors on this manuscript included: Ludmila Rizshsky, conducted all GC-MS analyses; 
Kimberly D. P. Hammer, provided guidance on the progress of PGE2 studies; Lankun Wu, 
conducted HPLC analysis on second round E. angustifolia fractions 3D and 3E; Avery K. S. 
Solco, conducted fractionations of E. purpurea, E. angustifolia, and E. pallida; Man-Yu 
Yum, provided statistical consultation; Basil J. Nikolau, provided GC-MS consultation; Eve 
S. Wurtele, mentored Lankun Wu on HPLC studies, Patricia A. Murphy, mentored Avery K. 
S. Solco on fractionation procedures; Meehye Kim, fractionated E. tennesseensis extract; and 
Diane F. Birt, mentored Carlie A. LaLone and provided guidance and edits to all research 
conducted and manuscript drafts.   Chapter 5 is made up of a manuscript, to be submitted to 
the Journal of Agricultural and Food Chemistry entitled “Enrichment of Echinacea 
angustifolia with Bauer alkylamide 11 and Bauer ketone 23 increased anti-inflammatory 
potential through interfering with COX-2 activity.”  Co-authors on this manuscript included: 
Nan Huang, aided in running qRT-PCR experiments; Ludmila Rizshsky, conducted all GC-
MS experiments; Man-Yu Yum, provided statistical consultation, Navarozedeep Singh, ran 
milliplex assay; Cathy Hauck, fractionated E. angustifolia extract; Basil J. Nikolau provided 
GC-MS consultation, Eve S. Wurtele, provided micro-array consultation; Marian L. Kohut, 
mentored Navarozedeep Singh during milliplex assay and provided immunological expertise; 
Patricia A. Murphy, provided fractionation expertise; and Diane F. Birt, mentored Carlie A. 
LaLone and provided guidance and edits to all research conducted and manuscript drafts.  
Finally, chapter 6 contains a general conclusion. 
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CHAPTER 2: LITERATURE REVIEW 
Inflammation and Inflammatory Diseases 
Heat, swelling, redness, pain, and loss of function are known to be the cardinal signs 
of inflammation, as described by the Roman writer Celsus in the first century AD (1), but 
below the surface of these symptoms lies a complex network of inflammatory mediators and 
immunological signaling molecules.  The inflammatory response plays three primary roles in 
the body to defend it from foreign antigens.  Inflammation allows for the maturation of 
monocytes circulating in the blood stream into effector macrophage cells that enter the site of 
inflammation providing a first defense against invading organisms (2).  Secondly, the 
inflammatory response inhibits the spread of the foreign antigen by causing microvascular 
coagulation (2).  The third major role of inflammation is to promote the healing of damaged 
tissue (2).  Key inflammatory mediators, such as lipid derivatives, oxygen and nitrogen 
radicals, and chemokines and cytokines are present at each step to guide the inflammatory 
process through its various stages and this will be the primary focus of the literature reviewed 
dealing with inflammation. 
Role of Macrophage in Inflammation 
The macrophage cell plays a dual role in the immune system acting in both innate and 
adaptive immune responses, as a phagocytic cell and antigen-presenting cell, respectively.  
This cell type has an important role in the inflammatory response leading the way to the 
cardinal symptoms of inflammation described previously, as well as to the resolution of the 
inflammatory response.  The macrophage is instrumental in the development of each of these 
processes.   
Macrophage cells are found in several locations throughout the body that act as 
barriers to the outside environment.  They can be found in epidermal tissues, in the lungs, in 
connective tissue, and in liver tissue (kupffer cells) (2).  The macrophages are in these 
 10
strategic locations so that they can act as “watchdogs” guarding the body from any foreign 
invaders.  When an antigen enters the body, perhaps through a wound in the skin, 
macrophage cells are present to engulf the antigen (phagocytosis) and release pro-
inflammatory cytokines (Interleukin-1, Interleukin-6, Tumor Necrosis Factor-α, and 
Interleukin-12) and chemokines (Monocyte Chemoattractant Protein, Interleukin-8) that 
signal other innate immune cells to aid in the body’s defense at the site of antigen infiltration 
and therefore inflammation (3).  Different cell surface molecules such as selectins (E and D) 
and intracellular adhesion molecules (ICAM 1 and 2) are then expressed on the surface of 
epithelial cells located in the veins (4).  Neutrophils, as well as monocytes have cell surface 
molecules, like leukocyte functional antigen-1 (LFA-1), that cause them to start rolling along 
the blood vessel and eventually extravasate out of the blood vessels following a chemokine 
gradient (IL-8), homing to the site of inflammation (5).  Receptors play a key role in leading 
the various immune cells to key locations to set up a controlled inflammatory response.   
Monocytes, which are immature macrophages that arise through the differentiation of 
progenitor cells in the bone marrow prior to their release into the blood stream, circulate in 
the blood until they are signaled into tissue to aid in innate immunity (6).  This infiltration of 
cells causes the redness, swelling, heat, and pain associated with inflammation.  In addition, 
the cytokines released from the macrophages cause vasodilation making the entrance of the 
other phagocytic cells more rapid, setting up an army of cells capable of destroying the 
invading antigen.  Inflammation also causes clotting in the microvessels around the site of 
inflammation to contain the pathogen (2).  Macrophages have receptors, such as mannose 
binding receptors, toll like receptors, and scavenger receptors that are capable of recognizing 
pathogen associated membrane patterns (6).  These receptors allow macrophages to identify 
invading bodies and phagocytose them as well as initiate inflammatory pathways such as 
nuclear factor κappa B (NF-κB) and mitogen activated protein kinase (MAPK) that lead to 
the expression of pro-inflammatory genes and genes involved in adaptive immunity.  
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Macrophages are able to release reactive oxygen species, such as nitric oxide within their 
phagocytic vesicles, which act to destroy the contents.  Nitric oxide has been shown to be 
responsible for the activation of macrophage apoptosis, macrophage cytoplasmic motility, 
neutrophil adhesion, and regulation of cytokine synthesis (7).  Macrophages also recognize 
antigen coated with complement and are able to take up and destroy these particles.  What 
has been described thus far occurs locally at the site of inflammation, but the macrophage is 
also activating adaptive immune responses outside of the area of local inflammation. 
Macrophage cells are one of the three main cells capable of presenting antigen, 
meaning that they are able to process foreign peptides that are engulfed through the process 
of phagocytosis and present those peptides on major histocompatability complexes (MHC) to 
T cells.  The interaction between T cell receptors, MHC antigen, and B7 co-stimulatory 
molecules on macrophage cells (CD80 and CD86) allow for the activation of T cells, forming 
either CD4 or CD8 T cells (2).  Macrophages play a role in the activation of more cells that 
will eventually aid in the site of inflammation, clearing up any foreign particles that could not 
be eliminated by innate immunity.  The CD4 cells come in two varieties, TH1 cells that 
activate lysosomes within macrophages to kill intracellular organisms have been 
phagocytosed and TH2 cells that activate B cells to produce antigen that can bind to foreign 
molecules either neutralizing, preparing for opsonizing, or activating complement.  These 
cells then hone to the site of inflammation and aid in clearing the foreign invader and 
therefore resolving the inflammatory response.  Two separate studies have shown that 
depletion of macrophages, either using antimacrophage serum and hydrocortizone in a 
guinea-pig model or in the PU.1-null mouse model (PU.1 is a transcription factor that plays a 
key role in the development of myeloid lineages and therefore prevents macrophage 
development) led to the failure to clear dead and damaged cells and other debris at the 
wounded site, providing convincing evidence of the important role the macrophage cell plays 
in resolution of the inflammatory response (8). 
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Eicosanoids Role in Inflammation 
The eicosanoid cascade can be activated during an inflammatory response releasing 
arachidonic acid (AA), which is a dietary derived polyunsaturated C20 fatty acid (metabolized 
from linoleic acid and α-linolenic acid) that is normally stored in the cell phospholipid 
membrane (9).  Arachidonic acid is liberated from the lipid membrane by phospholipase A2 
enzymes, of which there are 3 main classes:  secreted (sPLA2), intracellular (iPLA2), or 
cytosolic (cPLA2), to assume three possible fates, either reincorporation into phospholipid, 
diffusion out of the cell, or metabolism (10).  Experimental evidence has highlighted cPLA2 
as an integral component in the production of prostaglandins, known mediators of 
inflammation.  cPLA2 knockout mice show a decreased occurrence and less intense collagen-
induced arthritis (11) and cPLA2-deficient mice were shown to have decreased eicosanoid 
production (12).  Due to the crucial role of phospholipase A2 enzymes in the production of 
prostaglandins, it has been a target for inhibition of these inflammatory mediators. 
The metabolism of AA can be carried out by two distinct enzymatic pathways leading 
to the production of certain lipid mediators such as, prostanoids via cyclooxygenase or 
leukotrienes via lipoxygenase.  Cyclooxygenases (also known as prostaglandin H synthase or 
COX) act on arachidonic acid by adding a 15-hydroperoxy group therefore forming PGG2 
and then reducing the hydroperoxy group to the hydroxylated PGH2 (9).  There are two 
cyclooxygenase enzymes involved in the conversion of AA to PGH2, COX-1 and COX-2.  
Due to the fact that the 5’-flanking region of the COX-1 gene has few cis-acting response 
elements and no TATA box, the COX-1 gene has been considered a house keeping gene, 
although it is not expressed in all tissues or cells (13).  The COX-2 gene, on the other hand, 
has several regulatory elements in its 5’-flanking region, including two NF-κB, one Sp1, one 
NF-IL-6, and one CRE binding site, and is therefore an inducible gene (13).  COX-2 is also 
known to be constitutively expressed in the kidney, brain, female reproductive system, and 
bones, and is important in the normal functioning of these organs (14).  During an 
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inflammatory response IL-1α, IL-1β, TNF-α, interferon-γ (IFN-γ), 12-O-
tetradecanoylphorbol-13-acetate (TPA), and lipopolysaccharide (LPS) are inflammatory 
mediators that induce COX-2 gene expression and subsequent prostaglandin production (15).   
COX-1 and COX-2 isoenzymes are similar both structurally and mechanistically, 
both catalyzing a peroxidase and a cyclooxygenase reaction to form PGH2 (Figure 1).  These 
enzymes are present in the luminal surfaces of the endoplasmic reticulum and on both the 
inner and outer membranes of the nuclear envelope (13). When the mature enzymes of COX-
1 and COX-2 are produced they contain 576 amino acids and 587 amino acids, respectively 
(16).  The differences between amino acid sequences of the two proteins are minor in that a 
proline residue has been identified in COX-2 after Threonine106 and it contains an eighteen 
amino acid insertion at its C-terminus, neither of which are present in the COX-1 protein 
sequence (16).  At this time the function of these insertions in COX-2 protein are not known, 
but it is hypothesized that perhaps they may be present to signal subcellular trafficking or 
protein turnover (16).  Three structural domains make up the COX enzyme monomer, those 
being a N-terminal epidermal growth factor like domain (EGF), a membrane binding domain 
(MBD), and a C-terminal globular catalytic domain that includes a heme binding site that 
faces the solvent (17).  It has been suggested that EGF domains act to incorporate the enzyme 
into the lipid bilayer along with the MBD (18).   
For both COX-1 and COX-2 enzymes, fatty acid substrates or competing substrates 
must enter the narrow cyclooxygenase (COX) active site through the MBD directly from the 
lipid bilayer, suggesting that a conformation change may be necessary to allow for the entry 
and exit of the substrates (19).  The active site of COX extends from Arginine120 to 
Tyrosine385 (16).  Here, is where the addition of two O2 molecules to arachidonic acid takes 
place in the conversion to PGG2.  Arachidonic acid must bind the COX active site in an 
extended L-shaped conformation, interacting with Arginine120, the known substrate binding 
site (20). This substrate makes 48 van der Waals contacts and two hydrophilic contacts with 
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19 residues in the COX active site (20).  The amino acids deemed important for substrate 
binding have been identified through site directed mutagenesis.  It is known that arachidonic 
acid may adopt four conformations to bind the COX active site (21).  The COX active site for 
COX-2 enzyme has been shown to be larger than that of COX-1 allowing it to accommodate 
larger substrates without inactivation (16).   
Opposite the MBD lies the large groove of the peroxidase (POX) active site, which is 
a long hydrophobic channel with numerous side pockets and a branched water pocket (16).  
The POX active site is relatively open to the solvents, with Histidine207 thought to be 
important for the deprotonation and subsequent reprotonation that occurs to convert PGG2 to 
the alcohol PGH2 (22).  Glutamine203 has also been shown to be important during POX 
catalysis through site directed mutagenesis studies (22).   After the COX catalytic site has 
been activated its actions can function independently from the POX cycle, therefore the COX 
and POX reactions are not tightly coupled (23).  After the formation of PGH2 selective 
synthases act to produce the eicosanoids, such as the prostaglandins. 
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Prostaglandins (PG) are oxygenated C20 fatty acids, which have been shown to be 
produced in nearly every cell in the body, with PGE2 being the most abundant prostanoid.  
Prostaglandins are known to act in an autocrine or paracrine manner to signal changes in the 
immediate environment (24, 25).  Prostanoids formed by the metabolism of AA produce 3 
classes of lipid mediators that are involved in a host of different functions (Figure 2); 
including blood clotting, ovulation, initiation of labor, bone metabolism, nerve growth and 
development, wound healing, kidney function, blood vessel tone, and immune responses.  
The stable class of prostaglandins is made up of PGE2, PGF2α, PGD2, and PGJ2, the labile 
prostanoids are made up of PG endoperoxides, like PGG2 and PGH2, and thromboxane A2 
(TXA2), and finally the prostacyclin PGI2 (26).  The interplay between these lipid 
metabolites is thought to play a central role in normal human physiology by working to 
establish homeostasis.   
As explained earlier the PG endoperoxides, PGG2 and PGH2, are the intermediates 
that lead to the synthesis of the other eicosanoids, whereas TXA2 is a highly unstable 
metabolite that is involved with physiological actions such as platelet aggregation, smooth 
muscle contraction, and vasoconstriction (26, 27). TXA2 is prominently produced by platelets 
in response to various stimuli via the actions of COX followed by thromboxane synthase 
(TXS) (28).  Thromboxane A2 has been implicated in conditions such as asthma, modulation 
of acquired immunity, atherogenesis, neovascularization, and metastasis of cancer cells 
through binding to TXA2 receptor (TP), which is distributed in several areas throughout the 
body and highly expressed in the thymus and spleen (27).  Prostacyclin, PGI2, is formed from 
the actions of the COX enzymes with further manipulation of PGH2 by prostacyclin synthase 
(26).  Prostacyclin is produced primarily by the endothelium and is able to operate as an 
antagonist of TXA2, by preventing platelet formation and clumping involved in blood 
clotting and acting as a vasodilator (26).  Together TXA2 and PGI2 are considered 
“specialized” prostaglandins due to their abundance in specific tissues (14). 
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be the most stable prostaglandin playing a key role in ovarian function, endometrial cyclic 
changes, embryo development, tubal function, luteal maintenance of pregnancy, induction of 
labor, childbirth, and more recently has been implicated in inflammation, cardiovascular, and 
rheumatic diseases (29).  Another major cyclooxygenase product found in numerous tissues 
and cell types is PGD2, which is involved in platelet aggregation, relaxation of vascular and 
nonvascular smooth muscle, and nerve cell function (30).   Prostaglandin D2 undergoes 
dehydration to produce prostaglandins of the J variety like PGJ2, which has been shown to be 
actively transported to the cell nuclei.   In the nuclei, PGJ2 acts as a potent inducer of cell 
growth, inhibition and cell differentiation through inhibition of cell cycle progression, 
suppression of viral replication, induction of heat shock protein expression, and stimulation 
of osteogenesis (30).  It has been hypothesized that PGJ2 is capable of anti-inflammatory 
activity mediated through peroxisome proliferator-activated receptor-γ, which is a 
transcription factor present in adipose tissue (playing a central role in adipogenesis), and 
macrophages (involved in the inhibition of the inflammatory response by inducing apoptosis 
of activated macrophages) (31).  Another possible mechanism of the anti-inflammatory 
effects of PGJ2 may be through the inhibition of NF-κB activation.  Previous reports have 
indicated that 15d-PGJ2 inhibits NF-κB activity by binding to the IκB kinase (IKK) or the 
p65 or p50 transcriptional subunits of NF-κB (32).    
One of the most intensely studied prostaglandins is prostaglandin E2 (PGE2), which is 
a key lipid mediator of inflammation produced by a variety of cells in the body, including 
fibroblasts, macrophages, and some malignant cell types (33).  Though PGE2 is well known 
for its role in the inflammatory response it also plays an important part in neuronal functions, 
female reproduction, vascular hypertension, tumorigenesis, fever, gastric mucosal protection, 
pain hypersensitivity, kidney function, and anti-allergic responses (10).  Over production of 
PGE2 has been associated with various diseases, such as rheumatoid arthritis and even colon 
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cancer (1, 34).  For over 100 years the inhibition of PGE2 synthesis has been a crucial anti-
inflammatory strategy (35).   
The biological actions of PGE2 depend upon four types of PGE receptors, EP1, EP2, 
EP3, and EP4, which are found in various tissues throughout the body and lead to the 
regulation of intracellular signal transduction pathways (1).  EP1 receptor is known to 
stimulate intracellular calcium release, were as both EP2 and EP4 receptors activate 
adenylate cyclase and induce intracellular cAMP (36).  The genetic disruption of EP2 in 
adenomatous polyposis coli (Delta 716) knockout mice, has been linked to a significant 
reduction in the number of aberrant crypt foci, a precancerous colon cancer lesion, indicating 
an important role for prostaglandin E2 in oncogenesis (37).  Also, in female EP2 knockout 
mice ovulation was shown to be impaired (38).  Prostaglandin E2 plays many important roles 
maintaining homeostasis within various parts of the body.   For instance, a study examining 
the role of PGE2 and eicosanoid receptors in dextran sodium sulfate-induced colitis in mice 
provided evidence that PGE2-EP4 signaling was critical in the maintenance of the mucosal 
barrier and epithelial cell regeneration (39).  It was demonstrated that disruption of the EP4 
gene alone with administration of 3% DSS caused severe colitis and also the addition of 
PGE2 to wild type mice with DSS induced colitis completely obliterated symptoms of the 
disease (39).    Therefore it is also important to point out that in some instances, with site and 
receptor specificity, PGE2 is not always associated with a negative effect.   
PGE2 plays many roles in the body as a potent vasodilator affecting small vessels in 
the arterioles and is therefore important for the regulation of cardiovascular function (14).  In 
the renal system PGE2 is synthesized in the medulla and is vital for the regulation of salt and 
water excretion and in the gastrointestinal tract PGE2 contracts longitudinal muscle and 
relaxes circular muscle, as well as inhibits gastric secretion (14).  Prostaglandin E2 has been 
shown to be a bronchodilator in the respiratory system, balancing the bronchoconstrictor 
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functions of PGF2 (14).  During bone metabolism PGE2, produced in the bone has been 
identified as an important factor stimulating both bone formation and resorption (14).   
As mentioned earlier, the role PGE2 plays in immune modulation and therefore 
inflammation is substantial.  It is well known that PGE2 inhibits T-cell proliferation and has a 
profound effect on cytokines secreted by T-cells via the induction of T helper 2 (Th2)-type 
responses (2).  Prostaglandin E2 has the opposing effect on T helper 1 (Th1)-type cells, and 
inhibits the production of Th1 cytokines such as interferon γ and IL-2.  Other evidence 
pointing toward the importance of PGE2 in inflammation has been provided by studies 
showing that PGE synthase expression is induced by proinflammatory stimuli and during 
mucosal inflammation T cells are shown to up-regulate the expression of EP receptors (39).  
B cells are also affected by the actions of PGE2, with PGE2 suppressing the proliferation of 
immature B cells or otherwise inducing apoptosis of immature B-cells, without affecting 
mature B cells.  The modulatory affect of PGE2 can even be seen with “professional” antigen 
presenting cells, such as dendritic and macrophage cells, where this lipid mediator is partially 
responsible for the maturation of dendritic cells and the priming of T cells within the 
lymphoid organs and regulation of cytokine production by activated macrophages.  During 
an inflammatory response, PGE2 is produced in vast quantities by macrophages in retort to 
IL-1 and lipopolysaccharide (LPS).  Due to the fact that PGE2 is able to positively regulate 
its own expression through the up-regulation of COX-2 expression, it is hypothesized that 
PGE2 may be an autocrine feedback regulator. 
PGE2 can play a dual role with both inflammatory and anti-inflammatory effects.  In 
activated macrophage cells PGE2 is able to inhibit TNF-α, IL-6, IL-8, and IL-12 production 
and up-regulate IL-10 through the EP2 and EP4 receptors, shifting to an anti-inflammatory 
response (1). Eicosanoids derived from AA, such as PGE2, leukotriene B4, thromboxane A2, 
and 12-hydroxyeicosatetraenoic acid have been identified as present in various cancers, 
playing key roles in carcinogenesis via modulation of cell cycle responses (40).  Not only 
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does PGE2 have a profound effect in the inflammatory response but it has been shown to 
promote tumor cell survival, via inhibition of apoptosis and stimulation of cell proliferation, 
and was found at greater concentrations in cancer cells than in normal cells (41). 
There is tight regulation controlling the inflammatory response utilizing both 
mediators that initiate, sustain, and inhibit inflammation (42).  When one of these mediators 
loses control chronic inflammation can result.  Chronic inflammation has been linked to a 
variety of severe diseases, such as rheumatoid arthritis, inflammatory bowel disease, 
atherosclerosis, and various cancers (34, 43-45). The impacts of these diseases are 
astronomical.  For instance, 80% of patients with rheumatoid arthritis are disabled after 20 
years, with a life expectancy reduced by 3 to 18 years, not to mention the medical expense of 
such a disease is reported to average $5,919 per case per year in the United States (43).  In 
2005 it was reported that in the United States, approximately one-third of the adult 
population suffers from arthritis or chronic joint symptoms, that is nearly 70 million people 
(46).  Incidence of inflammatory bowel disease has increased dramatically from 1998 to 
2004, with a national estimate for total inpatient charges for Crohn’s disease and ulcerative 
colitis increasing from $762 million to $1,330 million and $592 million to $945 million, 
respectively (47).   
The battle against inflammatory diseases with symptoms such as pain and 
inflammation has been fought by two major classes of pharmaceuticals, those being non-
steroidal anti-inflammatory drugs (NSAIDS) or cyclooxygenase-2 specific inhibitors (COX-2 
inhibitors).  Back in 1893, the German chemist Felix Hoffman produced a molecule with 
analgesic activity called acetylsalicylic acid or aspirin, giving rise to a new class of drugs 
called NSAIDs (25).  In 2002, over 41 million prescriptions were filled in the United States 
for COX-2 inhibitors and the total prescription costs of NSAIDS were estimated at $6.5 
billion in 2003 (48).  Synthetic NSAIDs were designed to inhibit the activity of both 
cyclooxygenase isoforms, COX-1 and COX-2, in order to decrease the formation of 
 21
prostaglandins, which are responsible for inflammation, swelling, pain, and fever (49).  
These drugs also showed promise for cancer prevention, because they were shown to reduce 
the risk of certain cancers.  Over time it became clear that long term NSAID use caused 
gastrointestinal (GI) and renal toxicity, leading to peptic ulcer formation and increase of ulcer 
hemorrhage (50, 51).  There have been well designed studies matching NSAID users against 
controls showing NSAIDs to increase serious GI events by 1.5 to 7.2 fold (52, 53).   
Although it is now considered a naïve notion, it was once believed that COX-1 was 
the housekeeping enzyme responsible for maintenance of intestinal mucosal integrity and 
producer of basal levels of prostaglandins, which protected the gastric mucosa and it was 
therefore the inhibition of this isoform that was responsible for the notorious side effects 
observed in those who used NSAIDs (49).  It was hypothesized that in order to get rid of the 
severe GI side effects only one of the cyclooxygenase isoforms, COX-2, should be targeted 
for inhibition, as it was thought to be the more inducible enzyme after exposure to mitogens 
or inflammatory stimuli.  Selective COX-2 inhibitors were developed in the 1990s, originally 
for arthritis symptoms, but were later used in clinical trials for the treatment of colorectal 
cancers (46).   
Celecoxib was the first selective COX-2 inhibitor to be introduced into the 
pharmaceutical market in December of 1999, other synthetic inhibitors followed by the 
names of Rofecoxib (Vioxx), Valdecoxib, and Lumiracoxib (46).  The Vioxx Gastrointestinal 
Outcomes Research (VIGOR) study demonstrated a reduced incidence of GI lesions after 
long-term use of rofecoxib, compared to a popular NSAID called naproxen (54). In 
September of 2004, Merck and Co withdrew Vioxx from the market, due to data from the 
VIGOR study and another internal study providing evidence that the drug increased risk of 
heart related problems (46, 54). Although COX-2 is indeed inducible, it is also constitutively 
expressed in the glomeruli of the kidney and the cortex of the brain and the inhibition of this 
enzyme could help explain the reports of heart attack and stroke that are associated with long 
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term COX-2 inhibitor use (46).  It has been hypothesized that perhaps COX-2 is important in 
protecting cardiomyocytes from oxidative injury or that COX-2 dependent PGI2 production 
interacts with inducible nitric oxide synthase to increase the heart’s tolerance to future 
ischemic insults but further studies are required to pinpoint the mechanisms leading to these 
events (49).  Until researchers are able to develop or identify a natural or synthetic 
pharmaceutical capable of providing the benefit of relief from inflammatory disease, without 
the risk of GI or cardiac problems, patients must weigh the risk versus the benefit of taking 
such drugs and consume accordingly.  
Signal Transduction Pathways Important for Inflammation 
Nuclear factor-κB (NF-κB) is a transcription factor involved in the transcription of 
proinflammatory and antiapoptotic genes, including COX-2 and iNOS (55).  It is known that 
NF-κB is a key player in the progression of cancer, rheumatoid arthritis, inflammatory bowel 
disease, and asthma (56).  When the classical (canonical) NF-κB pathway is not stimulated, 
the pathway is inhibited by the association of inhibitor of NF-κB (IκB) with the Rel dimers 
that make up the NF-κB transcription factor.  IκB does not allow the Rel dimers to 
translocate into the nucleus and activate transcription of target genes (57).  The NF-κB 
canonical pathway can be stimulated by inflammatory cytokines (including TNF-α, LPS, 
growth factors, stress inducers, chemotherapeutic agents, etc.). Upon stimulation of the NF-
κB pathway, the high molecular weight inhibitor of NF-κB kinase (IKK), made up of three 
subunits IKKα, IKKβ, and IKKγ, is activated leading to the phosphorylation of four serine 
residues on the two subunits of the inhibitor of NF-κB kinase (IkB).  These phosphorylations 
lead to the ubiquitination and degradation of IκB by 26S proteosome (57).  The uninhibited 
NF-κB Rel subunits are then able to translocate into the nucleus of a cell and carry out 
transcription of target genes.   
An alternative or non-canonical pathway of NF-κB has been shown to occur in B 
cells, which appears to be responsible for the development, survival, and attenuation of 
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apoptosis of B cells (58).  This alternative pathway can be stimulated by lymphotoxin (LT) β 
receptor, B cell activating factor (BAFF) receptor, or CD40, as opposed to the TNF-α 
receptor known to activate the classical pathway (58).  During activation of the alternative 
NF-κB pathway processing of precursor protein p100 to p52 occurs, through the stimulation 
of NF-κB binding kinase (NIK) and IKKα resulting in the phosphorylation of p100.  The 
phosphorylated precursor protein, p100, then undergoes controlled proteolysis by the 
proteasome producing the mature protein, p52, which is then able to form dimers with RelB 
and activate transcription of target genes necessary for secondary lymphoid organogenesis, 
mature B cell function, and adaptive immunity (58). 
An important facet to the activation of the NF-κB response relies heavily on which 
dimers bind and act on the NF-κB consensus sequence.  There are five members of the NF-
κB transcription factor family that were discovered in the 1980s, p105 (constitutively 
processed to p50), p100 (processed to p52), p65 (also known as RelA), RelB, and c-Rel, each 
subunit having different functional domains (59).  All five members contain a Rel-homology 
domain (RHD) allowing them to bind to DNA, but only p65, RelB, and c-Rel contain 
transactivation domains (TADs) which sets the stage for which combinations of transcription 
factors are activating or repressive (60).  For example, one of the most common heterodimers 
of NF-κB consists of p50 and p65, which is able to activate transcription because TAD is 
present in p65, whereas a homodimer of p50 would be repressive because no TAD exists.  
Genetic knockouts have provided extensive information on the importance of each 
transcription factor on health and inflammation.  Mice with genetic deficiencies in genes that 
encode p50, p52, c-Rel, and Rel B have abnormal responses from immune cells dealing with 
B and T cell proliferation, antigen presentation, isotype switching, and cytokine production, 
although these mice appear healthy and develop normally (60).  It has also been 
demonstrated that knockouts for p65, IKKβ, and IKKγ die in late embryonic development or 
at the time of birth due to TNF-α regulated hepatocyte apoptosis (61).  Similar knockouts of 
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IKK subunits have been studied for their role in inflammatory diseases resulting in chronic 
inflammation in intestinal epithelial cells, showing a massive influx of macrophage cells 
expressing TNF-α (62).  This state was normalized by crossing the IKK knockouts with TNF 
receptor knockout mice, indicating a fragile equilibrium between the inflammatory response 
and apoptosis (60). 
Mitogen-activated protein (MAP) kinases are important serine/threonine kinases that 
play a major role in genetic signaling pathways crucial for the control of embryogenesis, cell 
differentiation, cell proliferation, and apoptosis (63).  There exists four known subgroups 
within the MAP kinase family, Extracellular signal-regulated kinases (ERK), c-jun N-
terminal or stress activated protein kinases (JNK/SAPK), ERK5/bigMAP kinase1 (BMK1), 
and p38 protein kinases.  p38 MAPK is the primary kinase from this family that is involved 
in inflammation, consisting of four homologs, p38α and β, which are isoforms of each other 
that are ubiquitously expressed, and p38δ and γ, which are differentially expressed.  The gene 
expression of p38δ has been observed in the lung, kidney, testis, pancreas, and small 
intestine, whereas p38γ expression is predominantly located in skeletal muscle (64).  Several 
extracellular stimuli are known to activate the p38 MAP kinase pathway, including microbial 
products, such as lipopolysaccharide (LPS), and a number of cytokines such as IL-1α, IL-2, 
IL-7, IL-17, IL-18, TGF-β, and TNF-α.  After the activation of this signaling cascade p38 
MAPK is known to up-regulate the expression of many genes involved in the inflammatory 
response, like TNF-α, IL-1β, IL-6, IL-8, COX-2, collagenase-1, -3. 
Echinacea 
The genus Echinacea (Purple Cone Flower) is a perennial flower native to the central 
United States.  Its name comes from the Greek word echinos, which means sea urchin or 
hedgehog, referring to the spiked floral receptacle (65).  There are nine species of Echinacea: 
E. purpurea, E. angustifolia, E. pallida, E. tennesseensis, E. sanguinea, E. simulata, E. 
laevigata, E. atrorubens, and E. paradoxa, each with moderate to extensive variations in 
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their phytochemical profile (66).  Echinacea has been used medicinally for several hundred 
years, dating back to Native American peoples use of this herb for various ailments, 
including pain relief for coughs and sore throats, fevers, smallpox, mumps, measles, 
rheumatism, arthritis, and antidotes for poisons and other venoms (67).  Echinacea 
angustifolia was the most popular species used by the Native Americans, though records 
show that they also used E. purpurea, and E. pallida (67).   The first published account of the 
medicinal use of E. purpurea was in 1762, in the 2nd edition of Gronovius’ Flora Virginicus, 
where Laurens Theodoor Gronovius reported its beneficial use for saddle sores on horses 
(65).  Echinacea has a long history of its use medicinally and yet still warrants further study 
and understanding of its potential therapeutic uses.   
Currently Echinacea is most commonly used to treat the common cold and other 
upper respiratory tract infections (URTI).  Formulations of this botanical supplement can be 
found in the form of salves, tinctures, capsules, teas, injections, etc. (68).   In the United 
States annual sales of Echinacea products have been estimated to range from more than $200 
million to more than $300 million (69).  With such large scale purchase and therefore use of 
this botanical supplement there are still questions of its efficacy in modulating the immune 
system and its mechanisms of action, as well as what constituents are important for various 
bioactivities.  Clinical trials investigating the usefulness of Echinacea in treating colds and 
URTIs have provided inconsistent results and will be the topic of further review in following 
sections.  A possible reason for the lack of congruity with Echinacea studies may be due to 
the preparations used in the studies.  The quality of plant material and commercial products 
available to consumers has been examined both in the United States and abroad.  In an 
analysis of 59 commercial products available in the United States and labeled as Echinacea, 
it was discovered that 10% had no detectable Echinacea content, 48% were inconsistent with 
their label when identifying the species present, and of 21 standardized preparations, 57% did 
not meet the standards declared on their labels (70).   
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Major Bioactive Constituents Identified in Echinacea Species  
The five major classes of compounds that are thought to be responsible for the 
bioactive properties identified in Echinacea extracts are alkylamides, caffeic acid derivatives, 
polyacetylenes (generically known as ketones), polysaccharides, and glycoproteins (65).   
Each species of Echinacea contains different, yet in some cases overlapping, chemical 
profiles that allow for their identification.  Structures of common alkylamides, ketones, and 
caffeic acid derivatives identified as present in the Echinacea species are drawn in Figure 3, 
along with the proper nomenclature for these constituents. 
Echinacea Alkylamides 
Twenty-five alkylamides, also known as alkamides, have been identified in 
Echinacea roots and aerial parts (65), and of these, fourteen have been found in the roots of 
E. angustifolia and eleven have been found in the roots and aerial portion of E. purpurea (71)  
The two major alkylamides found in E. angustifolia and E. purpurea, are dodeca-
2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (Bauer alkylamides 8 and 9) and are known 
to occur as a mixture (72).  Total alkylamide concentrations have been reported to range from 
0.004% to 0.039% dry weight (65).  When chewing on Echinacea roots or seeds a tongue 
tingling or numbing sensation is experienced due to the alkylamide constituents (65).  It has 
been hypothesized that alkylamides are beneficial to the Echinacea plant by acting as 
insecticides.  Clifford et al. conducted a mosquitocidal assay showing that the mixture of 
dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (Bauer alkylamides 8/9) caused 
87.5% mortality of mosquito larvae within 15 minutes at a concentration of 405 µM (73).  
Other research conducted on alkylamides isolated from arabidopsis indicates a possible role 
for this constituent in promoting plant growth and root development (74).  With many 
hypotheses circulating on how alkylamides may be critical to the Echinacea plant, others are 
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interested in alkylamides found in Echinacea due to their immune modulating capabilities in 
human, animal, and cell culture studies, as well as studies that are providing evidence that 
these constituents are bioavailable (75, 76). 
The inhibition of COX-2 has been of great interest to those studying inflammation 
and several studies set out to show that alkylamides from Echinacea have such inhibitory 
capabilities.  Early studies published in 1994 examined eight alkylamides isolated from an n-
hexane extract of E. angustifolia for their ability to reduce production of prostaglandin E2 
and 5-hydroxyeicosatetraenoic acid as a measure of cyclooxygenase and 5-lipoxygenase 
activities, respectively.  The E. angustifolia extract was shown to inhibit both activities at 
concentrations of 50 µg/ml for cyclooxygenase and 11.5 µg/ml for lipoxygenase, with an 
inhibition of 62.4% and 81.8%, respectively (77).  When the alkylamides were screened it 
was shown that a 1:1 mixture of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides 
(Bauer alkylamides 8/9) inhibited both cyclooxygenase by 54.7% at a concentration of 50 
µM and 5-lipoxygenase by 62.2% at a concentration of 50 µM (78).  In another study 
focusing on cyclooxygenase activity, alkylamides isolated from the roots of E. purpurea, 
undeca-2Z,4E-dien-8,10-diynoic acid isobutylamide (Bauer alkylamide 2), undeca-2E,4Z-
dien-8,10-diynoic acid 2-methylbutylamide (Bauer alkylamide 4), and dodeca-2E,4Z-dien-
8,10-diynoic acid 2-methylbutylamide (Bauer alkylamide 7) were shown to inhibit COX-1 
activity in an in vitro model from microsomal preparations of ram seminal vesicles, with 
inhibitions of 60%, 55%, and 48%, respectively (73).  COX-2 activity was also inhibited by 
Bauer alkylamides 2, 4, and 7 with inhibitions of 46%, 39% and 31%, respectively (73).  The 
concentration of alkylamide used to inhibit cyclooxygenase activity was actually quite high 
in the previously described study at 100 µg/ml, which is equivalent to 437 µM, 412 µM, and 
389 µM, for Bauer alkylamides 2, 4, and 7, respectively. Inhibition of cyclooxygenase-2 
dependent PGE2 was identified in neuroglioma cells (H4 cells) treated with alkylamides 
isolated from a CO2 extract made from the root material of E. angustifolia (78).  Only the E. 
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angustifolia extract and 10 µM of undeca-2Z-ene-8,10-diynoic acid isobutylamide (Bauer 
alkylamide13), dodeca-2E-ene-8,10-diynoic aid isobutylamide (Bauer alkylamide 14), and 
dodeca-2E,4Z-diene-8,10-diynoic acid 2-methylbutylamide (Bauer alkylamide 7) were able 
to significantly inhibit PGE2 of the eight alkylamides screened (78).  Further analysis of 
COX-2 protein and mRNA, showed an increase of COX-2 at the transcriptional and 
translational level, but a significant suppression of COX-2 enzyme activity with treatment of 
Bauer alkylamides 13, 14, and 7 (78).  The insight that was gained from the studies described 
above provided a basis for the hypothesis that perhaps alkylamides act by competing with 
arachidonic acid for the cyclooxygenase enzymes and that may be how PGE2 is attenuated, 
though more relevant studies are necessary. 
Another means by which alkylamides have been shown to modulate the immune 
system and act in an anti-inflammatory nature, through the activation of macrophage cells, is 
by inhibiting the production of nitric oxide (NO).  Chen et al. conducted a study to determine 
if 14 alkylamides from the roots of E. angustifolia, E. purpurea, and E. pallida could reduce 
the amount of NO produced after stimulation of RAW264.7 mouse macrophage cells with 
lipopolysaccharide (79).  The lowest NO ID50 was determined to be 12 µM for both dodeca-
2E,4Z-diene-8,10-diynoic acid isobutylamide (Bauer alkylamide 3) and dodeca-2E,4Z-diene-
8,10-diynoic acid 2-methylbutylamide (Bauer alkylamide 7), with dodeca-2E,4E,8Z,10E/Z-
tetraenoic acid isobutylamide (Bauer alkylamides 8/9), dodeca-2E,4E-dienoic acid 
isobutylamide (Bauer alkylamide 11), and dodeco-2E,4Z,10Z-trien-8-ynoic acid 
isobutylamide (Bauer alkylamide 15) coming in next with a ID50 of ~24 µM (79).  Cell 
viability was also measured using an MTT assay after treatment of RAW264.7 cells with 
alkylamides, showing TD50 at doses ≥50 µM with all alkylamides screened (79).  High levels 
of nitric oxide production (via iNOS and eNOS) plays an important role in the inflammatory 
response through increasing vascular permeability, angiogenesis, and the production of free 
radicals, such as peroxynitrites, which lead to tissue damage.  The importance of identifying 
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constituents in Echinacea that act in a multifaceted fashion during the process of 
inflammation, through the inhibition of multiple inflammatory endpoints, is essential to 
understanding the full potential of this herbal product. 
Alkylamides Proposed Mechanism Leading to Immune Modulation 
Little is understood about the molecular mechanism of action Echinacea employs to 
exert its immunomodulatory properties, but studies have been accumulating providing insight 
to this topic.  In 2004, Gertsch et al. published a study demonstrating that dodeca-2E,4E,8Z-
10E/Z-tetraenoic acid isobutylamides (Bauer alkylamides 8/9) induce TNF-α mRNA, as well 
as cAMP, p38/MAPK, and JNK signaling, and activate NF-κB in primary human 
monocytes/macrophages, but do not inhibit LPS induced TNF-α protein levels at nanomolar 
concentrations (80).  It was postulated that the mechanism leading to the described immune 
modulation was related to cannabinoid receptors, providing the first insight into a possible 
mechanism of action for Echinacea (80).   
Cannabinoid receptors (CB1 and CB2) are G protein coupled receptors that have been 
shown to potentially modulate a variety of immune cell functions in various species 
including humans (81).  The CB1 receptor is ubiquitously expressed in various regions of the 
brain and is partially responsible for catalepsy, depression of motor activity, analgesia, 
feelings of relaxation, and well being (82).  It should also be mentioned that CB1 receptor is 
highly expressed on monocytes, macrophages, dendritic cells, and osteoclasts (83). Whereas 
the CB2 receptor is located in the periphery and is known be present in immune cells, such as 
T cells, B cells, natural killer cells, macrophages, neutrophils, and mast cells (82).   
Anandamide (C:22) is a derivative of arachidonic acid and an endogenous ligand for 
the cannabinoid receptors (84).  Due to the fact that alkylamides share structural similarity 
with anandamide, Woelkart et al. assessed alkylamides isolated from E. angustifolia root for 
their ability to bind to rodent cannabinoid receptors using a receptor binding assay, as well as 
the metabolic stability of these constituents to fatty acid amidohydrolase (FAAH) (85).  
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FAAH is responsible for the hydrolysis and inactivation of anandamide and therefore may be 
involved in metabolism of alkylamides (86).  Bauer alkylamides 8/9, 10, 11, and 17 showed 
the greatest affinity for rat CB1 receptors with Ki values ranging from 6.7 µM to 11.0 µM, 
but when phenylmethanesulfonyl fluoride was added as an inhibitor of FAAH there was a 
slight decrease in the Ki concentrations for Bauer alkylamides 10, 11, and 17, suggesting that 
alkylamides are also susceptible to hydrolysis by serine-dependent proteases (85).  As for the 
CB2 receptor, Bauer alkylamides 7, 8/9, 10, 11, and 17 and tetradeca-2E-ene-10,12-diynoic 
acid isobutylamide showed the greatest affinity with Ki values ranging from 1.9 µM to 
12.7µM (85). There is particular interest in cannabinoid receptor CB2 ligands due to their 
potential to act as anti-inflammatory agents, without interfering with the detrimental brain 
function effects linked to CB1.   
Further studies on alkylamides and their ability to bind to human CB2 receptor 
determined that dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (Bauer alkylamide 9) 
and dodeca-2E,4E-dienoic acid isobutylamide (Bauer alkylamide 11) bound to the receptor 
more strongly than endogenous ligands, such as ∆9-tetrahydrocannabinol, anandamide, and 
2-AG (81).  The Ki values of Bauer alkylamides 9 and 11 were ~60 nM for CB2, with 
significantly less affinity for the CB1 receptor (81).  It was previously shown by Gertsch et 
al. that alkylamides influence cellular cAMP levels in human monocytes/macrophages and 
that they inhibit induced cAMP production, providing a basis to study whether alkylamides 
binding to CB2-positive or CB2-negtive cell lines effect total [Ca2+] (80, 81).  In the CB2-
positive cell line, Bauer alkylamides 9 and 11 induced [Ca2+], with no significant modulation 
of [Ca2+] in CB2-negative cells, indicating that CB2 is important for Ca2+ signaling with 
alkylamides (81). 
Macrophage cells have been identified as crucial cells involved in the inflammatory 
response and therefore scientists are interested in understanding how Echinacea alkylamides 
or caffeic acid derivatives may influence biomarkers, such as NF-κB expression, TNF-α 
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production and nitric oxide production, which are known to be inducible in macrophage 
cells.  A recent study described how certain classes of alkylamides affect these endpoints 
differently in the RAW264.7 mouse macrophage cell line (87).  It was determined that after 
treatment with LPS, cichoric acid at 8 ng/ml, a mixture of alkylamides from an Echinacea 
extract (EPL AA) at 2ng/ml, and (2E, 4E, 8Z,10Z)-N-isobutyldodeca-2,4,8,10-tetraenamide 
(Bauer alkylamide 11) at 2 ng/ml, which represents the 2,4-diene class of alkylamides, were 
shown to inhibit NF-κB reporter gene expression, but only cichoric acid at 0.8ng/ml and the 
mixture of alkylamides in an Echinacea fraction 2 ng/ml were able to decrease TNFα 
production (87).  Finally, only the mixture of alkylamides from the Echinacea fraction at 2 
µ/ml were shown to inhibit NO production (87).   
A similar study conducted by the same group that provided the macrophage study 
examined the effects of alkylamides on human T cells in an in vitro model system that 
utilized Jurkat cells (88).  T cells are another group of immune cells derived from the thymus 
that play an important role in both activating other cells, such as B cells and macrophages 
during an inflammatory response, or differentiating into cytotoxic T cells that are capable of 
killing virally infected cells (2).  The study was designed to observe the effect of two classes 
of alkylamides, 2-ene and 2,4-diene, and caffeic acid on the modulation of NF-κB expression 
in a luciferace model system (88).  NF-κB is a nuclear transcription factor which can be 
stimulated during an inflammatory response to express genes like TNFα, IL-1, and COX-2.  
It was determined that (2E)-N-isobutylundeca-2-ene-8,10-diynamide (Bauer alkylamide 12) 
at 2 µg/ml, which represents the 2-ene class of alkylamides was able to inhibit NF-κB gene 
expression after treatment with LPS and (2E,4E,8Z,10Z)-N-isobutyldodeca-2,4,8,10-
tetraenamide (Bauer alkylamide 11) at 0.2 µg/ml, which represents the 2,4-diene class of 
alkylamides was shown to significantly increase NF-κB reporter gene expression after LPS 
treatment.  When phorbol myristate acetate was treated prior to addition of alkylamide or 
caffeic acid derivative, both cichoric acid at 8 µ/ml and Bauer alkylamide 11at 2 µg/ml 
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significantly increased NF-κB gene expression, whereas Bauer alkylamide 12 at 0.2 µg/ml 
was shown to significantly decrease NF-κB luciferase expression (88).  Such a differing 
effect between 2-ene and 2, 4-diene alkylamides seen in the studies of RAW264.7 mouse 
macrophage cells and human T cells reviewed above should caution investigators of 
Echinacea to the importance of understanding which constituents are crucial for a particular 
bioactivity.  
Anti-viral Activity of Echinacea Alkylamides 
Other studies with alkylamides have provided evidence toward their dual action as 
both anti-inflammatory agents, as well as having an indirect anti-viral effect.  Interleukin-2 is 
required for the clonal expansion and activation of T cells during infection and has also been 
linked to decreased symptoms and reduction of virus revival in experimental rhinovirus 
infection (2, 89).  It has been hypothesized that modulatory effects on IL-2 protein 
production may manipulate T cell specific immunity toward infection (90).  Sesagawa et al. 
set out to identify whether aerial E. purpurea extracts or constituents could modulate 
phytohemagglutinin/phorbol 12-myristate 13-acetate induced IL-2 production in Jurkat E6.1 
T cells (90).  From this study it was determined that aerial extract of E. purpurea in 95:5 
ethanol/water inhibited IL-2 production by ~65% at 50 µg/ml and two standard alkylamides, 
dodeca-2E, 4E, 8Z,10Z-tetraenoic acid isobutylamide (Bauer alkylamide 9) and dodeca-
2E,4E-dienoic acid isobutylamide (Bauer alkylamide 11) at concentrations of 0.625 µg/ml to 
25 µg/ml (equivalent to that in the E. purpurea extract), were both capable of dose-dependent 
significant IL-2 suppression compared to a vehicle control, with caffeic acid derivatives 
showing no significant alteration of IL-2 production at concentrations present in the E. 
purpurea extract (90). 
Echinacea Caffeic Acid Derivatives 
Caffeic acid derivatives make up a major class of constituents found in Echinacea, 
that include, caftaric acid, chlorogenic acid, caffeic acid, cynarin, echinacoside, and cichoric 
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acid.  Pellati et al. reports the total phenolic content for E. angustifolia, E. pallida, and E. 
purpurea to be 10.49 mg/g, 17.83 mg/g, and 23.23 mg/g, respectively (91).  This class of 
compounds has been studied for anti-oxidant capabilities through measuring their ability to 
scavenge 2, 2-diphenyl-1-picrylhydrazyl (DPPH•) radicals.  Six caffeic acid derivatives were 
screened with the order of scavenging potency against DPPH• radicals as follows: 
echinacoside (EC50 = 6.6 µM) > cichoric acid (EC50 = 8.6 µM) > cynarin (EC50 = 11 µM) > 
chlorogenic acid (EC50 = 18.9 µM) > caffeic acid (EC50 = 19.1 µM) > caftaric acid (EC50 = 
20.5 µM) (91).  These results are consistent with previous reports indicating that the ability 
of phenolic compounds to scavenge free radicals is largely influenced by the number of 
hydroxyl groups on the aromatic ring, with more hydroxyl groups having greater activity 
(92).   
Caffeic acid derivatives have been studied for their anti-viral properties.  L-chicoric 
acid has been reported to potently inhibit human immunodeficiency virus type 1 (HIV-1) 
integrase activity, which is a key enzyme in the viral life cycle required for replication, in a 
HeLa CD4 LTR-β-gal cell line model transfected with HIV-1 (93).  Furthermore, it was 
shown that synthetic dicaffeoylquinic acids and dicaffeoyltartaric acids are potent and 
selective inhibitors of HIV-1 integrase and replication (94).  The antimutagenic potential of 
caffeic acid derivatives found in Echinacea (L) Moench was analyzed using the salmonella 
typhimurium tester strain TA100 in a plate-incorporation test, where revertants were counted 
(95).  The results demonstrated that cichoric acid actually increased the mutagenicity of 3-(5-
nitro-2-furyl)acrylic acid (5NFAA), whereas ferulic and caffeic acids were identified to be 
antimutagenic by decreasing the mutagenic effect of 5NFAA by approximately 50%, 
although it should be noted that extremely high concentrations of 300 to 5000  µg/ml were 
screened to identify this effect (95).  
Stability of Alkylamides and Caffeic Acid Derivatives 
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A major concern of researchers studying the bioactivity of the constituents found in 
Echinacea, as well as those using and preparing Echinacea treatments for medicinal 
applications, is the stability of active constituents after various preparations, storage 
temperatures, and storage periods.  It has been hypothesized that due to the known anti-
oxidant bioactivity of the caffeic acid derivatives that perhaps they are protective of the 
highly unsaturated alkylamides via preventing oxidation.  Several studies have set out to 
understand the ideal conditions of preparation and storage for Echinacea products and will be 
discussed below. 
During 1999, Livesey et al. used either an alcoholic Echinacea purpurea three year 
old root extract or a dried powder from that same extract to examine the stability of marker 
compounds (Bauer alkylamide 1/2 and a phenolic, cichoric acid) after storage at -20°C, 
25°C, or 40°C for seven months.  After the seven month period HPLC was used to determine 
that in the dried powder, alkylamide concentration decreased 88% at 25°C and 95% at 40°C, 
whereas the cichoric acid concentration was not significantly affected (96).  A reverse effect 
was identified for the liquid extract where the alkylamide level remained stable over the 
temperature range and cichoric acid content declined 80% at the higher temperatures (96).  
Another study looked at the effect of chopping, drying, and storage (both time and 
temperature) of E. purpurea roots and how those conditions affected alkylamide content.  It 
was determined that drying had no effect, whereas chopping did affect certain alkylamides 
slightly but to a non-significant degree.  The major findings were that alkylamides levels 
decreased by greater than 80% during storage at 24°C after a 64 week period (97).  
Echinacea roots stored at -18°C also experienced a significant decline in alkylamide levels 
after the same storage period, indicating that attention must be paid to storage temperatures.   
These were some of the earlier results to indicate that an optimization of preparation and 
storage conditions was necessary to maintain stability of two main constituents found in 
Echinacea.   
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A common method that is commercially used to dry harvested raw material from 
Echinacea is that where hot air is fan-forced over plant material.  In 2003, Stuart and Wills 
designed a study to examine the alkylamide and cichoric acid concentration of E. purpurea 
root and aerial portions dried in the fan-forced manner at temperatures ranging from 40-70°C 
(98).  Alkylamide content did not differ at the assorted drying temperatures in the root, stem, 
or leaf material, but there was a significantly higher amount of alkylamide in flowers dried at 
70°C as compared to those dried at 40°C (98).  The alkylamide data collected indicates great 
stability for these constituents at drying temperatures ranging from 40-70°C.  Overall, as the 
drying temperature increased, cichoric acid content significantly decreased in root, flower, 
stem, and leaf materials (98). 
Other studies sought to determine whether long term storage of Echinacea material 
had an effect on bioactivity.  In 2006, Senchina et al. determined that greater than one year 
storage of dry Echinacea roots from seven of the nine species maintained their cytokine-
modulating capabilities in an in vitro model of Type A influenza vaccination (99).  Another 
study examined the immunomodulatory effects of seven Echinacea species tinctures after 2 
years of storage at -20°C. Two sets of experiments were employed, one with human 
peripheral blood mononuclear cells (PMBC) treated with the Echinacea tinctures only and 
the other with PMBC collected from vaccinated individuals immunized with influenza 
vaccine and then treated with Echinacea tinctures and influenza virus.  Results indicated an 
increased alkylamide concentration for E. purpurea, E. simulata, and E. tennesseensis, with 
no change identified for E. angustifolia, E. pallida, or E. sanguinea after 2 years of storage at 
-20°C (100).  Another significant finding was that cytokine production was measured to be 
higher with fresh extracts than the stored extracts providing evidence that storage time may 
be detrimental to obtaining consistent results in bioassays (100). 
In 2007, Liu and Murphy determined that there were differences in the stability of 
alkylamides stored in solution versus dry extract and that phenolics, such as the caffeic acid 
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derivatives are likely to play a role in protecting alkylamides from degradation.  Four 
different accelerated storage conditions were used to prepare E. purpurea extracts, those 
being, phenolic-depleted and phenolic-rich dry and phenolic depleted and phenolic-rich 
dissolved in dimethyl sulfoxide (DMSO) (101).  Extracts were stored under 70°C, 80°C, and 
90°C.  The results from this study showed that dry E. purpurea alkylamides degraded 
significantly slower with phenolic acids present than without, but yet the alkylamides 
degraded faster in phenolic-rich DMSO extracts than those without phenolics (101).  A key 
finding from this study was that DMSO extracts maintained the stability of the alkylamides 
better than the dry extracts (101).  The authors concluded that different mechanisms must 
account for alkylamide oxidation in solution compared to the dry extracts. 
From the studies discussed in this section it can be concluded that several factors, 
such as preparation method, temperature during preparation, temperature during storage, and 
storage duration are very important for the biological evaluation of constituents found in 
medicinal herbs.  Also, because of the medium chained structure of alkylamides, its double 
bond contents, and unsaturated configuration this constituent is highly prone to oxidation, 
which perhaps under certain conditions is circumvented through the actions of radical 
scavenging caffeic acid derivatives (101).  These findings should make researchers mindful 
of the need to control for stable conditions of constituents of interest and to be diligent to 
conduct research in a timely manner to obtain meaningful results before degradation has the 
opportunity to occur. 
Echinacea Ketones 
Acetylenes, generically called ketones, are the major lipophilic compounds found in 
certain accessions of Echinacea pallida and until recently have not been studied as 
thoroughly as other constituents for their bioactive potential.  A study focusing on the 
cytotoxic properties of five ketones found in n-hexane extracts of E. pallida determined that 
pentadeca-(8Z,13Z)dien-11-yn-2-one (Bauer ketone 24) was able to cause a concentration 
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dependent decrease in cultured human colorectal (COLO320) and pancreatic (MIA PaCa-2) 
adenocarcinoma  cell viability, with an IC50 of 2.34±0.33 µM and 32.17±3.98 µM, 
respectively (75).  These results were quite significant because the study goes on to show that 
Bauer ketone 24 was more effective then the common cancer drug 5-flourouracil at 
decreasing cell viability in COLO320 cells and that this ketone causes cytotoxicity through 
activation of caspase 3/7 (75).  Another study analyzed the cytotoxic properties of Bauer 
ketone 24 on leukemia (Jurkat and HL-60), breast carcinoma (MCF-7), and melanoma 
(MeWo) cells, identifying significant cytotoxic properties with IC50 less than 2.5 µM for the 
Jurkat and MCF-7 cells (102).  The cytotoxic effect of the Echinacea ketone was determined 
to be due to cell cycle arrest during the G1 phase in the HL-60 leukemia cells (102). 
Further research has been conducted to better understand whether constituents found 
in Echinacea are able to influence the multidrug transporter P-glycoprotein (Pgp), which 
bestows resistance to anticancer chemotherapy when highly expressed in cancer cells.  In a 
human kidney cell line HK-2, made to constitutively over express high and constant levels of 
Pgp it was determined through a bioassay-guided fractionation of an Echinacea pallida 
extract that pentadeca-(8Z,13Z)dien-11-yn-2-one (Bauer ketone 24) was able to decrease the 
efflux of the Pgp probe calcein-AM by three-fold compared to the control at a concentration 
of 30 µM (103).  Although the inhibition measured with Bauer ketone 24 was minimal 
compared to that of other Pgp inhibitors it is interesting to consider the roles this inhibition 
may take in herb-drug interactions. 
In 2008 an attempt was made to determine a possible mechanism of action for 
reported immunomodulatory properties of ketones found in E. pallida (104).  Egger et al. 
chemically synthesized natural and non-natural ketoalkenes from E. pallida and tested for 
antagonistic activation via the cannabinoid receptors using a GTPase assay (104).  No 
ketoalkenes were capable of activation of GTPase activity to greater than 20% of basal levels 
and therefore were not considered cannabinoid receptor agonists (104).  Further studies will 
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need to be completed to determine a mechanistic basis for the bioactivities associated with 
ketones from Echinacea. 
A stability study was conducted with pentadeca-(8Z, 13Z)-dien-11-yn-2-ome (Bauer 
ketone 24) in cell culture medium (Roswell Park Memorial Institute 1640 medium 
supplemented with L-glutamine, fetal bovine serum, penicillin, and streptomycin) over a 72 
hour period under standard culture incubation conditions (102).  Results from this study 
indicated that oxidation of the ketone was relatively slow, with the area of hydroperoxide 
intermediate at approximately 25% at 72 hours and the final hydroxylated ketone derivative 
was not detected after 72 hours (102). 
Echinacea Polysaccharides 
Polysaccharides are constituents found in Echinacea extracts that have been 
recognized to possess macrophage activating bioactivity, including the ability to induce 
macrophages to develop high cytotoxicity against tumor cells.  It is noteworthy to point out 
that polysaccharides are extracted from Echinacea using water and therefore parallel screens 
for endotoxin levels should be performed in conjunction with the identification of 
bioactivities, to ensure that observed results are a direct consequence of the polysaccharide 
treatment and not due to increased endotoxin stimulation.  Endotoxin studies were not 
mentioned in the studies described hereafter.  In 1984 studies were conducted utilizing 
purified polysaccharides from E. purpurea extracts targeting immune cells both in vitro and 
in vivo that provided evidence that this class of compounds possess macrophage-activating 
properties, in both peritoneal macrophages and macrophages cultivated from bone marrow 
precursor cells (105).  It was shown that the polysaccharides activated the macrophages to 
develop extracellular cytotoxicity toward DBA/2 P815 mastocytoma cells, indicating a 
possible application for this group of constituents in combating tumor systems (105).   
Luettig et al. further explored polysaccharides and macrophage activation by isolating 
highly purified acidic arabinogalactan from cell cultures of E. purpurea and published further 
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evidence that thioglycollate-induced peritoneal macrophages were stimulated to produce 
TNF-α, bone marrow macrophages were stimulated to secrete IFN-beta, and resident 
peritoneal macrophages were stimulated to produce IL-1 when treated with arabinogalactan 
(106).  This same study explained that arabinogalactan activated macrophages to kill TNF-α 
sensitive WEHI164 tumor cells and increase phagocytosis of the parasite Leishmania enrietti 
(106).  Another study that verified these results was described by Steinmuller et al. 
demonstrating that polysaccharides separated from E. purpurea cell cultures were able to 
activate peritoneal macrophages in animals after administration of cyclophosphamide or 
cyclosporin A, known immunosuppressors, by increasing the production of TNF-α, as well as 
increase cytotoxicity against WEHI164 fibrosarcoma tumor cells and an intracellular parasite 
Leishmania enrietti (107).  Evidence is accumulating suggesting that arabinogalactan and 
other polysaccharides may exert therapeutic effects against certain cancer cells as well as 
various parasites, due to their cytotoxic properties.   
Melchart et al. conducted a clinical study utilizing a polysaccharide fraction isolated 
from an E. purpurea extract to neutralize the adverse side effects experienced by individuals 
having chemotherapy treatments for advanced gastric cancer (108).  Thirteen patients 
received daily i.v. injections of 2 mg of a polysaccharide fraction for 10 days, beginning 3 
days before initiating their chemotherapy regimen (108).  Results were very unclear for this 
study due to the control group coming from historical records of past patients with gastric 
carcinoma that were treated with the same chemotherapy agents (108).  The study at most 
suggested a slight yet non-significant decrease in leukopenia, which is a decrease in 
circulating white blood cells that leaves the patient overly susceptible to infection, in the 
patients that received the polysaccharide fraction (108).   
Echinacea Glycoproteins 
Other studies discuss the possible role glycoproteins may have in the 
immunostimulating effects observed with E. purpurea extracts through the activation of 
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complement.  Mechanistic studies have shown that arabinogalacatin protein type II (AGP) 
isolated from the pressed juice of E. purpurea binds to C1q, can enhance C3-consumption, 
and further induce an increase of C5b-9, which is the membrane attack complex, thereby 
stimulating potent complement activation (109).  Alban et al. verified these results using a 
haemolytic complement assay, providing evidence that AGP was able to activate both the 
classical and alternative pathways of complement (110).   
Classen et al. studied the proliferative effect of different concentrations of AGPs on 
mouse spleen cells, describing that AGPs isolated from E. pallida roots dose-dependently 
activated proliferation, whereas AGPs purified from suspension culture of E. purpurea were 
ineffective proliferators (111).  Further results demonstrated that APGs isolated from both E. 
pallida and E. purpurea increased IgM-titres in spleen cell cultures from NMRI mice, 
indicating an ability to activate B-lymphocytes (111).  When alveolar mouse macrophages 
were treated with E. pallida and E. purpurea AGPs, a dose-dependent increase was observed 
in IL-6 production and nitrite production, which is an expected outcome of macrophage 
activation (111). 
The Anti-viral Activity of Echinacea Preparations 
In western countries the common cold is one of the most prevalent diseases with 
direct medical costs reported to reach approximately $16.8 billion annually (112).  In the 
U.S. an adult suffers from 2 to 4 colds per year, accounting for approximately 23 million 
days of work absence (112).  With the vaccination for rhinoviruses remaining elusive and 
clinical benefits from zinc, vitamin C, and other antihistamines unclear, there is a need to 
identify other sources for treatment of these viruses that cause the symptoms associated with 
the common cold (113).   
Echinacea has been touted for its use to prevent or treat upper respiratory tract 
infections (URI), as well as the common cold.  Although several prevention trials, self-
treatment, and treatment trials have been conducted to examine the efficacy of Echinacea 
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products in preventing or treating URIs and cold symptoms, a clear answer still eludes 
researchers.  There have been a mixture of positive and negative results, due to several 
different experimental variables, including time to initiation of treatment, virus type and 
dose, immune competence of volunteers, and proper characterization of the Echinacea 
products being studied (12, 114).  Due to the variability associated with the results from 
Echinacea clinical trials, meta-analyses are being used to pool results from well designed 
studies looking for a common endpoint, that being the efficacy of Echinacea extracts to 
prevent and limit the duration of symptomatic development of a naturally induced or an 
experimentally induced cold.   
In a meta-analysis reported by Schoop et al. in 2006, 231 of 234 articles were 
eliminated because they were used to study spontaneous common colds, leaving 3 high 
quality, double blind, placebo controlled, adequately randomized studies to be pooled for the 
analysis of Echinacea’s efficacy in treating the common cold after clinical inoculation (113).  
Two studies were conducted by Turner et al. in 2000 and then in 2005, utilizing different 
species with each study, with the earlier E. purpurea extracts and the later E. angustifolia 
extracts (115, 116).  Sperber et al. provided the third study included in the Schoop et al. 
meta-analysis, treating subjects with E. purpurea extracts (117).  In the meta-analysis of 
these three studies, the data for the Echinacea extracts were pooled and compared with 
placebo, providing evidence for prophylactic efficacy (113).  It was determined that the 
probability of developing a clinical cold was 55% higher in the placebo control group than 
those that received Echinacea as a treatment (113).  Another meta-analysis was conducted in 
2007 by Shah et al. that included trials that were randomized placebo-controlled, used to 
evaluate Echinacea-containing products (extracts containing E. purpurea, E. angustifolia, E. 
pallida, or a combination of species), measuring prevention and/or treatment of the common 
cold, and contained adequate data on either cold incidence or duration (118).  After inclusion 
parameters were considered, 14 studies were chosen for meta-analysis, providing evidence 
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that Echinacea decreased the odds of contracting a cold by 58% and decreased the duration 
of cold by 1.4 days (118).  It is important to note that the Shah et al. meta-analysis pooled 
trials regardless of the product tested and incorporated trials even when Echinacea 
preparations were combined with other herbal products (113).  Both meta-analyses discussed 
here point toward a beneficial outcome when considering the efficacy of Echinacea products 
to prevent or treat the common cold, yet there is still a need to conduct larger prevention 
trials in order to arrive at a distinct conclusion. 
The clinical studies along with the meta-analysis described in the previous section 
have provided a strong basis to identify Echinacea as having anti-viral properties.  A micro-
array study looking at which genes are differentially expressed when human bronchial 
epithelial cells either infected with human rhinovirus type 14 (RV14) or uninfected and 
treated with an aqueous polysaccharide-enriched extract from the aerial portion of E. 
purpurea (E1) or an ethanolic tincture from the roots of E. purpurea (E2) found several 
affected genes lie in the immune response category (119).  From this study it was determined 
that E1 and E2 increased expression of certain cytokines like MIP-1α, IL-8, and TNF-α, but 
decrease the expression of IL-6, IL-1β, and IL-10 (119).  When RV14 viral infection 
increased the expression of two genes known to be involved in the innate immune response, 
mycovirus resistance gene MS1 and IFNα-induced protein 15, both E1 and E2 reversed the 
viral stimulation (119).   
Anti-oxidant Properties of Echinacea Extracts 
Echinacea extracts have also been reported to be free radical scavengers and possess 
anti-oxidant properties.  In 2004, Sloley et al. showed that the roots of E. purpurea exhibited 
significantly greater free radical scavenging capabilities than either E. angustifolia or E. 
pallida based on a model measuring the accumulation of 2,2’azino-bis(3-ethylbenzthiazoline-
6-sulfonic acid) radical (120).  That same study also determined that root or leaf extracts of 
E. purpurea, E. angustifolia, and E. pallida inhibited Fe2+-induced lipid peroxidation (120).   
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Echinacea and Immune Modulation 
Echinacea extracts have been touted as having immunomodulatory properties, yet 
most of the time in the literature, only ethanol extracts are assayed.  Pillai et al. used flow 
cytometry to determine which type of extract, EtOH or water, was able to stimulate CD4+ 
cells to the greatest extent (121).  Mature T helper cells express the glycoprotein CD4+ 
which can be used as an indicator of immune activation (2).  It was determined that only the 
aqueous extracts from E. purpurea were significantly active, stimulating CD4+ cells by 24 % 
at a concentration of 100 µg/ml, whereas EtOH material was inactive even at very high 
doses, though it is important to point out that endotoxin levels were not measured in this 
experiment, which may be higher in the water extract (121).  From this study the authors 
suggest that it is the water soluble (polysaccharides) that are responsible for the 
immunostimulatory activity found in the Echinacea species (121).  More studies are 
warranted to make conclusions about a certain group of constituents accounting for 
immunomodulatory properties, based on the evidence presented in the Pillai et al. study only 
measured one endpoint.   
Another study focusing on an aqueous extract of E. purpurea determined through 
flow cytometric methods that this extract at 0.01 µg/ml was able to activate natural killer 
cells, indicated by the expression of CD69 and down regulation of CD16, increase NK-target 
cell binding, and increase killer cell frequency in human peripheral blood mononuclear cells 
(122).  These results again suggest a role of Echinacea polysaccharides in NK maturation 
and possibly support the idea that Echinacea has anti-viral properties. 
Regulation of Dietary Supplements Including Echinacea 
One of the greatest misconceptions that has developed out of public opinion on herbal 
products has been that these products are natural, (being from the environment) so they are 
therefore safe to use medicinally.  This common belief among consumers may be due to the 
fact that dietary supplements, including botanical supplements, are not regulated directly by 
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the U.S. Food and Drug Administration (FDA) in the same manner as synthetic 
pharmaceuticals.   
The 1994 Dietary Supplement Health and Education Act (DSHEA) allowed 
Americans to enjoy access to vitamins, minerals, and herbal products.  DSHEA requires 
manufacturers to study and identify the uses of the products labeled under this act and 
provide the FDA with adequate safety information 75 days prior to marketing their product.  
DSHEA also sets provisions as to how these supplements can be labeled which allows the 
manufacturer to make structure/function or nutritional support claims that must be truthful 
and indicate the role of the nutrient in supporting wellness or heath.  Another labeling 
requirement brought about by this act states that the dietary supplement label must list the 
name and quantity of each active ingredient, identify the product as a dietary supplement, and 
if the supplement is an herb the manufacturer must identify the part of the plant from which it 
is taken.  Unfortunately, there has been misleading information identified from studies 
analyzing herbal content on manufacturer’s labels.  For example, in Germany a study was 
conducted to analyze alkylamide and cichoric acid content in commercial root preparations 
of E. purpurea showing that out of 25 preparations some products were highly concentrated, 
whereas others neither class of constituent was detectable, identifying excessive variability in 
chemical profile amongst various preparation methods labeled as Echinacea (123). The 
results from this study indicate that it is necessary to quantitate potentially bioactive 
constituents, especially in preparation for clinical trials examining efficacy of this herb in the 
prevention of cold symptoms, etc.   
In the United States 25 commercial preparations of Echinacea were also assessed for 
labeling accuracy, finding that only 56 % passed the assessments for their quality.  Some of 
the products were flawed in that they were improperly labeled, contained a different species 
than what was present on the label, contained excessive amounts of microbes, or contained 
no trace of constituents claimed on the label (124).  These studies provide evidence to the 
 48
consumer that not all manufacturers are strictly following the guidelines and regulations 
placed by DSHEA.  The consumer must realize that just because something is marketed as a 
natural product does not mean that it is safe.  Although few adverse side effects have been 
reported with the use of Echinacea, the fact of the matter is that research is still under way to 
determine the safety and efficacy of this herbal product.  Consumers must continue to be 
leery and identify which dietary supplement products have the potential to be beneficial for 
their health and weigh the risk of potential side effects, interactions with other drugs, or cost.      
DSHEA also established the Office of Dietary Supplements (ODS) within the 
National Institutes of Health to identify the role of dietary supplements in improving health 
and encouraging scientific research that seeks to establish the benefits of dietary supplements 
dealing with the prevention of or cures for disease 
(http://www.fda.gov/opacom/laws/dshea.html).  Through the diligent work by ODS, 
researchers studying dietary supplements, and mainstream media becoming more educated 
on topics of herbal supplements, scientists and consumers alike are developing a better 
understanding of the safety and efficacy of many of these products being marketed today.   
Adverse Effects Associated with Echinacea 
Echinacea products are among the most commonly self prescribed herbal remedies 
selected today, with approximately 16% of patients undergoing chemotherapy using them to 
supplement cancer therapy (125).  A recent study focused on the interference of fractions and 
pure compounds segregated from E. angustifolia roots, with doxorubicin, a common 
anticancer drug known to be cytotoxic against several cancer cell lines (125).  Doxorubicin 
was treated to cervical and breast cancer cells at two doses (0.05 µM and 0.5 µM), either in 
the absence or presence of E. angustifolia fraction, cynarine, chicoric acid, or echinacoside 
(125).  This study follows up a previous study which discovered that Echinacea has the 
ability to interact with anticancer drugs oxidized by the cytochrome p450 isoform, 3A4 
(126).  Cervical cancer HeLa cells were shown to increase in cell growth after treatments 
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with cynarine by 48-125 % or 29-100 % with simultaneous treatments of 0.05 µM and 0.5 
µM doxorubicin, respectively (125).  Chicoric acid was able to significantly increase cell 
growth of the HeLa cells by 23-100 % when also treated with 0.05 µM doxorubicin (125).  
Studies conducted with the MCF-7 breast cancer cells did not identify a significant 
interaction between doxorubicin and the caffeic acid derivatives, but did determine that the 
ethyl acetate fraction increased cell growth by 20-25 % (125).  It can be concluded from this 
study that certain compounds and fractions isolated from E. angustifolia have growth 
promoting activity in certain cancer cells, which actually can adversely affect the cytotoxic 
activity of the common chemotherapy drug doxorubicin.  Interactions with herbal 
supplements need to be more thoroughly examined in order to protect the consumer. 
It is becoming increasingly more popular for atopic individuals to use complementary 
alternative medicines (CAM) and is therefore not surprising that allergic responses to CAM 
are quite common in these people (127).  An Australian study evaluated 5 patients who 
suffered adverse reactions to Echinacea exposure, including anaphylaxis, acute asthma, mild 
asthma, and rash (128).  The patients were subjected to skin prick testing (SPT), including a 
commercially available glycerinated extract of Echinacea, where three of the five had 
positive SPT results.  Echinacea belongs to the Asteraceae family, which consists of greater 
than 20,000 species worldwide and therefore exposure to members of this family is inevitable 
throughout a lifetime, with sensitization to Asteraceae being quite common (127).  The 2004 
Australian study also examined fifty-one adverse drug reports indicating that Echinacea as 
the culprit, but determined that only 26 of these cases were suggestive of IgE mediated 
hypersensitivity (128).  The study concluded that atopic people were over represented in the 
group reporting adverse consequences from Echinacea and that it was possible that other 
environmental allergens cross-react with Echinacea to set off the reported allergic reactions.  
From this data it should be noted that atopic individuals should be leery when consuming any 
botanical.  
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A single case of Echinacea induced cholestatic autoimmune hepatitis has been 
reported in the medical literature based on a case with a 45-year-old male, who was admitted 
into hospital care complaining of fatigue and jaundice for a duration of 1 week (129).  He had 
revealed that he took 1500 mg/day of Echinacea root after catching a cold the previous 
month (129).  The liver biopsy demonstrated interface hepatitis, obvious cholestasis, and 
portal lymphoplamocytic and eosinophilic granulocyte infiltration.  One month after 
discontinuing use of the Echinacea supplementation the patient had elevated liver enzymes, 
positive IgG, and spontaneous normalization of laboratory values (129). 
Bioavailability and metabolism of constituents found in Echinacea 
Bioavailability can be defined as the portion of a particular dose of constituent that 
arrives at the systemic circulation as an intact constituent (130).  A major weakness with 
most studies dealing with botanicals and bioactivity is accounting for how much of the 
particular extract or compound actually enters the cells or the body of the model being 
studied.  Within the past seven years more and more studies are focusing on the 
bioavailability of constituents found in Echinacea.  Alkylamides, caffeic acid derivatives, 
and more recently ketones found in Echinacea have been studied for their bioavailability 
through a popular model of the intestinal epithelial barrier called the Caco-2 monolayer 
system (76, 131).   
An early study conducted in 2002 examined the bioavailability of dodeca-
2E,4E,8Z,10E/Z-tetra-enoic acid isobutylamides (Bauer alkylamides 8/9) through the Caco-2 
cells over a 6 hour time period (131).  Results from this study indicated that after loading the 
apical side of the monolayers with 25 µg/ml of Bauer alkylamides 8/9, approximately 15% of 
these constituents were detectable within 30 minutes on the basolateral side, with similar 
results recorded when the adenocarcinoma colonic cell line was pretreated with 
lipopolysaccharide or phorbol 12-myristate-13-acetate in order to mimic an inflammatory 
state (131).  It was also noted that no significant metabolism had occurred, because 
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approximately 80% of alkylamides 8/9 were recovered on the basolateral side after the 6 hour 
incubation.  In a separate experiment using this model system twelve alkylamides were 
reported to readily cross from the apical to the basolateral side of the monolayers (apparent 
permeability >10-6 cm/s), with this process taking only 90 minutes for over half of the 
compounds (76).  This study also showed that 2,4-dienes were more readily transported than 
the equivalent 2-ene alkylamides (76). Within the 90 minute time period the caffeic acid 
derivatives, such as, cichoric acid, caftaric acid, cinnamic acid, echinacoside, and tartaric 
acid exhibited poor uptake through the Caco-2 monolayers, with less than 5% transported 
(76).  Chicca et al. also used the Caco-2 monolayer in vitro assay to provide evidence that 8-
hydroxy-pentadeca-(9E,13Z)-dien-11-yn-2-one, pentadeca-(8Z,13Z)dien-11-yn-2-one (Bauer 
ketone 24), and tetradeca-(8Z)-ene-11,13-diyn-2-one (Bauer ketone 22) were readily 
permeable through the cell system, with Bauer ketone 22 showing the highest apparent 
permeability at 32±3 x 10-6 cm/s (75).  These studies indicate that alkylamides, as well as 
certain ketones, are likely to cross the intestinal barrier and therefore should be able to carry 
out their bioactivities in vivo and that caffeic acid derivatives are less likely to do so.  As 
previously discussed it has been shown that Bauer ketone 24 at 30 µM was able to inhibit P-
glycoprotein (Pgp) drug transport in a HK-2 cell line model, which would have important 
implications on drug interactions (103).  A more recent study published in 2008 identified 
that an ethanol extract of E. purpurea was able to significantly decrease the basal to apical 
transfer of digoxin at concentrations ranging from 0.4 to 6.36 mg/ml in a Caco-2 monolayer 
cell system (132).  These results provide evidence that high concentrations of E. purpurea are 
capable of a dose dependent inhibition of Pgp which may have limited importance to drug 
bioavailability. 
Alkylamides have been the focus of research dealing with constituents found in 
Echinacea due to the various, previously mentioned bioactivities these constituents possess.  
It is no surprise that alkylamides have also been the focus of clinical trials looking at 
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bioavailability of Echinacea.  In vitro models have suggested that alkylamides are 
bioavailable and clinical trials that have been conducted are mounting stronger evidence that 
this is indeed the case (76, 130, 133, 134).  Dietz et al. conducted preliminary studies to 
optimize a technique to measure alkylamide content in human blood (135).  Blood was 
collected from 4 humans on regular diets and spiked with four dilutions of dodeca-
2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (Bauer alkylamides 8/9) to create a 
calibration curve and subjected to HPLC, having recovery rates greater than 95 % (135).  
One healthy human subject consumed an E. purpurea tincture containing 4.3 mg Bauer 
alkylamides 8/9, which was shown to be detectable by HPLC and quantified to 44 ng/ml 
blood, providing the basis for more clinical work (135).   
In 2005, two single dose human clinical trials were published, again providing 
evidence that alkylamides are bioavailable.  Matthias et al. examined plasma samples from 9 
healthy subjects that had ingested tablets manufactured from EtOH root extracts of E. 
angustifolia and E. purpurea after consuming a high fat breakfast, reporting rapid absorption 
of alkylamides (sum of alkylamides averaging 336±131 ng eq/ml plasma) that were 
detectable 20 minutes after the tablet was taken (133).  This study also reported that 130 mg 
of caffeic acid derivatives were also ingested from the tablets, yet none were detectable in 
any of the plasma samples, coinciding with the previous Caco-2 monolayer work (133).  
Woelkart et al. recruited 11 volunteers to fast overnight and consume an oral dose of 2.5 ml 
of 60% EtOH root extract of E. angustifolia.  Undeca-2E/Z-ene-8,10-diynoic acid 
isobutylamides (Bauer alkylamides12/13) were the first to reach their maximum plasma 
concentration of 1.87 ng/ml at 20.1 minutes and dodeca-2E,4E,8Z, 10E/Z-tetraenoic acid 
isobutylamides (Bauer alkylamides 8/9) showing the greatest maximum plasma 
concentration of 10.88 ng/ml after 30.3 minutes, indicating that alkylamides can be quickly 
absorbed in rather high amounts with certain structures (135).   
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Because Echinacea is used in many formulations throughout the world, another 
clinical trial examined the bioavailability of 3 different preparations of E. purpurea in the 
form of Echinaforce tablets, Echinaforce Junior tablets, and Echinacea sore throat spray, 
as well as the pharmacokinetics of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides 
(Bauer alkylamides 8/9) after ingestion (130).  In this cross-over study, after an overnight fast 
volunteers were orally administered either 12 Echinaforce tablets containing 143.2 µg of 
Bauer alkylamides 8/9, 10 Echinaforce Junior tablets containing141.3 µg of  Bauer 
alkylamides 8/9, or 4.4 ml of Echinacea sore throat spray, and plasma was collected at five 
time points after dosing (130).  Bauer alkylamides 8/9 were shown to be bioavailable in all 
formulations distributed to the human volunteers although they appeared at different time 
points (ranging from 28 minutes with the Echinaforce tablets to 68 minutes with the 
Echinaforce Junior tablets), but with similar Cmax ranging from 0.22 – 0.23 ng/ml (130).   
From these clinical studies it is becoming more evident that alkylamides are 
constituents that should be capable of eliciting their pharmacological effects in vivo, but other 
studies examining how constituents are metabolized by the gut microflora may suggest a 
need to examine other aspects of the physiology involved in bioavailability besides the 
presence of these constituents in blood plasma. 
Due to potential interactions with other herbal supplements or pharmaceuticals, it is 
necessary to understand how alkylamides from Echinacea are metabolized in the liver or in 
other tissues.  In 2005, Matthias et al., studied the metabolism of the alkylamide constituents 
from Echinacea premium liquid, in human liver microsomes and provided evidence that 
NADPH dependent cytochrome p450 metabolized 2-ene and 2,4-dienes differently (136).  
When cofactor-, enzyme-, and time-dependent degradation of substrates were analyzed as a 
measure of metabolism it was shown that synthetic 2,4-dienes were quickly metabolized with 
only 9% and 2% of the original concentration remaining of Bauer alkylamides 9 and 11, 
respectively (136).  A number of metabolites from Bauer alkylamide 9 were identified with 
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LCMS, showing peaks with apparent molecular weights that would indicate epoxidation, 
hydroxylation, and N-dealkylation (136).   
In a follow-up study, Jurkat human T cells were used to assess the influence of 
Echinacea alkylamides and metabolites on cytokine production after previous incubation 
with human liver microsomes (137).  It was previously shown that alkylamide metabolism by 
cytochrome p450 was dependent on the presence of NADPH and thus alkylamides were 
incubated in human liver microsome in the presence of NADPH and major metabolites were 
detected, including a novel carboxylic acid metabolite (dodeca-2E,4E,8Z,10E/Z-tetraenoic 
acid isobutylamide, also known as Bauer alkylamides 8/9) by LC-MS.  It was determined 
that incubation times around 120 minutes of Bauer alkylamides 8/9 and NADPH with human 
liver microsomes favored the formation of the carboxylic acid metabolite.  Further results 
from this study showed that an E. purpurea extract containing 4 µg/ml of Bauer alkylamides 
8/9 significantly repressed IL-2 secretion by 47% in the Jurkat T cells, but when NADH was 
present with the same treatment the significant suppressive effect on IL-2 secretion was 
lessened, indicating the importance of understanding the metabolism of constituents found in 
Echinacea and how it affects different bioactivities (137). 
Hypothesis and objective 
One long-term goal of the Center for Research on Dietary Botanical Supplements is 
to optimize and enhance the production of anti-inflammatory constituents present in 
Echinacea to make this botanical an effective supplement for the relief of inflammatory 
symptoms.  The goal of this particular research project was to identify Echinacea extracts, 
fractions, and alkylamides capable of inhibiting prostaglandin E2 (PGE2), and elucidate the 
signaling targets involved in this anti-inflammatory contribution, as well as identify which 
constituents found in Echinacea are of greatest importance for PGE2 inhibition.  The central 
hypothesis for this research stated that Echinacea extracts, fractions, and alkylamides inhibit 
the NF-kB signal transduction pathway, which in turn inhibits the expression of 
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cyclooxygenase-2 and further inhibits the production of prostaglandin E2 in RAW264.7 
mouse macrophage cells, with alkylamides playing a key role in this anti-inflammatory 
response.   
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CHAPTER 3:  ECHINACEA SPECIES AND ALKYLAMIDES INHIBIT 
PROSTAGLANDIN E2 PRODUCTION IN RAW264.7 MOUSE 
MACROPHAGE CELLS 
Modified from a paper published in The Journal of Agricultural and Food Chemistry 
Reproduced with permission from J. Ag. Food Chem. 2007, 55, (18), 7314-22. 
© 2007 American Chemical Society. 
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Kim, Kwon II Seo, Mark P. Widrlechner, and Diane F. Birt    
Abstract 
Inhibition of prostaglandin E2 (PGE2) production in lipopolysaccharide-stimulated 
RAW264.7 mouse macrophage cells was assessed with an enzyme immunoassay following 
treatments with Echinacea extracts or synthesized alkylamides.  Results indicated that 
ethanol extracts diluted in media to a concentration of 15 µg/ml from E. angustifolia, E. 
pallida, E. simulata and E. sanguinea significantly inhibited PGE2 production.  In further 
studies, PGE2 production was significantly reduced by all synthesized alkylamides assayed at 
50 µM, by Bauer alkylamides 8, 12A analog, 14, Chen alkylamide 2, and Chen alkylamide 2 
analog at 25 µM and by Bauer alkylamide 14 at 10 µM.  Cytotoxicity did not play a role in 
the noted reduction of PGE2 production in either the Echinacea extracts or synthesized 
alkylamides.  High performance liquid chromatography analysis identified individual 
alkylamides present at concentrations below 2.8 µM in the extracts from the six Echinacea 
species (15 µg/ml crude extract).  Since active extracts contained less than 2.8 µM of specific 
alkylamide and our results showed that synthetic alkylamides must have a minimum 
concentration of 10 µM to inhibit PGE2, it is likely that alkylamides may contribute toward 
the anti-inflammatory activity of Echinacea in a synergistic or additive manner.  
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Introduction 
The use of Echinacea as a medicinal herb is prominent in the United States, with 
sales encompassing approximately 10% of the total U.S. market in botanical supplements (1). 
With the increasing popularity of Echinacea, it is important to identify its active constituents 
and determine extraction methods that yield the proper doses of active constituents to elicit 
the desired medicinal effect.  Three species: E. purpurea, E. angustifolia, and E. pallida are 
commonly used in current botanical preparations (medicinal species).  The use of these 
medicinal species originated from Native American peoples who utilized Echinacea roots, 
aboveground parts, or a combination of both as treatments for different ailments ranging 
from toothache to rheumatism and as an antidote for poisons and venoms (2).   
Four classes of active compounds have been identified within Echinacea, yielding 
different chemical profiles among its nine species (3).  It has been hypothesized that 
alkylamides, caffeic-acid derivatives, polysaccharides, and glycoproteins are the classes of 
compounds responsible for the bioactivity of Echinacea (4).  Echinacea purpurea contains 
alkylamides, caffeic-acid esters (mainly cichoric acid), polysaccharides and polyacetylenes, 
whereas in E. pallida, alkylamides are mostly absent and the main caffeic-acid ester is 
echinacoside (5).  Furthermore, levels of constituents vary during growth and across 
development (3, 5).   
The chemical diversity these plants exhibit has made it difficult for researchers to 
determine if Echinacea can be effective in treating colds and other respiratory infections (6).  
Inconsistent results have been obtained from several placebo-controlled studies designed to 
determine whether Echinacea preparations were effective in the prevention of the common 
cold and other upper respiratory infections.   These conflicting results were perhaps due to 
the use of different species and plant parts, different preparations and doses, inconsistent 
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times of treatment initiation, and different virus types and doses (5, 6).  Some studies 
revealed a shorter duration of cold symptoms after Echinacea treatment in comparison to 
placebo (7, 8), whereas others showed no significant differences between treatment and 
placebo groups (9, 10).  Though the controversy regarding   efficacy continues, studies are 
accumulating that indicate Echinacea may have anti-viral, antioxidant, and anti-
inflammatory properties making it a very promising medicinal botanical (4, 11, 12).    
Alkylamides, also known as alkylamides, are a major group of lipophilic, bioactive, 
phytochemicals found abundantly in certain species of Echinacea.  Evidence indicates that 
alkylamides possess anti-inflammatory properties since they have been shown to 
significantly reduce nitric oxide production in lipopolysaccharide (LPS) stimulated 
RAW264.7 macrophages (12).  Thus, much attention is being directed toward alkylamides to 
better understand their potential use as anti-inflammatory agents as well as how they interact 
with other constituents found in Echinacea (12). 
Prostaglandin E2 (PGE2) is a critical inflammatory mediator that is produced through 
the arachidonic acid cascade. Two cyclooxygenase isoforms, COX-1 and COX-2 catalyze the 
reaction converting arachidonic acid, released by phospholipase A, to PGE2.  LPS is a 
common endotoxin used to stimulate macrophage cells to produce PGE2, mimicking an 
inflammatory response in vitro (13).  The use of RAW264.7 mouse macrophage cells has 
been established as a reliable cell model for purposes of identifying anti-inflammatory 
activity (12).   
The purpose of our study was to compare the bioactivity of species of Echinacea and 
assess levels of variability based on repeat extractions and different harvest years. It was also 
important to determine whether specific alkylamides play a clear role in the anti-
inflammatory properties of six Echinacea species.  To this end, we have conducted (to our 
knowledge) the first large scale screen of nine synthesized alkylamides found in Echinacea, 
three synthesized analogs, two of Bauer alkylamide 12 (14) and one of Chen alkylamide 2, 
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and one synthesized isomer of Chen alkylamide1 (12) for their ability to reduce LPS-
stimulated PGE2 production.  
Materials and Methods 
Plant Material and Extraction  
Plant samples were provided by Frontier Natural Products Co-op (FNPC, Norway, 
IA) and the USDA-ARS North Central Regional Plant Introduction Station (NCRPIS, Ames, 
IA).  The FNPC supplied E. purpurea, which had been harvested in Bulgaria in 1999 during 
its budding stage, where it was air-dried and, in 2001, shipped to FNPC.  Roots of plants 
representing the following ten Echinacea accessions were obtained from the NCRPIS, where 
they were harvested in October, 2004, November, 2004, and November, 2005: cultivated 
populations of E. purpurea (Ames 28189), E. angustifolia (Ames 28187), and E. pallida 
(Ames 28188), all originally acquired from Johnny’s Selected Seeds (Winslow, ME), and 
wild populations of E. purpurea (PI 631307 and PI 633665), E. angustifolia (PI 631285), E. 
pallida (PI 631293), E. simulata (PI 631251), E. sanguinea (PI 633672), and E. tennesseensis 
(PI 631250).  Information about the specific provenance of all accessions obtained from the 
NCRPIS is available on the Germplasm Resources Information Network database at 
http://www.ars-grin.gov/npgs/acc/acc_queries.html.  Roots were harvested and the plant 
material was prepared for storage by drying for 8 days at 38°C in a forced-air dryer with 
constant humidity. The dried material was ground with a 40-mesh screen and stored at -20°C 
until extraction. Extractions were made by using 6g of dried Echinacea root per population.   
Extracts were prepared by one of two methods, either the Soxhlet method (6 hours) or 
room temperature shaking (24 hours).  Solvents ranging in hydrophobicity were used for 
extraction, consisting of ethanol (70%, 95%, or 100%), water, chloroform (100%), hexane 
(100%), or sequential extractions.  Sequential extractions were performed by extracting first 
with chloroform (70%, 95%, or 100%) or hexane (70%), removal of the solvent, and then 
evaporation.  The residue plant material was re-extracted with ethanol.  FNPC plant material 
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was extracted with either 100% ethanol using the Soxhlet method (heating solvent to its 
boiling point) or shaking with 70% ethanol at room temperature.  The Soxhlet method was 
determined to yield optimal material and was therefore used to extract NCRPIS Echinacea 
material with 95% ethanol.  Upon complete drying of the extract by evaporation, the residue 
was re-dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) at the 
highest concentration that was soluble.  Extracts were stored at -30°C in the dark and used as 
stock solutions.   
Endotoxin 
Echinacea extracts from NCRPIS were all screened for endotoxin by using the 
Limulus Amebocyte Lysate Test (BioWhittaker, Inc., Walkersville, MD) according to 
manufacturer’s specifications for a microplate assay.  After accounting for the dilutions used 
in the PGE2 assay, the range of endotoxin levels presented to RAW264.7 macrophage cells 
varied between undetectable to 0.0082 EU/ml.  At these levels the endotoxin found was well 
below the required amount needed (>5 EU/ml) to induce the production of PGE2 in 
RAW264.7 cells (Hammer et al. in press).   
Cell Culture 
RAW264.7 mouse monocyte/macrophage cells were obtained from American Type 
Culture Collection (cat: TIB-71, Manassas, VA) and cultured as described by Hammer et al. 
(15).  NIH/3T3 mouse fibroblast cells, SW480 human colon cancer cells, and HaCaT human 
skin cancer cells were cultured according to procedures described by Schmitt et al. (16). 
Alkylamide Synthesis 
Chemical synthesis of Bauer (14) and Chen alkylamides (12) were conducted 
according to the procedures outlined by Wu et al. (17), Kraus and Bae (18), and the thesis of 
Jaehoon Bae (Iowa State University, 2006) (19).  The synthesized alkylamides allowed for 
the comparison of activity of purified alkylamide constituents, both those found in Echinacea 
and derivatives of those alkylamides. 
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Measurement of Prostaglandin E2  
Echinacea extract and alkylamide treatments of RAW264.7 cells and the PGE2 
enzyme immunoassay (EIA) used to detect the amount of PGE2 (GE Biosciences; 
Piscataway, NJ) were previously described by Hammer et al. (15). Preparations of E. 
purpurea extracts from FNPC were extracted with several solvents including: Soxhlet EtOH, 
room temperature (RT) EtOH, Soxhlet chloroform, Soxhlet hexane, as well as sequential 
Soxhlet extracts with chloroform/EtOH, and hexane/EtOH.  Initial screens for PGE2 
production comparing different solvents resulted in significant increases in PGE2 levels with 
all solvents except Soxhlet EtOH, RT EtOH, and Soxhlet chloroform in the absence of LPS.  
These results as well as the common use of ethanol in herbal supplements guided our lab to 
use Soxhlet EtOH extract preparations in our assays.  Also, Soxhlet EtOH extracts performed 
optimally in our assays, compared to water extracts that generally had higher endotoxin 
contamination (data not shown).  Work conducted by Bauer et al. (14) supports the use of 
ethanol extractions of Echinacea, which allow for the enrichment of lipophilic compounds 
including the ethanol-soluble alkylamides (20).  Baicalein (5,6,7-trihydroxyflavone), found 
in the Chinese medicinal herb Scutellaria baicalensis, and quercetin (3,5,7,3’4’-
pentahydroxy flavon), present in the aboveground parts of E. purpurea (21), are flavonoids 
that are known to exert anti-inflammatory as well as antioxidant effects and were used as 
positive controls for the PGE2 assay due to these properties (baicalein was synthesized by 
Iowa State University and quercetin was purchased from Sigma Aldrich, St. Louis, MO). 
Cytotoxicity 
Celltiter96 Aqueous One Solution Cell Proliferation Assay (Promega Corp., Madison, 
WI) was used to analyze cytotoxicity following a modified version of Schmitt et al.’s 
protocol (16).  RAW264.7 cells were plated into 48 well plates at a density of 
0.5x105cells/well and incubated at 37°C for 24 hours before treatment.  Treatments were 
prepared by diluting the 6g of Echinacea extract or alkylamide in DMSO and then further 
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diluting with media to the concentrations specified in the results section.  The stock extracts 
diluted to 1% of the total treatment concentration (0.1% if shown to be cytotoxic at 1%) or 
synthesized alkylamide diluted to 0.1% of the total treatment concentration were randomly 
assigned to plate wells and incubated for 24 hours (8 hours if shown to be cytotoxic at 24 
hours) along with pure media and DMSO as solvent controls.  Ursolic acid, a triterpenoid 
known for its cytotoxic activities (22), was used as a positive control at concentrations of 10 
µM, 30 µM, and 50 µM, yielding significant cytotoxicity (p<0.0001) at the two higher 
concentrations.  Following the 24 hour incubation period, treatment solutions were removed, 
and fresh media and Celltiter96 dye were added for 195 minutes, which was found to be the 
optimal incubation time for this study. The metabolized dye solutions were then transferred 
to 96 well plates for absorbance measurement at 562 nm. The number of viable cells for each 
treatment was compared to the media + DMSO control and the percent of control survival 
was determined for each extract or alkylamide. 
High Performance Liquid Chromatography Analysis 
The HPLC method was described in previously published work (17, 23).  Briefly, into 
320 µl of Echinacea extracts, 40 µl (1 mg/ml) N-isobutylundeca-2-ene-8, 10-diynamide 
(C15H21O2) and 40 µl (1 mg/ml) 3, 5-dimethoxy-4-hydroxy-cinnamic acid (C11H12O5) were 
added as internal standards for quantification of lipophilic metabolites and hydrophilic 
metabolites, respectively. Fifteen µl of each extract were injected into a HPLC.  The 
instrumentation and solvent system for HPLC separation were the same as those previously 
published (23). For compound identification, Bauer alkylamides 8/9, cichoric acid, 
echinacoside, caftaric acid, and cynarin were purchased from Phytolab, (Vestenbergsgreuth, 
Germany); chlorogenic acid was purchased from Sigma-Aldrich (St.Louis, MO, USA); and 
Bauer alkylamides 2,10-14 and ketone 20-22 were synthesized  (17, 18). Peaks were 
identified according to retention time and mass spectra obtained from LC-MS and/or GC-
MS.  In the absence of standards, Bauer alkylamides 1, 3, 4, 5, 7, 15, 16, 17 and ketone 24 
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were identified by HPLC fractionation coupled with GC-MS analysis.  Specifically, eluted 
HPLC fractions were collected and subsequently subjected to GC-MS analysis; six replicate 
runs were carried out, and appropriate peaks were pooled to ensure sufficient yield of each 
alkylamide. Compounds contained in each pooled fraction were identified by comparing their 
recorded mass spectra and online UV spectra with those from published literature (24).  
Compounds were quantified based on the internal standards.     The percent repeatability and 
limits of detection for HPLC quantification of Bauer alkylamides 2, 8/9, 10, 11, 12, 13, 14, 
ketones 20, 21, 22, caftaric acid, chlorogenic acid, cynarin, echinacoside, and cichoric acid 
with reference standards range between 1.64 – 2.86 % and 0.02 µg/ml - 0.16 µg/ml, 
respectively. The repeatability was determined by analyzing repeated injections of the 
standard solution (n = 6). The standard deviation values of the repeatability are less than 3%, 
illustrating the precision of the HPLC method. 
Statistical Analysis 
For both PGE2 data and cytotoxicity data, in separate analysis, the results were log 
transformed and normalized to the media + DMSO control allowing for the combination of 
treatments on different plates. Cytotoxicity was analyzed by using a mixed model, where the 
plate was considered a random effect.  A two-way ANOVA was used followed by a Dunnett 
multiple comparison test (25) for PGE2 and cytotoxicity assays.  Data are represented as 
percent of media + DMSO control set to 100%.  Statistical significance was defined as 
p<0.05 and 95% confidence intervals were used.  PGE2 data from alkylamide treatments 
were analyzed the same as the Echinacea extracts, except data are expressed as mean percent 
reduction as compared to media + DMSO control set at 0%.  The statistical program used for 
all analyses was SAS 9.1 (SAS Institute Inc., Cary, NC). 
Results 
Extracts from Echinacea Species Inhibit PGE2 Production  
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 To assess anti-inflammatory properties of six Echinacea species, Soxhlet EtOH 
extracts were initially screened in RAW264.7 cells at their highest concentration (ranging in 
final concentrations from 21 µg/ml to 53 µg/ml) for their ability to reduce PGE2 levels after 
stimulation with LPS (Figure 1).  Echinacea angustifolia and E. pallida extracts from 
NCRPIS and Johnny’s Selected Seeds significantly inhibited PGE2 levels at concentrations 
above 21 µg/ml.  Neither E. purpurea accession screened in Figure 1 significantly inhibited 
PGE2 (28 µg/ml of extract from NCRPIS and 24 µg/ml of extract from Johnny’s Selected 
Seeds).  Treatments analyzed without the addition of LPS reduced PGE2 levels in E. 
purpurea and E. angustifolia compared to media + DMSO control.  Baicalein and quercetin 
were included as positive controls for every PGE2 experiment. After initial screening the 
extracts were diluted to 15 µg/ml in DMSO for activity comparisons across species.  There 
was no significant difference among harvest year, accession, or Soxhlet EtOH extract 
preparation for E. purpurea (6 extracts), E. angustifolia (4 extracts), E. pallida (4 extracts), 
E. sanguinea (2 extracts), E. simulata (2 extracts), or E. tennesseensis (2 extracts), which 
allowed data to be pooled.  Of the three medicinal species, E. angustifolia and E. pallida 
significantly inhibited PGE2 levels (p<0.05) (Figure 2).  Three non-medicinal species were 
also screened for anti-inflammatory activity.  Echinacea sanguinea and E. simulata 
significantly reduced PGE2 production (p<0.001 and p<0.05, respectively).  Of the six 
species being compared in this study, E. purpurea and E. tennesseensis showed the least 
activity in this assay.  Of the four active species that reduced PGE2 production, none was 
significantly more active than the other when comparing confidence intervals across species.     
Screening for Cytotoxicity of Extracts of Echinacea Species 
To determine whether any of the NCRPIS Soxhlet EtOH extracts had the ability to 
arrest metabolic activity in RAW264.7 macrophage cells and to provide further evidence that 
the observed PGE2 reduction with treatment of Echinacea extracts was not due to 
cytotoxicity, a parallel study using the Celltiter96 Aqueous One Solution Cell Proliferation 
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Assay was conducted.  Table 1 displays an initial screening of each extract at a 1% 
concentration of extract diluted in media for a 24 hour incubation.  This initial screening used 
10-fold higher concentrations than those used in the PGE2 screens.  All extracts showed 
significant cytotoxicity (p<0.0001), with 25% - 72% survival at the 1% concentration 
(ranging from 240 to 1102 µg/ml of extract) and 24 hour incubation.   
All extracts cytotoxic at the 1% concentration were screened again at the 0.1% 
concentration of extract diluted in media (concentrations ranging from 24 to 110 µg/ml of 
extract) after a 24 hour incubation.  Results in Table 1 show that only one extract of E. 
pallida from the 2003 harvest (PI631293) remained significantly cytotoxic at the 0.1% 
dilution after a 24 hour incubation, but when this same extract was screened for cytotoxicity 
at the same dilution after an 8 hour incubation, equivalent to the incubation period in the 
PGE2 assay, no significant cytotoxicity remained (p = 0.9968).  The screens conducted at 
0.1% concentration matched concentrations used in PGE2 screens. 70%, 95% or 100%), 
Cytotoxicity Screen of Frontier National Product Co-op Echinacea purpurea Extracts  
Viability of NIH/3T3 mouse fibroblast cells, SW480 human colon cancer cells, and 
HaCaT human skin cancer cells treated with FNPC E. purpurea extracts was assessed by 
using the Celltiter96 Aqueous One Solution Cell Proliferation Assay.  Cytotoxicity was not 
observed in any of the FNPC E. purpurea extracts at a concentration of 10 µg/ml. Significant 
cytotoxicity was observed only at high concentrations (≥ 95 µg/ml of extract), with the 
exception of one extract showing significant cytotoxicity (p<0.01) at 39 µg/ml ((RT) 70% 
Hexane 24hr, SW480 cells). This extract protocol was not used in further studies.  Results 
from these data indicate that all other extracts prepared from FNPC E. purpurea showed little 
or no cytotoxicity in the three different cell lines at concentrations less than 100 µg/ml. 
Synthesized Alkylamides from Echinacea Species Inhibit PGE2 Production  
To further probe the inhibition of PGE2 production in RAW264.7 cells observed with 
treatments of Echinacea extracts, another PGE2 screening was conducted on chemically 
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synthesized alkylamides, one of Echinacea’s major classes of bioactive constituents.  Data 
from Table 2 shows that all of the synthesized alkylamides screened significantly inhibited 
the production of PGE2 (p<0.001) at 50 µM.  At 25 µM, Bauer alkylamide 8, Bauer 
alkylamide 12A analog, Bauer alkylamide 14, Chen alkylamide 2, and the Chen alkylamide 2 
analog significantly reduced PGE2 levels (p<0.05).  Only Bauer alkylamide 14 significantly 
inhibited PGE2 production at 10 µM (p<0.05).  A subsequent PGE2 EIA experiment was 
conducted to attempt to determine if PGE2 could inhibit at a concentrations less that 10 µM. 
After having stored Bauer alkylamide 14 at -24°C for one year, HPLC analysis indicated 
Bauer alkylamide 14 had degraded to 31% of the original concentration. The concentrations 
screened for PGE2 production were 3.1 µM and 0.230 µM, and Bauer alkylamide 14 was 
unable to significantly inhibit PGE2 at these concentrations (data not shown).   
Screening for Cytotoxicity of Synthesized Alkylamides   
Parallel cytotoxicity screenings were carried out for the alkylamides by using the 
Celltiter96 Aqueous One Solution Cell Proliferation Assay in RAW264.7 mouse macrophage 
cells.  The alkylamides were all screened at 50 µM for a 24 hour incubation.  None of the 13 
alkylamides demonstrated any significant cytotoxicity (85% - 113% survival), indicating that 
cell death was not a factor in the data obtained from the PGE2 screening (data not shown). 
HPLC Analysis of Echinacea Extracts at 15 µg/ml  
 High performance liquid chromatography was performed with 15 µg/ml of 
Echinacea extracts from NCRPIS to identify and analyze innate concentrations of known 
constituents (Table 3).  Echinacea angustifolia, E. sanguinea, E. purpurea, and E. 
tennesseensis contained greater quantities of Bauer alkylamides than of ketones or caffeic-
acid derivatives.  Bauer alkylamides 3 and 8-13 were present in E. angustifolia at 
concentrations greater than 0.1 µM, with Bauer alkylamide 9 reaching concentrations of 2.8 
µM and 1.6 µM in the two extracts analyzed.  All accessions of E. sanguinea also contained 
Bauer alkylamides 3, 8, 9, 12, 13, 14, and 17 at concentrations ranging from 0.16 to 1.15 µM.  
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Two different accessions of E. purpurea (PI 63665 and PI 631307) were analyzed by HPLC 
and were found to both contain similar alkylamides, including Bauer alkylamides 1-3 and 7-9 
(>0.1 µM).  Cichoric acid was present in one extract of each accession from the 2003 harvest 
of E. purpurea.  Echinacea tennesseensis (2003 and 2004 harvest) contained Bauer 
alkylamide 12 at concentrations greater than 0.3 µM and Bauer alkylamide 13 with 
concentrations greater than 0.6 µM.  Two species, E. pallida and E. simulata, were 
determined to possess greater amounts of ketones than of alkylamides.  Echinacea pallida 
had concentrations exceeding 0.1 µM for ketones 22 and 24.  Ketone 22 was also present in 
E. simulata extracts (>0.1 µM of ketone).  Chen alkylamide 1, Chen alkylamide 1 analog, 
Chen alkylamide 2 analog, Bauer alkylamide 12A analog, and Bauer alkylamide 12B analog 
from Table 2 were not detected in this analysis, but may be present in concentrations below 
the detection limits of our instrument.  Some alkylamides, ketones, and caffeic acid 
derivatives were present in only certain extracts within the species and are identified in Table 
3. 
Discussion 
The results presented in this study demonstrate the inhibition of PGE2 by several 
Echinacea species, which may be one process contributing to the reported anti-inflammatory 
capabilities of these herbs (12).  All Soxhlet EtOH extracts from the six species screened, 
when tested at their highest concentration, reduced PGE2 levels, except E. purpurea.  To 
compare inhibition potential among these species, extracts were diluted to 15 µg/ml in 
DMSO, with E. angustifolia, E. pallida, E. sanguinea, and E. simulata significantly 
inhibiting the production of PGE2 in LPS induced RAW264.7 mouse macrophage cells.  
Echinacea purpurea extracts (15 µg/ml) did not significantly inhibit PGE2, which was 
notable since many Echinacea supplements contain E. purpurea as a major ingredient (21).  
Another interesting finding was that variability between species was greater than that 
observed between repeat extractions or harvest years. Results obtained from screening 
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Echinacea extracts in RAW264.7 cells for cytotoxicity coincide with observations from 
NIH/3T3 mouse fibroblast cells, SW480 human colon cancer cells, and HaCaT human skin 
cancer cells, which found these extracts to be cytotoxic only at high concentrations (>240 
µg/ml of extract). 
Alkylamides have become a major focus for researchers studying Echinacea, due to 
their abundance in both aboveground and underground parts of the plant in most species.    
Studies link this class of compounds to a vast repertoire of immunomodulatory activities, 
including anti-viral, anti-microbial, anti-bacterial, anti-oxidant, as well as anti-inflammatory 
properties (26).  Alkylamides may be best known through recent studies indicating their 
ability to modulate the immune system, potentially, by binding to the cannabinoid 2 receptor 
(CB2) (27). This receptor has been shown to be expressed in many types of inflammatory 
and immune-competent cells and it has been suggested that the CB2 receptor may play a part 
in inflammatory reactions (28).  Alkylamides have been shown, through the use of CB1 and 
CB2 antagonists and signal transduction pathway inhibitors, to upregulate TNF-α mRNA, 
increase cAMP, p38/MAPK, and JNK signaling, as well as activate NF-kB though the CB2 
receptor in human monocyte/macrophage cells (29).   
Our results provide further support to previous studies indicating that alkylamides are 
key constituents found in Echinacea that possess anti-inflammatory properties.  Our 
experiments indicated that alkylamides are consistent inhibitors of PGE2 production at a 
concentration of 50 µM, with selected alkylamides having the capability to significantly 
inhibit PGE2 levels at concentrations of 25 µM or even 10 µM.  Although many alkylamides 
have been identified, it is possible that undescribed isomers as well as analogs of many of the 
known alkylamides may exist naturally in some of the Echinacea species, and based on our 
results, some of these may also be inhibitors of inflammatory mediators.  Cytotoxicity did not 
appear to contribute to reduced PGE2 production by extracts or alkylamides, suggesting that 
the observed inhibition was a true inhibition of PGE2 and not an artifact due to cell death.  
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The data presented strengthen the research indicating that alkylamides present in Echinacea 
contribute to immunomodulatory properties dealing with regulation of inflammation (27).  
 Questions as to how alkylamides act together and in concert with other constituents 
arise from our HPLC analysis.  Our data identify alkylamides present in crude Echinacea 
extracts at concentrations below 2.8 µM, which is well under the 10 µM concentration 
observed for inhibitory activity of PGE2 seen with chemically synthesized Bauer alkylamide 
14.  Regardless, several of the crude extracts of Echinacea, containing a variety of 
alkylamides, ketones, and caffeic-acid derivatives at low concentrations, were able to 
significantly inhibit PGE2 production.  For example, E. sanguinea extracts at 15 µg/ml, 
containing Bauer alkylamides 8, 12, 13, and 14, at higher concentrations than other 
constituents present, showed the greatest inhibition of PGE2 among the species we evaluated, 
with a percent reduction of 59%, whereas none of these alkylamides would be able to inhibit 
PGE2 production alone at such low concentrations.  Therefore, we hypothesize that the noted 
inhibition of PGE2 and, by extension, the anti-inflammatory properties found in Echinacea 
extracts was not simply due to one constituent, but several acting in a synergistic or additive 
manner.  Synergism has been reported previously between alkylamides and caffeic acid 
derivatives and their ability to inhibit the oxidation of low-density lipoproteins, as an 
indicator of antioxidant activity (4).  Our HPLC analysis revealed no clear pattern of 
identifiable constituents that led to the observed inhibition of PGE2 by extracts from E. 
angustifolia, E. pallida, E. simulata, or E. sanguinea, indicating that more research is needed 
to understand the complex nature of interacting constituents within each species and to 
determine mechanisms behind the identified PGE2 inhibition.  A possible explanation for the 
resemblance of constituents found in E. pallida and E. simulata, may be related to the 
hypothesis that E. simulata is one of the diploid progenitors of the tetraploid species, E. 
pallida (30).   A PGE2 screening of synthesized ketones and caffeic-acid derivatives 
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individually may lead to a better understanding of Echinacea’s anti-inflammatory 
capabilities.   
A study performed by Chen et al. (12) indicated that alkylamides had anti-
inflammatory activity as measured by inhibition of nitric oxide (NO) production in LPS 
stimulated RAW264.7 cells. NO is a proinflammatory mediator that was significantly 
reduced by total alkylamide (a mixture consisting of several alkylamides) ranging from 1.6 to 
30 µg/ml.  Chen et al. (12) also examined individual alkylamides and inhibition doses that 
caused reduction of LPS-mediated NO production in comparison to an LPS control.  The 
ID50 for Bauer alkylamide 2 was 54 µM, Bauer alkylamide 8 was 24 µM, Bauer alkylamide 
10 was 40 µM, Bauer alkylamide 11 was 24 µM, Bauer alkylamide 13 was 108 µM, Chen 
alkylamide 1 was 49 µM, and Chen alkylamide 2 was 35 µM.  The inhibition of NO 
measured by the ID50 corresponds to our PGE2 data in that our results show significant 
inhibition of another inflammatory mediator, PGE2, at 50 µM for all alkylamides screened, as 
well as Bauer alkylamide 8 and Chen alkylamide 2 significantly inhibiting at 25 µM.  Also, 
in that study (12), cytotoxicity sufficient to cause 50% cell death was reported for individual 
alkylamides ranging in concentration from 50 to 217 µM.  Only Bauer alkylamide 11 showed 
50% cell death at 50 µM in the Chen et al. study, which contradicts our results showing 
Bauer alkylamide 11 to produce 94% survival in the Celltiter96 Aqueous One Solution Cell 
Proliferation Assay at the same concentration.  All other alkylamides screened by Chen et al. 
(12) were at concentrations higher than those screened by our lab for cytotoxicity, perhaps 
accounting for the cytotoxicity noted in their study.   
Studies are providing convincing evidence that alkylamides can play important roles 
in the bioactivity observed in Echinacea species, and questions about the bioavailability of 
this class of constituents are still being answered.  Alkylamides have been shown to be 
readily bioavailable through the Caco-2 cell monolayer, more so than other active 
compounds, such as the caffeic-acid derivatives found in Echinacea (31).  Another study had 
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previously supported these data by finding that (2E, 4E, 8Z, 10Z)-N-isobutyldodeca -2, 4, 8, 
10-tetraenamide could be completely transported from the apical to the basolateral side of the 
Caco-2 monolayer, with no significant metabolism occurring (32).  Results from a study 
investigating the metabolism of natural and synthetic alkylamides from Echinacea by using 
human liver microsomes determined that cytochrome P450 mediated epoxidation, 
hydroxylation, and dealkylation of alkylamides occurred (33).  A recent human study 
analyzed 11 human subjects for bioavailability of an oral administration of a 60% ethanolic 
extract of E. angustifolia root, which was known to contain six identified alkylamides, 
showing that after 30 minutes one of the six alkylamides, dodeca-2E, 4E, 8Z, 10E/Z-
tetraenoic acid isobutylamide, appeared in plasma samples at 10.88 ng/ml for a 2.5 ml dose 
(34).  Another human study analyzed 9 volunteers who consumed tablets of 675mg of E. 
purpurea and 600 mg of E. angustifolia, after a high fat breakfast or after a fast, for 
alkylamide content in their plasma (35).  Total 2, 4-diene alkylamides were found in the 
plasma from the high fat group with a maximum concentration ranging from 60 - 1137 
ng/ml.  Although it is becoming increasingly evident that alkylamides are bioavailable, more 
experimentation is warranted to determine whether alkylamides can exert anti-inflammatory 
or other immunomodulatory effects at the low concentration of 10 µM, which was the lowest 
concentration found to be bioactive in our PGE2 studies.  Without more definitive 
bioavailability data, a difficulty arises in making assumptions about alkylamides anti-
inflammatory properties based on cell culture data.   
In summary, this study indicates that Echinacea extracts may be able to modulate 
inflammation though their inhibitory activity on PGE2 production and that alkylamides are 
possible key constituents in the observed anti-inflammatory properties, most likely acting 
additively or synergistically with other constituents.  Therefore, because innate 
concentrations of individual alkylamides found in crude extracts do not reach concentrations 
shown to have significant PGE2 inhibition capabilities found from tests of pure, synthesized 
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alkylamides, it is clear that the presence of individual alkylamides alone cannot explain the 
observed anti-inflammatory activity.  
Abbreviations Used 
E. = Echinacea 
PI = Plant Introduction  
FNPC = Frontier Natural Products Co-op 
NCRPIS = North Central Regional Plant Introduction Station 
PGE2 = Prostaglandin E2 
LPS = Lipopolysaccharide 
Safety 
Organic solvents, such as hexane and chloroform used for extractions, are toxic 
chemicals and should be properly handled in a fume hood.  LPS compounds are pyrogenic 
and should not be inhaled or allowed to enter the bloodstream.  
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Table 2.  Inhibition of PGE2 production by alkylamide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* p-value for comparison of alkylamide treatment to control (media + DMSO + LPS).  
Bolded p-value represent statistical significance as defined as a p-value <0.05.  Media + 
DMSO + LPS control set to 0% reduction.  There was no difference between extracts in 
media alone having an overall % reduction (95% CI) of 2 (-27, 24) and media + DMSO 
controls.  Baicalein (6 µM) and Quercetin (10 µM) were used as positive controls having 
overall % reductions (95% CI) of 72 (62, 79) and 88 (85, 91), respectively.  All samples in 
the table are treated with 1 µg/ml LPS.  Alkylamide treatments did not affect PGE2 levels 
without LPS treatment (Data not shown).  Bauer alkylamides are found in Bauer et al. (14) 
and **Chen alkylamides from Chen et al. (12).  Isomers and analogs of naturally occurring 
alkylamides are indicated with the + symbol and have not been detected to date from 
Echinacea species extracts in our laboratories.   
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Figure Legends 
Figure 1.  Inhibition of PGE2 production by Soxhlet ethanol extracts of medicinal species of 
Echinacea treated at their highest concentration (6 g of extract diluted initially in DMSO and 
then prepared as 0.1% of the media). Each bar represents three replicates ± standard 
deviation.  Dry material was obtained from the 2005 harvests grown by NCRPIS.  Johnny’s 
Selected Seeds accessions are denoted JS on the graph and PI is indicative of accessions from 
NCRPIS.  * p<0.05 and ** p<0.001 for comparison of extract to control.  Media + DMSO 
and media + DMSO + LPS treatments were represented by gray and black bars, respectively.   
Figure 2.   Inhibition of PGE2 production by extracts of three medicinal and three non-
medicinal species of Echinacea (diluted to 15 µg/ml of extract in DMSO) obtained from 
NCRPIS with different harvest dates and accession numbers.  Each species mean was 
represented by a bar (2-6 replicates each) and variability was represented as 95% confidence 
intervals of the mean.  Treatments analyzed without the addition of LPS did not affect PGE2 
levels with values for PGE2 as % of media + DMSO control less than 20% (data not shown).  
One E. angustifolia extract, from the 2004 harvest, treated without LPS, was excluded from 
the analysis based on the optical density data point being outside the standard curve.  * 
p<0.05 and ** p<0.001 for comparison of extract to control (media + DMSO + LPS).  
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Figure 1.  Inhibition of PGE2 production by medicinal species Soxhlet EtOH extracts  
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Figure 2.  Comparison of PGE2 inhibition among Echinacea species extracts 
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CHAPTER 4:  ENDOGENOUS LEVELS OF ECHINACEA 
ALKYLAMIDES AND KETONES ARE IMPORTANT 
CONTRIBUTORS TO THE INHIBITION OF PROSTAGLANDIN E2 
AND NITRIC OXIDE PRODUCITON IN CULTURED MACROPHAGES 
Modified from a paper published in The Journal of Agricultural and Food Chemistry 
Reproduced with permission from J. Ag. Food Chem. 2009, 55, (18), 7314-22. 
© 2009 American Chemical Society. 
Carlie A. LaLone, Ludmila Rizshsky, Kimberly D.P. Hammer, Lankun Wu, Avery K.S. 
Solco, Man-Yu Yum, Basil J. Nikolau, Eve S. Wurtele, Patricia A. Murphy,  Meehye Kim, 
and Diane F. Birt   
Abstract 
Due to the popularity of Echinacea as a dietary supplement, researchers have been 
actively investigating which Echinacea constituent or groups of constituents are necessary 
for immune modulating bioactivities.  Our prior studies indicate that alkylamides may play 
an important role in the inhibition of prostaglandin E2 (PGE2) production.  HPLC 
fractionation, employed to elucidate interacting anti-inflammatory constituents from ethanol 
extracts of E. purpurea, E. angustifolia, E. pallida, and E. tennesseensis identified fractions 
containing alkylamides and ketones as key anti-inflammatory contributors using 
lipopolysaccharide induced PGE2 production in RAW264.7 mouse macrophage cells.  Nitric 
oxide (NO) production and parallel cytotoxicity screens were also employed to substantiate 
an anti-inflammatory response.  Echinacea pallida showed significant inhibition of PGE2 
with a first round fraction, containing GC-MS peaks for Bauer ketones 20, 21, 22, 23, and 24, 
with 23 and 24 identified as significant contributors to this PGE2 inhibition.  Chemically 
synthesized Bauer ketones 21 and 23 at 1 µM each significantly inhibited both PGE2 and NO 
production.  Three rounds of fractionation were produced from an E. angustifolia extract. 
GC-MS analysis identified the presence of Bauer ketone 23 in third round fraction 3D32 and 
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Bauer alkylamide 11 making up 96% of third round fraction 3E40.  Synthetic Bauer ketone 
23 inhibited PGE2 production to 83 % of control and synthetic Bauer alkylamide 11 
significantly inhibited PGE2 and NO production at the endogenous concentrations 
determined to be present in their respective fraction, thus each constituent partially explained 
the in vitro anti-inflammatory activity of their respective fraction.  From this study two key 
contributors to the anti-inflammatory properties of E. angustifolia were identified as Bauer 
alkylamide 11 and Bauer ketone 23.      
Keywords: Echinacea purpurea; Echinacea angustifolia; Echinacea pallida; Echinacea 
angustifolia; Prostaglandin E2; Nitric Oxide; Bauer alkylamides; Bauer ketones; Anti-
inflammatory; Fractionation 
Introduction 
Sales of Echinacea as a botanical supplement have remained high over recent years in 
the United States reaching approximately twenty-one million dollars in 2005 (1).  The 
efficacy and health benefits of taking Echinacea as a supplement have yet to be verified 
scientifically and researchers are still unclear as to how the constituents of Echinacea act 
individually or in concert to elicit the bioactive properties that have been observed in 
numerous studies, both in vitro and in vivo (2, 3).  Although Echinacea extracts are complex 
mixtures consisting of several constituents, alkylamides and caffeic acid derivatives have 
received considerable attention recently for their abilities to modulate the immune system.  
Recent studies have shown that alkylamides of Echinacea are partially responsible for anti-
inflammatory responses such as inhibition of PGE2, TNF-α, and NO production in 
RAW264.7 mouse macrophage cells (2-5), as well as inhibition of cyclooxygenase activity in 
neuroglioma cells and other in vitro model systems (4, 6).  Studies have further validated that 
alkylamides are capable of binding to and activating the cannabinoid receptor type-2 
providing insight into the mechanism by which these constituents may modulate immune 
function (7, 8).  Caffeic acid derivatives have been associated with anti-viral and anti-oxidant 
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properties (9-11).  It has been hypothesized that alkylamides and caffeic acid derivatives 
interact, perhaps synergistically, with each other or other compounds to elicit 
immunomodulatory effects (9).   
Prostaglandin E2 is a major lipid mediator of inflammation that is produced through 
the activation of the arachidonic acid cascade, via the enzymatic activity of the 
cyclooxygenase isoforms.  The inducible nature of PGE2 production when macrophage cells 
are stimulated by lipopolysaccharide (LPS) makes this eicosanoid an ideal target for 
measuring an inflammatory response in vitro.  
Our studies were conducted to identify Echinacea constituents that are responsible for 
the previously described PGE2 inhibition (2).  Methods have been developed to quantitatively 
determine the amount of alkylamides and caffeic acid derivatives present in different parts of 
the Echinacea plant using reverse phased HPLC and GC-MS analysis (12, 13).  Semi-
preparative reverse phased HPLC was utilized to fractionate Echinacea extracts into fractions 
and sub-fractions that separate phytochemicals according to their hydrophobic properties, 
concentrating a reduced number of constituents to analyze for anti-inflammatory potential.  
Eluents from HPLC fractionations were monitored for absorbance at wavelengths of 260 nm 
and 330 nm in order to identify lipophilic alkylamides and phenolic compounds, such as 
caffeic acid derivatives.   Further fractionation was guided by identifying fractions capable of 
inhibiting PGE2 production, allowing for a thorough investigation into the hypothesized 
synergistic or additive interactions that are thought to occur among the constituents of 
Echinacea extracts and allow for the identification of key anti-inflammatory constituents 
through the use of GC-MS analysis.  In order to have a more complete view of how 
interacting constituents found in Echinacea inhibit inflammatory mediators, NO production 
was also assessed in RAW264.7 macrophage cells treated with chemically synthesized 
phytochemicals, which were identified to be important in the PGE2 assay with E. 
angustifolia. 
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Materials and Methods 
Plant Material and Extraction 
Plant materials were provided by the USDA North Central Regional Plant 
Introduction Station (NCRPIS, Ames, IA).  E. angustifolia (PI631285), E. purpurea 
(PI631307), E. pallida (PI631293), E. tennesseensis (PI631250) were used for the semi-
preparative HPLC fractionation.  Root material from each species was collected as 
previously described (2) from a 2006 harvest.  Further information about the accessions can 
be found on the Germplasm Resources Information Network database at http://www.ars-
grin.gov/npgs/acc/acc_queries.html provided by NCRPIS.  Plant materials were stored at -
20°C under nitrogen in zip-lock bags prior to use.  The Echinacea plant materials were all 
dried root powders.  They were previously washed then completely dried at 40°C forced air 
conditions, followed by grinding through a 40-mesh screen Wiley grinder (14). 
For each accession, 6 grams of Echinacea root material was extracted with 95 % 
ethanol and 5 % endotoxin-free water using Soxhlet apparatus for 6 hours for exhaustive 
extraction, following the protocol created by Liu (15).  To avoid endotoxin contamination the 
glassware was heated to 180°C for at least 2 hours prior to use.  After the extraction, the 95 
% aqueous ethanol solvent was evaporated using a Rotavap (Buchi rotavaps model R-144, R-
110, R-111, and R-200, Switzerland) to obtain the dried extract, which was weighed.  The 
dried extracts were redissolved in endotoxin-free water, and ethanol was added at a ratio of 
1:3 (water : ethanol) to obtain a concentration of no more than 0.6 g of extracted material/ml 
for a 5 ml injection though the semi-preparative HPLC fractionation.  The extracts were 
stored at -20ºC overnight prior to fractionation.  
Semi-Preparative HPLC Fractionation 
The 95 % ethanol extracts of Echinacea were filtered through a 0.45 µm filter prior to 
injection into the semi-preparative HPLC system consisting of two Beckman Model 110B 
pumps controlled by a Module406 Beckman System Gold Analogue Interface (Beckman 
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Coulter, Fullerton, CA) using a YMC-PACK ODS-AM 250*10 mm I.D. s-5 µm, 12 nm 
reversed phase C18 columns (Waters Corp.) and a 5 ml loop on a Rheodyne model 7010 
injection valve. 
Fractionation was conducted with a solvent gradient designed with acetonitrile as 
solvent B and 0.1 % HPLC grade glacial acetic acid in endotoxin-free Milli-Q water as 
solvent A.  The gradient started at 10 % B, with a flow rate of 3 ml/min, and increased to 30 
% B in 30 min.  At 30 min, the gradient increased to 90 % B over 50 min.  At 80 min, the 
gradient increased to 100 % B in 10 min.  The gradient was held at 100 % B for 20 min.  
Fraction 1 was collected in the first 30 min of the gradient.  Fraction 2 was collected between 
30 and 40 min; fraction 3 was collected between 40 and 80 min; fraction 4 was collected 
between 80 and 90 min; and fraction 5 was collected between 90 and 110 min.  Second round 
fractions were generated by collecting at 1 min intervals across the same gradient profile 
within bioactive fractions.  For bioassay purposes, subfractions of E. angustifolia Fraction 3 
(3A, 3B, 3C, 3D, and 3E) were created by pooling 8 min intervals across the 40 min of 
Fraction 3.  For example, 3B represents eluent collected between min 9 and min 16 within 
Fraction 3 (or at min 49 to min 56 of gradient time).  The third round fractions were then 
collected at 1 min intervals.  For example, Fraction 3D28 was the 3 ml fraction collected at 
28 minutes into Fraction 3 (or at min 68 of gradient time).   The fractions and subfractions 
were dried, first by removal of the organic phase by rotary evaporation, and second, by the 
amount of water by freeze-drying.  Compounds in first round fractions of all Echinacea 
species and second round fractions produced from E. angustifolia were identified using 
HPLC compared to synthetic standards.  The literature has shown that alkylamides dissolved 
in liquid form and stored at -20°C are stable over extended periods of time (15-17). 
Therefore, all fractions were diluted in dimethyl sulfoxide (DMSO, Sigma; St. Louis, MO) 
and stored at -20°C to maintain the stability of alkylamides and thawed at room temperature 
in preparation for analysis.   
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High Performance Liquid Chromatography Analysis of E. angustifolia Second Round 
Fractions 
 HPLC analysis and quantification of constituents found in second round fractions of 
E. angustifolia was performed as previously described (2). 
GC-MS Analysis 
GC-MS analyses were performed using an Agilent Technologies (Palo Alto, CA, 
USA) gas chromatograph (6890 series), equipped with a model 5973 mass detector operating 
in the electron impact ionization mode (70 eV).  The analyses were carried out by injecting in 
split-less mode.  Analytes were separated using an Agilent Technologies capillary column 
(HP-5MS fused silica column coated with 5% diphenyl 95% dimethyl polysiloxane, with the 
dimensions 30 m length x 250 µm bore, 0.25 µm film thickness).  Helium was used as the 
carrier gas at the flow rate of 1.2 ml/min.  Identification of compounds was facilitated by 
using the Agilent Technologies enhanced ChemStation Software, version D.02.00.275.   
Alkylamide and Ketone Synthesis 
Alkylamide synthesis was conducted as described previously (2).  Ketones were 
chemically synthesized according to the procedures outlined by Kraus et al. (18) and in the 
thesis of Jaehoon Bae (19).  Alkylamide and ketone concentrations were calculated after 
correcting for percent purity, yielding concentrations equivalent to 100 % pure synthetic 
constituent.  Calculated percent purity before correction for Bauer alkylamide 10 was 82 %, 
Bauer alkylamide 11 was 92 %, Bauer ketone 20 was 82 %, Bauer ketone 21 was 76 %, 
Bauer ketone 23 was 90 %, and Bauer ketone24 was 99%.  All synthetic alkylamides and 
ketones were stored at -80°C under argon gas. 
Cell Culture 
The cell culture model used for these studies was RAW264.7 mouse 
monocyte/macrophage cells that were obtained from American Type Culture Collection (cat: 
TIB-71, Manassas, VA).  All culturing conditions and procedures were previously described 
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by Hammer et al. (20) with the exception of maintaining optimal growth conditions at 95% 
humidity. 
Measurement of Prostaglandin E2  
Prostaglandin E2 production was analyzed using PGE2 enzyme immunoassay (GE 
Biosciences; Piscataway, NJ) after treating RAW264.7 mouse macrophage cells for eight 
hours with fractions from E. angustifolia, E. purpurea, E. pallida, and E. tennesseensis and 
with or without lipopolysaccharide (E. coli O26:B6, Sigma; St. Louis, MO) as previously 
described (2).  Quercetin (3, 5, 7, 3’4’-pentahydroxy flavon), a common flavanoid found in 
many plant species including Echinacea, was used as the positive control at a concentration 
of 10 µM (Sigma; St. Louis, MO).  Also, baicalein (5,6,7-trihydroxyflavone), a flavanoid 
found in the medicinal herb Scutellaria baicalensis was used as a positive control at a 
concentration of 6 µM (Synthesized by G. A. Kraus’s laboratory at Iowa State University). 
Measurement of Nitric Oxide Production 
Nitric oxide production was analyzed using Griess Reagent System (Promega; 
Madison, WI) following the manufacturers protocol.  RAW264.7 cells were plated at a 
density of 1.57 x 105 cells/ well in a 24 well cell culture plate and incubated overnight.  
Chemically synthesized ketones of Echinacea and combinations of alkylamides and/or 
ketones were then added to the cells either with or without LPS for a 24 hour time period.  
Each treatment contained four controls which were media, media + DMSO (vehicle control), 
media + LPS, and media + DMSO + LPS.  Quercetin was used as the positive control at a 
concentration of 10 µM (Sigma; St. Louis, MO).  After the 24 hour treatment period, the cell 
supernatants were collected, stored at 4°C until used in the NO assay. 
Cytotoxicity of Echinacea Fractions 
The method used to detect cytotoxicity was previously described by LaLone et al. (2) 
using the Celltiter96 Aqueous One Solution Cell Proliferation Assay (Promega Corp., 
Madison, WI).  Cytotoxicity analysis was carried out for all fractions from all Echinacea 
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species analyzed.  Each fraction was screened for cytotoxicity at concentrations comparable 
to those used in the PGE2 assay and incubated for 24 hours.  Ursolic acid (Fisher Scientific; 
Hanover Park, IL) was used as the positive control at three concentrations, 10 µM, 30 µM, 
and 50µM, with significant cytotoxicity identified at the two highest concentrations.  
Synthetic Bauer alkylamide 11 and Bauer ketone 23 were also screened for cytotoxicity after 
incubation with macrophages for 72 hours. 
Statistical Analysis 
Both log transformed PGE2 data and NO data were analyzed using randomized 
complete block design with variable levels of treatment, followed by a t-test based on pooled 
error variance to determine statistical significance compared to the (Media + DMSO + LPS) 
control.  In all figures, the data are represented as % of control ± standard error, normalizing 
the (Media + DMSO + LPS) control to 100% PGE2 or NO production within each block and 
summarizing across all blocks to obtain the mean and standard error.  The three subsamples 
of cytotoxicity values in each block were averaged before analysis as a randomized complete 
block design as above.  The cytotoxicity data are also presented as % of control ± standard 
error, normalizing the (Media + DMSO) control to 100% cell survival.  All statistical 
analysis was conducted using the GLM procedures in SAS (version 9.1, SAS Institute Inc.; 
Cary, NC). 
Results 
Fractions from E. pallida, E. purpurea, and E. tennesseensis Inhibit PGE2 Production 
In order to elucidate key constituents capable of inhibiting select inflammatory 
mediators, a Soxhlet ethanol extract of E. pallida was fractionated into five fractions and 
each was assessed for its effect on PGE2 production in RAW264.7 mouse macrophage cells.  
The analysis yielded one fraction, Fraction 3, capable of significantly inhibiting PGE2 
production (36.8 % of control) at a concentration of 5 µg/ml (Figure 1).  Another interesting 
observation was that Fraction 3, at a concentration of 5 µg/ml, inhibited PGE2 production to a 
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greater extent than the initial ethanol extract of E. pallida at a concentration of 25 µg/ml, 
indicating the importance of enriching selected constituents and separating them from others 
using fractionation.  When fraction 3 from E. pallida was diluted from 5 µg/ml to 1 µg/ml, 
inhibition of PGE2 production was still observable (71.2 % of control, p = 0.07).  In a parallel 
cytotoxicity study it was determined that the fractions from E. pallida were not cytotoxic to 
the RAW264.7 mouse macrophage cells, indicating that cell death could not account for the 
observed inhibition of PGE2 production (Figure 1).  GC-MS analysis indicated that fraction 
3 contains numerous constituents, including Bauer ketones 20, 21, 22, 23, and 24 (Figure 
2A). Quantification of Bauer ketones, 20, 21, 23, and 24 present in Fraction 3 yielded 
concentrations of 0.7 µM, 0.6 µM, 2.6 µM, and 5 µM, respectively.  Combinations of 
quantified Bauer ketones were analyzed for their ability to inhibit PGE2 production (Figure 
2B).  This analysis indicated that Bauer ketones 23 and 24 were the most important of the 
identified ketones in partially explaining the PGE2 inhibitory capabilities of Fraction 3 from 
E. pallida.  Chemically synthesized Bauer ketones 20, 21, and 23, which are constituents of 
E. pallida ethanol extracts and HPLC generated fractions (Figure 3A), were analyzed for 
their ability to inhibit PGE2 production and NO production at three concentrations (5 µM, 2.5 
µM, and 1 µM) to determine if they played a key role in the significant inhibition of PGE2 
identified with fraction 3.  It was determined that Bauer ketones 21 and 23 were capable of 
significant inhibition of PGE2 (p<0.05) and NO (p<0.0001) production at a concentration as 
low as 1 µM (Figure 3B).   
Fractionation of a Soxhlet ethanol extract of E. purpurea yielded seven fractions, 
none of which were able to significantly inhibit PGE2 production and none were found to be 
cytotoxic (Table 1). 
A Soxhlet ethanol extract of E. tennesseensis, which is a less studied species, was 
fractionated into five fractions by reverse phase HPLC in order to identify PGE2 inhibitory 
capabilities.  Fraction 3, containing Bauer alkylamides 12, 13, 14, 16, and 17, was able to 
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significantly inhibit PGE2 at a concentration of 41 µg/ml or 20 µg/ml, but when the fraction 
was diluted to 5 µg/ml its inhibitory ability was lost (Table 1).  The initial ethanol extract (59 
µg/ml) and HPLC Fraction 5 (23 µg/ml) of E. tennesseensis were significantly cytotoxic to 
the RAW264.7 cells, but due to their inability to significantly inhibit PGE2 production further 
dilutions were not carried out. 
Three Rounds of Bioactivity Guided Fractionation of an E. angustifolia Ethanol Extract  
Inhibition of PGE2 production was used to guide three rounds of HPLC fractionation 
initiated with a Soxhlet ethanol extract of E. angustifolia.  Figure 4 outlines the fractionation 
scheme.  The first round of fractionation produced 5 fractions.  The alkylamide rich fraction 
3, from E. angustifolia, was shown to significantly inhibit PGE2 production (51.1 % of 
control) at a concentration as low as 1 µg/ml (Figure 5).  Although fraction 4 had the ability 
to significantly inhibit PGE2 production at a concentration of 16 µg/ml, it proved to be 
significantly cytotoxic for the RAW264.7 cells.  Therefore, fraction 3 was identified for 
further rounds of fractionation. 
The second round of fractionation, initiated with fraction 3 from the previous round, 
yielded five second-round fractions labeled 3A through 3E.  Of these, fractions 3D and 3E, at 
a concentration of 5 µg/ml, significantly inhibit PGE2 production at 47.1 % and 38.6 % of 
control, respectively, without any obvious cytotoxicity (Figure 6A).  HPLC analysis of 
solids from 0.15 mg  second round fractions 3D and 3E led to the detection of several 
alkylamides (as detected by absorbance at 260 nm) in fraction 3D (Figure 6B), and 
identification of Bauer alkylamides 10 and 11 in fraction 3E (Figure 6C).  Concentrations of 
Bauer alkylamides 10 and 11 were estimated in fraction 3E from the HPLC analysis at 5.62 
and 9.48 µM, respectively (Table 2).  PGE2 production was analyzed to determine whether 
these chemically synthesized Bauer alkylamides, individually or in combination at the 
concentrations detected in Fraction 3E were able to explain the inhibition of PGE2 production 
observed with fraction 3E.  The combination of Bauer alkylamides 10 and 11 at the 
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concentrations detected by the HPLC analysis of fraction 3E, inhibited PGE2 production 82.6 
% of control, which indicates therefore that the two alkylamides could not be the sole 
components responsible for the observed bioactivity of fraction 3E (Figure 7).  In these 
experiments, cell viability was not significantly different than the media + DMSO control.  It 
was interesting to note that synthetic Bauer alkylamides 10 and 11 when screened alone in 
the PGE2 production assay were significantly inhibitory at the concentrations found in 
fraction 3E, but additive effects were not detected in the PGE2 production screen. The 
combination of alkylamides found in fraction 3D was not carried out as fraction 3E was more 
effective at inhibiting PGE2 production and there were several other alkylamides identified in 
fraction 3D, many of which are not synthetically available.   
A third round of HPLC fractionation was carried out starting with the material from 
second round fractions 3D and 3E to further elucidate key constituents found in E. 
angustifolia that contribute to the inhibition of PGE2 production.  Fractionation of fractions 
3D and 3E each produced eight fractions labeled fractions 3D25 through 3D32 and fractions 
3E33 through 3E40, respectively.  One of these, fraction 3D32 was significantly inhibitory of 
PGE2 production (44.9 % of control) at a concentration of 1 µg/ml (Figure 8A).  The 
fractionation of fraction 3E produced two fractions that significantly inhibited PGE2 
production at a concentration of 1 µg/ml, fraction 3E33 that inhibited PGE2 production at 
14.1 % of control, and fraction 3E40 that inhibited PGE2 production at 18.4 % of control 
(Figure 8B).  These third round fractions were not significantly cytotoxic to the RAW264.7 
mouse macrophage cells. 
GC-MS Analysis of Selected Third Round E. angustifolia Fractions 
Selected fractions from the third round fractionation of E. angustifolia were analyzed 
by GC-MS based on their activity in the PGE2 production assay (Table 3).  Fractions 3D32, 
3E33 and 3E40 were selected for GC-MS analysis due to their ability to significantly inhibit 
PGE2 production at a concentration of 1 µg/ml. Two fractions, fraction 3D28 and 3E38, were 
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also selected for further analysis because they were fractions that did not significantly inhibit 
PGE2 production.  These analyses, determined that Bauer ketone 23 is a major constituent of 
fraction 3D32, occurring at a concentration of 0.83 µM.  Bauer ketone 23 and Bauer 
alkylamide 10 were detected in 1 µg/ml of fraction 3E33 at concentrations of 0.15 µM and 
0.25 µM, respectively and Bauer alkylamide 11 was quantified to be present at a 
concentration of 3.55 µM in fraction 3E40. 
Combinations of synthetic constituents and individual synthetic constituents, 
identified to be present through GC-MS analysis of these third round HPLC fractions were 
screened for their ability to modulate PGE2 and NO production at the concentrations present 
in their respective third round fractions.  Synthetic Bauer ketone 23 was shown to 
significantly inhibit PGE2 and NO production previously at a concentration of 1 µM (Figure 
3B), and after further dilution of Bauer ketone 23 to the concentration of 0.83 µM inhibition 
of PGE2 production remained significant whereas NO production was not significantly 
inhibited (55.2 % of control and 68.2% of control, respectively) (Figure 9 for PGE2 data).  
Bauer ketone demonstrated no cytotoxicity after incubation for 72 hours (109.1% of control).   
Synthetic Bauer alkylamide 11, at a concentration of 3.55 µM significantly inhibited PGE2 
production (70.6 % of control) and NO production (75.1 % of control) (Figure 10), without 
any cytotoxicity after a 72 hour incubation (94.1% of control).  The combination of synthetic 
Bauer alkylamide 10 and Bauer ketone 23 did not inhibit PGE2 production at the 
concentrations present in fraction 3E33 (121.0 % of control).  Neither synthetic Bauer ketone 
23 alone nor the combination of Bauer alkylamide 10 and Bauer ketone 23 at the 
concentrations present in the respective bioactive fractions significantly modulated NO 
production or cell viability (p ≥ 0.09).   
Although identified alkylamides and ketones found in these bioactive fractions were 
stable under our storage and experimental conditions (analyzed by GC-MS), instability of 
bioactivity was identified with these third round bioactive fractions of E. angustifolia.  Thus, 
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although these fractions were significantly bioactive when initially assayed soon after 
fractionation, in February 2007, when these fractions were re-assayed for bioactivity when 
the synthesis of Bauer alkylamides and ketones became available in 2008, these fractions did 
not retain the same level of inhibitory activity in the PGE2 production assay at the 
concentrations previously analyzed (Table 4). 
Discussion 
The study reported here illustrates the important role Echinacea alkylamides and 
ketones play in the inhibition of the production of inflammatory mediators and the 
complexities associated with the examination of these interacting constituents.  The 
significant discoveries from the present study are the identification of Bauer ketones 21 and 
23 as potential anti-inflammatory agents capable of significant inhibition of PGE2 and NO 
production at 1 µM concentrations and the finding that chemically synthesized Bauer ketone 
23 and Bauer alkylamide 11 when screened for inhibition of PGE2 production at 
concentrations present in their respective E. angustifolia fractions, are capable of inhibiting 
and partially explaining the significant PGE2 suppression identified with their respective 
plant derived fractions.  Also, Bauer ketones 23 and 24 were identified as key components 
responsible for the inhibition of PGE2 identified with E. pallida fraction 3.  Another key 
observation is that caffeic acid derivatives found in Echinacea are not likely to be key 
contributors to the inhibition of certain inflammatory mediators due to the fact that these 
constituents were concentrated in fraction 1 of all of the species fractionated, and none of 
these fractions demonstrated the ability to significantly inhibit PGE2 production at 
concentrations ranging from 26 µg/ml to 329 µg/ml. 
Ethanol extracts from E. tennesseensis and E. purpurea were unable to produce 
fractions capable of inhibiting PGE2 production to a significant degree at concentrations 
below 5 µg/ml.  Therefore, studies on these two species ceased after the first round of 
fractionation.   
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Of the four species screened E. pallida and E. angustifolia were expected to produce 
the most active fractions because of previous results (2) indicating that extracts from these 
plants were inhibitory in the PGE2 assay.  The fractionation conducted with a ketone rich 
accession of E. pallida provided insight into the anti-inflammatory potential of ketones found 
in this species.  Compared to our previous studies that examined chemically synthesized 
alkylamides and their ability to inhibit PGE2 production (2), it appears that ketones are able 
to significantly inhibit this inflammatory endpoint at a much lower concentration.  For 
example, the most potent alkylamide (Bauer alkylamide 14) was reported to significantly 
inhibit PGE2 production, at a concentration of 10 µM (2), whereas Bauer ketone 23 could do 
so at a concentration of 1 µM.  Significant cytotoxicity was not identified for any of the 
Bauer ketones screened at concentrations below 20 µM, coinciding with a recent cell 
viability study reporting that Bauer ketone 21 had IC50 values of >100 µM and 80.13 µM in 
human pancreatic and colorectal adenocarcinoma cells, respectively (10).  By examining the 
ability of selected polyacetylenes isolated from n-hexane extracts of E. pallida to cross the 
Caco-2 monolayer, this study also provided evidence that Bauer ketones 22 and 24 are likely 
to be bioavailable, with apparent permeabilities of 32 x 10-6 cms-1 and 10 x 10-6 cms-1, 
respectively (10).  Therefore, these results warrant further elucidation with ketones found in 
other species of Echinacea to identify their full anti-inflammatory potential. 
Previous studies have shown that Echinacea polyacetylenes, generically called 
ketones, were able to modulate the multidrug transporter P-glycoprotein (Pgp), which 
bestows resistance to anticancer chemotherapy when highly expressed in cancer cells.  In a 
human kidney cell line (HK-2), made to constitutively over express high and constant levels 
of Pgp, it was determined through a bioassay-guided fractionation of an E. pallida extract 
that Bauer ketone 24 decreased the efflux of the Pgp probe calcein-AM by three-fold 
compared to the control at a concentration of 30 µM (21).  To our knowledge there are no 
reports regarding the anti-inflammatory potential of the Bauer ketones, yet there are studies 
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describing anti-inflammatory effects of polyacetylenes in other species.  For example, 
polyacetylenes of Daucus carota L. have been shown to inhibit LPS induced nitric oxide 
production in the RAW264.7 macrophage cell line (22) and polyacetylene spiroketals from 
Plagius flosculosus have been identified to inhibit LPS induced IL-1, IL-6, TNF-α, and PGE2 
production, as well as inhibit the degradation of IkB and further DNA binding of NF-kB 
(23). 
Echinacea angustifolia, classified as one of the three Echinacea medicinal species, 
has been featured in other studies due to its alkylamide rich composition (2, 24, 25).  The 
first round of HPLC fractionation of the ethanol extract of E. angustifolia yielded one 
fraction, fraction 3, which inhibited PGE2 production by 51.1% of control at a concentration 
of 1 µg/ml, therefore establishing a rationale for additional fractionation.  Results from the 
second round of HPLC fractionation yielded two fractions, fraction 3D and 3E, which 
significantly inhibited PGE2 production.  Multiple alkylamides were identified in fraction 3D, 
which made this fraction an excellent candidate for further fractionation.   
HPLC analysis of fraction 3E indicated the occurrence of two highly abundant 
alkylamides, Bauer alkylamides 10 and 11, which had previously been chemically 
synthesized for our studies (2).  We hypothesized that Bauer alkylamides 10 and 11, when 
combined at concentrations similar to those found in fraction 3E, could explain that fractions 
PGE2 inhibitory capabilities.  Synthetic Bauer alkylamide 10 and 11 individually were 
capable of significant inhibition of PGE2 production at concentrations of 5.6 µM and 9.5 µM, 
respectively.  However, the combination of synthesized Bauer alkylamides 10 and 11 at 
concentrations present in fraction 3E could not explain fraction 3E’s PGE2 inhibitory 
capabilities.  Previous studies in our lab found that individually, chemically synthesized 
Bauer alkylamide 10 and 11 were not capable of significant PGE2 inhibition at 
concentrations lower than 50 µM.  We attribute this significant change in activity to a couple 
of modifications in our screening protocol.  The first major change was using optimal growth 
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conditions for the RAW264.7 cells by setting the incubation humidity to 95% as opposed to 
our previous studies that used 70% humidity.  Second, in the current study we analyze each 
chemically synthesized preparation prior to its use as an inhibitor of PGE2 production, 
allowing for impurities in the alkylamide preparations, and normalizing to a concentration at 
100% purity; this normalization was not conducted in our previous studies of the inhibition 
of PGE2 production.  These changes have therefore allowed for greater sensitivity in our 
screening of inflammatory mediators using the RAW264.7 mouse macrophage cell line. 
GC-MS analysis of the third round of HPLC fractions of E. angustifolia identified 
Bauer ketone 23 to be present in two of these fractions; fraction 3D32 contained Bauer 
ketone 23 at a concentration of 0.83 µM, and several other unidentifiable peaks.   To our 
knowledge this is the first study to identify the presence of Bauer ketone 23 in E. 
angustifolia.  Bauer ketone 23 partially explained the inhibition of PGE2 production observed 
with fraction 3D32 (44.9 % of control) and can therefore be identified as a key constituent 
contributing to the immune modulating properties of E. angustifolia and perhaps other 
species.  Chemically synthesized Bauer alkylamide 11 showed significant inhibition of PGE2 
and NO production at the concentration that this alkylamide occurs in fraction 3E40.  
Although this constituent appeared to account for approximately 96% of the mass that 
occurred in this fraction, it only partially explained the PGE2 inhibition observed with its 
respective fraction.  Through these studies, Bauer alkylamide 11 of E. angustifolia was 
identified as another key contributor to the suppression of PGE2 and NO.  This alkylamide 
was shown to have bioactivities at concentrations relevant to those found in the plant extracts 
and contributed to anti-inflammatory properties throughout an inflammatory response 
measured via PGE2 production at eight hours and nitric oxide production at 24 hours after 
induction with LPS to induce the mouse macrophage cells.  Chen et al. previously identified 
Bauer alkylamide 11 as an inhibitor of NO production in the RAW264.7 cells with an ID50 of 
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23.9 µM (3) and our studies add to this by determining that inhibition of NO production can 
be accomplished at alkylamide concentrations available in E. angustifolia.   
Two main observations from these studies have led us to the hypothesis that other 
unidentified constituents found in Echinacea are critical components to the anti-
inflammatory potential of this botanical.  First we have demonstrated that individually Bauer 
alkylamides and ketones can significantly inhibit PGE2 and NO production, but only partially 
explain the activity found in the fractions from the species.  Also, when known constituents 
were combined at concentrations relevant to extracts and partially purified fractions there 
was no evidence of an additive or synergistic effect on inhibition of PGE2 or NO production.  
Secondly, although the concentrations of Bauer alkylamide 10 and 11, and Bauer ketone 23 
did not change over storage time throughout our studies, the most convincing argument for 
this hypothesis developed through the instability we observed throughout our studies with the 
bioactivity of E. angustifolia third round fractions.  Significant inhibition of PGE2 production 
was lost after storing selected third round fractions at -20°C for approximately one year, 
without any significant decrease in the concentrations of Bauer alkylamides and ketones.  
These observations provide evidence to the hypothesis that other unstable constituents 
contribute to the identified inhibition of PGE2 production. 
In summary, this research confirmed our previous studies that E. angustifolia and E. 
pallida are important species of Echinacea for discovering the anti-inflammatory properties 
of this botanical genus, and further allowed for the identification of constituents that are key 
contributors to those properties.  From the fractionations of E. pallida and E. angustifolia 
extracts two major compounds, Bauer alkylamide 11 and Bauer ketone 23, were identified to 
play a key role in the inhibition of PGE2 by RAW264.7 mouse macrophage cell model.  
These constituents were also identified as inhibitors of NO production, indicating that they 
are important mediators for an extended period throughout the inflammatory response.  The 
analysis of Bauer ketone 23 at the concentration present in fraction 3D32, and of Bauer 
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alkylamide 11 at the concentration present in fraction 3E40, indicates that more studies 
should be directed toward the identification and synthesis of known and unknown 
compounds and the roles they may play, either individually or in concert with known 
constituents, to modulate mediators of the inflammatory response.   
The results obtained from this study may pave the way for the production of 
Echinacea species that are better suited for anti-inflammatory medicinal purposes.  These 
could be produced through the fabrication of genetically modified plants, the detection of 
other plant organs and tissues that are rich in specific constituents, or the identification of 
optimal growth conditions for the enhanced availability of constituents such as Bauer ketones 
21, 23, and 24 and Bauer alkylamides 10 and 11.  
Abbreviations Used 
E. = Echinacea 
PI = Plant Introduction  
DMSO = Dimethyl Sulfoxide 
PGE2 = Prostaglandin E2 
NO = Nitric Oxide 
LPS = Lipopolysaccharide 
GC-MS = Gas Chromatography Mass Spectrometry 
HPLC = High Performance Liquid Chromatography 
ID50 = Inhibition Dose producing 50 % inhibition 
Safety 
LPS compounds are pyrogenic and should not be inhaled or allowed to enter the 
bloodstream.  
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Table 2.  HPLC analysis of the constituents found in E. angustifolia Fractions 3D and 3Ea 
 Fraction 3D 
Metabolite Concentration 
Fraction 3E 
Metabolite Concentration 
Metabolite (µg/ml) (µM) (µg/ml) (µM) 
Chen  Alkylamide 2 0.7 0.2 0.0 0.0 
Bauer Alkylamide 5 2.1 0.5 0.0 0.0 
Bauer Alkylamide 8 36.6 9.0 0.0 0.0 
Bauer Alkylamide 9 15.3 3.8 0.0 0.0 
Bauer Alkylamide 10 0.0 0.0 22.6 5.6 
Bauer Alkylamide 11 0.1 0.03 37.8 9.5 
Bauer Alkylamide 14 2.1 0.5 0.0 0.0 
Bauer Alkylamide 16 0.8 0.2 0.0 0.0 
Bauer Alkylamide 17 1.7 0.5 0.0 0.0 
aHPLC analysis identified alkylamides present in 10 µg/ml of second round fractions 3D and 
3E, as well as the metabolites concentration in µM.  Structures of alkylamides have been previously 
described (2, 6). 
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Table 3. GC-MS analysis of selected third round E. angustifolia fractionsa 
 
Echinacea 
angustifolia 
Fraction 
Compound Identified 
% of 
Fraction 
by Dry 
Weight 
Approximate 
Concentration 
of Compound 
(µg) 
Approximate 
Concentration 
of Compound 
(µM) 
3D28 Bauer Alkylamide 8-9 18 0.18 0.64 
3D32 Bauer Ketone 23 75 0.75 0.83 
3E33 Bauer Alkylamide 10 Bauer Ketone 23 
34 
12 
0.34 
0.12 
0.15 
0.25 
3E38 Bauer Alkylamide 11 87 0.87 3.47 
3E40 Bauer Alkylamide 11 96 0.96 3.55 
aGC-MS analysis identified constituents present in 1 µg/ml of third round fractions, as well 
as the metabolites concentration.  All identified constituents were confirmed via synthetic standards.  
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Table 4. Change in PGE2 activity over storage time with third round E. angustifolia fractions 
 
E. angustifolia  
Fraction 
PGE2 production 
(% of control) 
August 2007 
PGE2 production 
(% of control) 
June 2008 
3E33 14.1 ± 6.9** 133.1 ± 43.5 
3E40 18.4 ± 6.1** 81.0 ± 3.9 
** indicates significant p-value <0.0001.  Bauer Alkylamides and Ketones identified to be present 
in Table 3 were quantified prior to PGE2 analysis in 2007 and again after PGE2 analysis in 2008 
yielding no difference in these constituent concentrations.  Data represents % of control ± standard 
error, with 100 % of control for 2007 Fractions 3E33 and 3E40 at 1.9 ng/ml and for 2007 Fraction 
3E33 and 3E40 at 3.5 ng/ml and 4.7 ng/ml, respectively. 
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Figure Legends 
Figure 1. Fraction 3 from a 2005 extract of Echinacea pallida (PI631293) significantly 
inhibited PGE2 production in RAW264.7 cells.  The black bars represent PGE2 levels after 
induction with 1 µg/ml LPS and treatment with an Echinacea fraction or ethanol extract (n = 
3).  All treatments + LPS were compared to media + DMSO + LPS control that was set at 
100 % (2.0 ng/ml).  Treatments were also performed without LPS induction showing no 
significant reduction in PGE2 production (p ≥ 0.21).  The treatments without LPS were 
compared to the media + DMSO control set at 100 % (0.2 ng/ml).  Media alone did not 
inhibit PGE2 production (104 % of control). Baicalein and quercetin were used as positive 
controls and showed significant inhibition of PGE2 production (p<0.001). Parallel 
cytotoxicity screens were conducted yielding no significant cytotoxicity with any of the E. 
pallida fractions (data not shown).  * and ** are representative of p<0.05 and p<0.001.  Each 
bar represents % of control ± standard error.   
Figure 2. (A) GC-MS chromatogram of fraction 3 from E. pallida, identifying key ketones.  
All identified constituents were confirmed via synthetic standards.  (B)  Significant inhibition 
of LPS induced PGE2 production in RAW264.7 cells after treatment with chemically 
synthesized Bauer ketones at concentrations present in fraction 3 from E. pallida.   The black 
bars represent PGE2 levels after induction with 1 µg/ml LPS and treatment with an 
Echinacea fraction or synthetic Bauer ketone (n = 3).  All treatments + LPS were compared 
to media + DMSO + LPS control that was set at 100 % (5.6 ng/ml) with the combination of 
Bauer ketones 21, 23, and 24 showing significant reduction of PGE2 production (p = 0.032). 
Treatments were also performed without LPS induction and compared to the media + DMSO 
control set at 100 % (0.03 ng/ml) and no significant changes were observed with any of the 
treatments in this comparison.  Media alone did not inhibit PGE2 production (99 % of 
control). * and ** are representative of p<0.05 and p<0.001.  Each bar represents % of 
control ± standard error.  Quercetin was used as the positive control. 
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Figure 3.  (A)  Structures and nomenclature for Bauer ketones identified in Fraction 3 from 
E. pallida.  (B)  Significant inhibition of LPS induced PGE2 and NO production in 
RAW264.7 cells after treatment with chemically synthesized Bauer ketones 21 and 23.   The 
black bars represent PGE2 levels and the white bars represent NO levels after induction with 
1 µg/ml LPS and treatment with a ketone (n = 3).  All treatments + LPS were compared to 
media + DMSO + LPS control that was set at 100 % PGE2 production (3.7 ng/ml) and NO 
production (12.4 ng/ml).  Treatments were also performed without LPS induction showing 
significant reduction of PGE2 production with Bauer ketone 21 at 1 µM (p = 0.046). The 
treatments without LPS were compared to the media + DMSO control set at 100 % PGE2 
production (0.02 ng/ml).  There was no significant difference in NO production in treatments 
without LPS.  Quercetin was used as a positive control for both studies and showed 
significant inhibition of PGE2 and NO production (p<0.0001). * and ** are representative of 
p<0.05 and p<0.001.  Each bar represents % of control ± standard error.  Parallel cytotoxicity 
screens were conducted yielding no significant cytotoxicity with any of the chemically 
synthesized Bauer ketones (data not shown) 
Figure 4. Semi-preparative reverse phased HPLC fractionation scheme of E. angustifolia 
extract from 2006 harvest (PI631285).  Bolded fractions represent those showing significant 
inhibition of LPS induced PGE2 production.  Numbers in parenthesis indicate % of control ± 
standard error of PGE2 production compared to the media + DMSO + LPS control set at 
100% PGE2 production.  * and ** are representative of p<0.05 and p<0.001.  See figures 4-8 
for details on PGE2 data including concentrations studied. 
Figure 5. Inhibition of LPS induced PGE2 production and cytotoxicity analysis after 
treatments with first round fractions from a 2006 extract of E. angustifolia (PI631285) in 
RAW264.7 cells.  The black bars represent PGE2 levels after induction with 1 µg/ml LPS and 
treatment with an Echinacea fraction or ethanol extract (n = 3).  All treatments + LPS were 
compared to media + DMSO + LPS control that was set at 100 % PGE2 production (2.2 
127 
ng/ml).  Treatments were also performed without LPS induction showing significant 
reduction of PGE2 with fractions 1, 3, 4, and ethanol extract (p ≤ 0.035).  The treatments 
without LPS were compared to the media + DMSO control set at 100 % PGE2 production 
(0.1 ng/ml).  Grey bars symbolize cell survival compared to the media + DMSO control set at 
100 % cell survival.  Baicalein was used as the positive control in the PGE2 analysis and 
showed significant inhibition of PGE2 production (p<0.0001).  ND indicates analysis not 
determined.  Ursolic acid was used as a positive control in the cytotoxicity assay and showed 
significant cell death at 30 µM and 50 µM (p<0.0001).  Media alone was also used as a 
negative control showing no significant inhibition of PGE2 or cytotoxicity.  * and ** are 
representative of p<0.05 and p<0.001.  Since fraction 3 showed no cytotoxicity at 5 µg/ml it 
was not assessed for cytotoxicity at 1 µg/ml.  Each bar represents % of control ± standard 
error.  
Figure 6. (A) Inhibition of LPS induced PGE2 production in RAW264.7 cells after 
treatments with second round fractions from fraction 3 of E. angustifolia (from figure 4).   
The bars represent PGE2 levels after induction with 1 µg/ml LPS and treatment with an 
Echinacea fraction or ethanol extract (n = 3).  All treatments + LPS were compared to media 
+ DMSO + LPS control that was set at 100 % PGE2 production (1.8 ng/ml).  Treatments 
were also performed without LPS induction showing significant reduction of PGE2 with 
fraction 3 and 3E (p ≤ 0.029).  The treatments without LPS were compared to the media + 
DMSO control set at 100 % PGE2 production (0.1 ng/ml).  Baicalein and quercetin were used 
as positive controls.  Parallel cytoxicity screens were conducted yielding no significant 
cytotoxicity with any of the fractions (Data not shown).  * and ** are representative of 
p<0.05 and p<0.001.  Each bar represents % of control ± standard error. (B) HPLC 
chromatograms of second round fractions 3D and (C) 3E, identifying key alkylamides 
(Quantification from HPLC present in Table 2). Black lines represent 260 nm and grey lines 
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represent 330 nm. The internal standard used for both (B) and (C) was N-isobutylundeca-2-
ene-8, 10-diynamide (C15H21O2). 
Figure 7. Combination of Bauer alkylamides 10 and 11 at the concentrations found in 
fraction 3E (Table 2).  The bars represent PGE2 levels after induction with 1 µg/ml LPS and 
treatment with an Echinacea fraction (n = 3). All treatments + LPS were compared to media 
+ DMSO + LPS control that was set at 100 % PGE2 production (4.4 ng/ml).  Treatments 
were also performed without LPS induction showing significant reduction of PGE2 with 
fraction 3E (p = 0.0275).  The treatments without LPS were compared to the media + DMSO 
control set at 100 % PGE2 production (0.2 ng/ml).  Quercetin was used as the positive 
control.  * and ** are representative of p<0.05 and p<0.001.  Each bar represents % of 
control ± standard error. 
Figure 8. (A) Inhibition of LPS induced PGE2 production analysis after treatments with E. 
angustifolia third round D fractions.  The black bars represent PGE2 levels after induction 
with 1 µg/ml LPS and treatment with an Echinacea fraction or ethanol extract (n = 3).  All 
treatments + LPS were compared to media + DMSO + LPS control that was set at 100 % 
PGE2 production (2.8 ng/ml).  Treatments were also performed without LPS induction 
showing significant reduction of PGE2 with fractions 3D, 3D26, 3D27, 3D30, and 3D31 (p ≤ 
0.04).  The treatments without LPS were compared to the media + DMSO control set at 100 
% PGE2 production (0.2 ng/ml).  Baicalein was used as a positive control (p<0.05).  Parallel 
cytoxicity screens were conducted yielding no significant cytotoxicity with any of the third 
round fractions.  * and ** are representative of p<0.05 and p<0.001.  Each bar represents % 
of control ± standard error.  (B) Inhibition of LPS induced PGE2 production after treatments 
with E. angustifolia third round E fractions.  The black bars represent PGE2 levels after 
induction with 1 µg/ml LPS and treatment with an Echinacea fraction or ethanol extract (n = 
3).  All treatments + LPS were compared to media + DMSO + LPS control that was set at 
100 % PGE2 production (1.9 ng/ml).  Treatments were also performed without LPS induction 
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showing significant reduction of PGE2 with fractions 3E, 3E33, 3E34, 3E36, 3E37, and 3E38 
(p ≤ 0.027).  The treatments without LPS were compared to the media + DMSO control set at 
100 % PGE2 production (0.1 ng/ml).  Baicalein was used as a positive control (p<0.05).  
Parallel cytoxicity screens were conducted yielding no significant cytotoxicity with any of 
the third round fractions.  * and ** are representative of p<0.05 and p<0.001.  Each bar 
represents % of control ± standard error. 
Figure 9. Inhibition of LPS induced PGE2 production after treatment of synthetic Bauer 
ketone 23 at concentration present in third round E. angustifolia fraction 3D32.  The black 
bars represent PGE2 levels after induction with 1 µg/ml LPS and with the ketone or fraction 
(n = 3).  All treatments + LPS were compared to media + DMSO + LPS control that was set 
at 100 % PGE2 production (3.8 ng/ml).  Treatments were also performed without LPS 
induction showing no significant differences in PGE2 production.  Quercetin was used as a 
positive control. * and ** are representative of p<0.05 and p<0.001.  Each bar represents % 
of control ± standard error.  A parallel cytotoxicity screen was conducted yielding no 
significant cytotoxicity with Bauer ketone 23 at the concentrations measured (data not 
shown). 
Figure 10. Significant inhibition of LPS induced PGE2 and NO production in RAW264.7 
cells after treatment with chemically synthesized Bauer alkylamide 11.   The black bars 
represent PGE2 levels and the white bars represent NO levels after induction with 1 µg/ml 
LPS and treatment with alkylamide (n = 3).  All treatments + LPS were compared to media + 
DMSO + LPS control that was set at 100 % PGE2 production (4.7 ng/ml) and NO production 
(11.6 ng/ml).  Treatments were also performed without LPS induction showing no significant 
differences in PGE2 or NO production. ND indicates analysis not determined.  Quercetin was 
used as a positive control for both studies and showed significant inhibition of PGE2 and NO 
production at 10 µM (p<0.0001). * and ** are representative of p<0.05 and p<0.001.  Each 
bar represents % of control ± standard error.  Parallel cytotoxicity screens were conducted 
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yielding no significant cytotoxicity with Bauer alkylamide 11 at the concentrations screened 
(data not shown). 
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Figure 1.  
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Figure 2. 
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Figure 4. 
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Figure 5. 
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Figure 6.  
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Figure 9. 
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Figure 10. 
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CHAPTER 5: ENRICHMENT OF ECHINACEA ANGUSTIFOLIA WITH 
BAUER ALKYLAMIDE 11 AND BAUER KETONE 23 INCREASED 
ANTI-INFLAMMATORY POTENTIAL THROUGH INTERFERING 
WITH COX-2 ACTIVITY 
Modified from a paper to be submitted to the Journal of Agricultural and Food Chemistry 
Carlie A. LaLone, Nan Huang, Ludmila Rizshsky, Man-Yu Yum, Navarozedeep Singh, 
Cathy Hauck, Basil J. Nikolau, Eve S. Wurtele, Marian L. Kohut, Patricia A. Murphy, and 
Diane F. Birt  
Abstract 
Previous studies have indicated that Bauer alkylamide 11 and Bauer ketone 23 were 
key compounds from Echinacea angustifolia that were partially responsible for the anti-
inflammatory properties identified with this botanical.  We hypothesized through the 
enrichment of an E. angustifolia fraction with chemically synthesized Bauer alkylamide 11 
and Bauer ketone 23, that an elevated anti-inflammatory response would be achieved 
compared to the fraction itself, measured by the inhibition of prostaglandin E2 (PGE2) and 
nitric oxide (NO) production by lipopolysaccharide (LPS) induced RAW264.7 mouse 
macrophage cells.  Using microarray, qRT-PCR, western blots, and activity assays we set out 
to explain the molecular mode of action leading to the inhibition of PGE2 production after 
treatments with fraction, enriched fraction, combination of Bauer alkylamide 11 and Bauer 
ketone 23, and these compounds individually.  It was determined that the enriched fraction 
was capable of a more potent inhibition of LPS induced PGE2 than the fraction alone, 
although NO production was not affected by either treatment.  From the microarray analysis, 
no differentially expressed genes were identified with the treatments compared to the control 
after an eight hour treatment.   Follow-up time-course qRT-PCR studies indicated a 
significant decrease in TNF-α and an increase of iNOS with a 24 hr incubation of treatment 
with the LPS induced RAW264.7 cells.  Interestingly, LPS induced COX-2 protein was 
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significantly increased by the fraction and Bauer ketone 23 individually.  COX-2 activity was 
significantly decreased with all treatments after an eight hour incubation.  In conclusion these 
studies provide evidence that the identified inhibition of PGE2 production was due to the 
direct targeting of Echinacea products to the COX-2 enzyme.    
Keywords:  Echinacea angustifolia; Prostaglandin E2; Nitric Oxide; Bauer Alkylamides; 
Bauer Ketones; Anti-inflammatory; Fractionation 
 Introduction 
Echinacea has been used medicinally for hundreds of years for the treatment of 
numerous ailments, including inflammation (1).  Several studies have been conducted to 
elucidate the cellular mechanism of action for the immune modulatory properties of 
Echinacea (2-5).  These studies have mainly focused on one particular class of compounds of 
Echinacea, alkylamides, and their ability to interact with cannabinoid receptors. 
The cannabinoid receptors, CB1 and CB2, are G protein coupled receptors that have 
been implicated in the modulation of the central nervous system and the inflammatory 
response.  CB1 receptors are found in neurons from the central and peripheral nervous 
system and concentrated in the brain, while CB2 receptors are mainly in immune cells, 
including macrophages (6).  Studies attempting to unravel the mechanism of action for the 
immune modulatory effects of Echinacea have led to the finding that alkylamides, which are 
a class of constituents prominent in certain Echinacea species, can act as cannabinomimetics 
(7).  Endogenous ligands for the cannabinoid receptors include anandamide (AEA) and 2-
arachidonyl glycerol (2-AG) sharing structural similarity with Echinacea alkylamides (8). 
Previous studies have determined that certain alkylamides have the ability to bind the CB2 
receptor having Ki values around 60 nM with greater affinity than the natural ligands (7).  
The role of the CB2 receptor in the immune modulatory effect of Echinacea was further 
strengthened by Gertsch et al. who provided evidence that the gene expression of an 
important inflammatory cytokine released by macrophage cells, tumor necrosis factor alpha 
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(TNF-α), was induced via the CB2 receptor by a standardized preparation of Echinacea 
called Echinaforce™ (3).  This activity was attributed to certain alkylamides present in the 
Echinaforce™ preparation, including Bauer alkylamide 11 at 0.5 µM.  Recently Echinacea 
ketones have been shown to have anti-tumorigenic and anti-inflammatory properties (9, 10).  
Therefore, Egger et al. set out to determine whether various ketoalkenes or ketoalkenynes of 
E. pallida could mediate their immune modulatory effects through the cannabinoid receptors, 
identifying no significant activity (2). 
Significant inhibition of prostaglandin E2 (PGE2) and nitric oxide (NO) production 
have been achievable with the treatment of Echinacea extracts, fractions, and pure 
constituents providing two excellent endpoints for the elucidation of species, as well as 
classes of compounds, that are important for the in vitro anti-inflammatory properties of 
Echinacea (10-13). Enzymes upstream of these endpoints, such as cyclooxygenase-2 (COX-
2) and inducible nitric oxide synthase (iNOS), for PGE2 and NO respectively, have been 
studied in order to further delineate how Echinacea modulates inflammation.  Due to the 
involvement of the arachidonic acid cascade in the production of PGE2 Muller-Jakic et al. 
determined that alkylamides isolated from an Soxhlet n-hexane extract of E. angustifolia 
were capable of inhibiting both cyclooxygenase and 5-lipoxygenase activity in vitro (14).  
Another study showed that certain alkylamides from a CO2 extract of E. angustifolia 
abrogate COX-2 activity, but have no effect on COX-2 mRNA or protein in neuroglioma 
cells (15).  Zhai et al. described the inhibition of NO identified with Soxhlet ethanol extracts 
of E. angustifolia, E. pallida, and E. purpurea was due to an inhibition of iNOS protein 
expression, attributing this effect to the lipophilic alkylamides (13).   
The presence of Bauer alkylamide 11 at a concentration of 3.55 µM and Bauer ketone 
23 at 0.83 µM of E. angustifolia fractions capable of inhibition of prostaglandin E2 was a 
key finding in our laboratory (10).  During a re-fractionation of E. angustifolia we identified 
a first round fraction capable of significant PGE2 inhibition, but to a lesser extent than 
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previously identified in our prior studies.  It was determined that the decreased activity may 
be due to the lower concentration of Bauer alkylamide 11 and the absence of Bauer ketone 23 
in the new fraction.  This observation led to the hypothesis that through enrichment of 
Echinacea products with certain constituents at the proper concentrations it may be possible 
to tailor this botanical to effectively target specific bioactivities.  Our studies were conducted 
to examine how enrichment of an E. angustifolia fraction with Bauer alkylamide 11 and 
Bauer ketone 23, as well as these synthetic compounds in combination or individually 
influence PGE2 and NO production in the RAW264.7 mouse macrophage cell line and 
further elucidate a mechanism of action leading to the modulation of these inflammatory 
endpoints.   
Materials and Methods 
Plant Material and Extraction 
E. angustifolia (PI636395) root material was provided by the USDA North Central 
Regional Plant Introduction Station (NCRPIS, Ames, IA) and collected, stored, and Soxhlet 
ethanol extracted as previously described (11). Further information about the accessions can 
be found on the Germplasm Resources Information Network database at http://www.ars-
grin.gov/npgs/acc/acc_queries.html provided by NCRPIS.   
Semi-Preparative HPLC Fractionation 
The fractionation of a 95 % ethanol extract of Echinacea angustifolia was conducted 
using Semi-Preparative HPLC using methods to avoid endotoxin contamination as previously 
described (10). 
GC-MS Analysis 
GC-MS analyses was used to determine concentrations of known compounds present 
in E. angustifolia fractions through the use of synthetic standards as described by LaLone et 
al. (10). 
Alkylamide and Ketone Synthesis 
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Alkylamide and ketone synthesis was conducted as described previously accounting 
for percent purity when determining concentrations of compounds (10, 11). 
Cell Culture 
RAW264.7 mouse monocyte/macrophage cells were purchased from American Type 
Culture Collection (cat: TIB-71, Manassas, VA).  The conditions under which the cells were 
cultured have been previously described (11, 16). 
Echinacea angustifolia Fraction and Constituent Treatments 
 Five treatments were consistently used for each assay, which were: (1) E. angustifolia 
fraction 3 at 1 µg/ml; (2) enriched fraction 3 consisting of E. angustifolia fraction 3 at 1 
µg/ml (which contained Bauer alkylamide 11 at a concentration of 0.05 µM), synthetic Bauer 
alkylamide 11 at 3.5 µM, and Bauer ketone 23 at 0.83 µM; (3) the combination of Bauer 
alkylamide 11 at 3.55 µM and Bauer ketone 23 at 0.83 µM; (4) chemically synthesized Bauer 
alkylamide 11 at 3.55 µM; and (5) chemically synthesized Bauer ketone 23 at 0.83 µM. 
Measurement of Prostaglandin E2, Nitric Oxide, and Cytotoxicity   
The production of prostaglandin E2 was assessed using a PGE2 enzyme immunoassay 
(GE Biosciences; Piscataway, NJ) after treating RAW264.7 mouse macrophage cells for 
eight hours with fractions from E. angustifolia and with or without lipopolysaccharide (E. 
coli O26:B6, Sigma; St. Louis, MO) as previously described (11). Quercetin (3, 5, 7, 3’4’-
pentahydroxy flavon), was chosen as the positive control for this assay due to its anti-
inflammatory properties at a concentration of 10 µM (Sigma; St. Louis, MO).   
Nitric oxide production was analyzed after a 24 hour incubation with Echinacea 
fraction or pure constituent using Griess Reagent System (Promega; Madison, WI) following 
the manufacturers protocol.  The assay has been previously described using the RAW264.7 
cell line and outlined in LaLone et al. (10). 
Cytotoxicity was analyzed using the Celltiter96 Aqueous One Solution Cell 
Proliferation Assay (Promega Corp., Madison, WI) as previously described (11). Each 
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fraction and compound was screened for cytotoxicity at the concentrations in the PGE2 assay 
and incubated for 24 hours.   
Western blots 
RAW264.7 cells were grown in 10 cm Petri dishes to 80% confluency (overnight) 
and treated for eight hours.  Cells were washed twice with ice cold 1X phosphate buffered 
saline (PBS) and lysed on ice for 5 minutes with 500 µl of lysis buffer (50 mM Tris-
hydrochloride, 2mM ethylenediamine tetraacetic acid, 2 mM ethylene glycol tetraacetic acid, 
150 mM sodium chloride, 2 mM phenylmethanesulphonylfluoride, 25 mM leupeptin, 10 mM 
aprotinin, 10 mM sodium fluoride, 10 mM sodium orthovanadate, 10 mM sodium 
pyrophosphate, 0.5% Triton X-100).  After lysis, the cells were collected using a rubber 
policeman and centrifuged at 4°C to form cell pellet.  The supernatant was isolated and the 
protein concentration in the cell lysate was identified using the BCA Protein Assay Reagent 
(Pierce, Rockford, IL).  COX-1 (sc-19998), COX-2 (sc-19999), iNOS (sc-7271) and α-
tubulin mouse monoclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were 
diluted 1:2000, 1:1000, 1:600, and 1:2000, respectively in 5% milk Tris buffered saline 
containing 0.5% Tween-20.  Immunoblot separation was carried out as described by 
Przybyszewski et al. (17) and visualized using ECL detection.  ImageQuaNT software was 
used for semi-quantitative analysis as previously described (18). 
RNA extraction and DNAse digestion 
RAW264.7 mouse macrophage cells were grown in 75cm flasks to 80% confluency 
and treated for eight hours for the microarray study.  The cells were grown in 6 well plates to 
80% confluency for the qRT-PCR studies collected at six separate time points (0.5 h, 1 h, 2 
h, 4 h, 8 h, and 24 h).  The treatments selected for the qRT-PCR studies were E. angustifolia 
fraction 3, enriched fraction 3, the combination of Bauer alkylamide 11 and Bauer ketone 23, 
and these constituents individually.  These treatments were incubated with and without LPS.  
Cells were collected using a rubber policeman after washing flask or plate twice with PBS.  
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The Trizol method (Invitrogen, Carlsbad, CA) of extraction was used to isolate RNA and 
further purification was carried out using an RNeasy purification kit in combination with an 
RNAse-free DNAse kit (Qiagen, Valencia, CA).  Following extraction, RNA was analyzed 
for quality and quantity using an Agilent Bioanalyzer 2100 and RNA Nano 6000 Labchip kit 
(Agilent Technologies, Palo Alto, CA).   
Microarray 
The microarray experiment was carried out using the GeneChip® Mouse Genome 
430A 2.0 Array, which consisted of approximately 22,600 probe sets, representing 14,500 
well-substantiated genes (Affymetrix, Santa Clara, CA).  The five treatments selected for the 
microarray analysis were the media + DMSO and media + DMSO + LPS controls, and E. 
angustifolia fraction 3 (1 µg/ml) + LPS, fraction 3 (1µg/ml) + synthetic Bauer alkylamide 11 
(3.5 µM) + Bauer ketone 23 (0.83 µM) + LPS, and synthetic Bauer alkylamide 11 (3.55 µM) 
+ Bauer ketone 23 (0.83 µM) + LPS.  The controls were used to establish that the LPS effect 
was consistent with current literature.  Our study was designed to determine differentially 
expressed (DE) genes important for the inhibition of LPS induced PGE2 production, 
therefore treatments without LPS were not included in the microarray study.  Four replicates 
of each treatment were analyzed on separate chips and RNA labeling was performed 
according to manufacturer (Affymetrix, Santa Clara, CA).  The gene chips were ran using a 
Gene Chip fluidics station 450 and a GeneChip Scanner 3000 7G conducted at the Gene Chip 
Facility at Iowa State University.   
qRT-PCR 
An iScript cDNA synthesis kit (BioRad, Hercules, CA) was used to reverse-transcribe 
RNA to cDNA.  Primers were designed with an annealing temperature of 55°C for COX-1, 
COX-2, TNF-α, iNOS, and GADPH using Primer3 (19) and procured from Integrated DNA 
Technologies, Inc. (Coralville, IA) (Table 1).   Amplification conditions for the qRT-PCR 
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were set at 95°C for 3 minutes, and 40 cycles of 95°C for 30 seconds, 56°C for 30 seconds, 
and 72°C for 30 seconds, followed by 95°C for 1 minute, and 55°C for 1 minute. 
Plasmid preparation for standard curves has been described previously (Hammer et 
al., unpublished), with the exception that PCR products were cloned into MAX Efficiency® 
DH5α™ Competent Cells. 
COX activity assay 
COX activity was measured using a COX Fluorescent Activity Assay Kit according 
to manufacturer’s directions (Cayman Chemicals, Ann Arbor, MI) after an 8 hour treatment 
with E. angustifolia fraction 3, enriched fraction 3, combination of Bauer alkylamide 11 and 
Bauer ketone 23, as well as these constituents individually (with and without LPS).  The 
assay measures the peroxidase component of the cyclooxygenase enzymes by monitoring the 
reaction between PGG2 and 10-acetyl-3, 7-dihydroxyphenoxazine after the addition of 
arachidonic acid, which generates the fluorescent compound resorufin.  The common plant 
flavanoid, quercetin, was used as a positive control at 25 µM. 
Milliplex 
RAW264.7 cells were plated in 24 well plates (1.57 x 105 cells/well) and grown 
overnight. The treatments that were selected for analysis were the E. angustifolia fraction 3, 
enriched fraction 3, the combination of Bauer alkylamide 11 and Bauer ketone 23, and these 
constituents individually.  Each treatment was applied with and without LPS induction (1 
µg/ml) and treated for twenty four hours.  After the twenty four hour treatment the 
supernatant was collected for the assay.  Supernatant was analyzed using the 
MILLIPLEXMAP Mouse Cytokine 32plex Panel following the manufacturer’s protocol 
(Millipore, Billerica, MA). 
Statistical Analysis 
Both log transformed PGE2 data and NO data were analyzed using randomized 
complete block design with variable levels of treatment, followed by a t-test based on pooled 
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error variance to determine statistical significance compared to the (media + DMSO + LPS) 
control.  In all figures, the data are represented as % of control ± standard error, normalizing 
the (media + DMSO + LPS) control to 100% PGE2 or NO production within each block and 
summarizing across all blocks to obtain the mean and standard error.  The three subsamples 
of cytotoxicity values in each block were averaged before analysis as a randomized complete 
block design as above.  The cytotoxicity data are also presented as % of control ± standard 
error, normalizing the (media + DMSO) control to 100% cell survival.  All statistical analysis 
was conducted using the GLM procedures in SAS (version 9.1, SAS Institute Inc.; Cary, 
NC). 
The microarray experiment has a randomized complete block design with 4 
replications as fixed block and 5 treatments (media + DMSO, media + DMSO + LPS, 
fraction 3 + LPS, enriched fraction 3 + LPS, Bauer alkylamide 11 + Bauer ketone 23 + LPS). 
Within each replication, the cultured cells and gene chips were randomly assigned to receive 
one of the 5 treatments. The raw data were normalized by the robust multi-array average 
method (RMA) using the affy package in Bioconductor 2.0.8. The log expression data were 
then analyzed with SAS version 9.1. 
All the pairwise comparisons of interest were tested by unadjusted t-test. 
Differentially expressed genes were identified with false discovery rate (FDR) less than 
0.0001% using Benjamini and Hochberg’s method (1995). 
Genes with significant treatment effects (FDR < 0.0001%) were included in a 
hierarchical cluster analysis. The standardized averages for each treatment of each gene were 
used to compute a Euclidean distance matrix. The average linkage method was used to 
measure the distance between clusters. The analysis was done in R version 2.5.1. 
Results 
Enrichment of Echinacea angustifolia Fraction 
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Semi-preparative reversed phase HPLC was used to fractionate an extract of root 
material from E. angustifolia into five fractions and analyzed for their effect on LPS induced 
PGE2 production in the RAW264.7 mouse macrophage cell line.  The study led to the 
identification of three fractions that were capable of significantly inhibiting PGE2 production 
(Figure 1A).  Fraction 3, an alkylamide rich fraction equivalent in fractionation preparation 
to the E. angustifolia fraction 3 (inhibited PGE2 to 1.1 ng/ml PGE2) published by LaLone et 
al., showed potent PGE2 reduction (inhibited PGE2 to 1.8 ng/ml PGE2) at a concentration as 
low as 1 µg/ml (Figure 1B).  GC-MS analysis was conducted to identify the prominent 
constituents present in fraction 3, as well as to quantify the concentrations of Bauer 
alkylamide 11 and ketone 23 (Figure 1B).  From this analysis it was determined that Bauer 
alkylamide 11 was present at a concentration of 0.05 µM and there was no trace of Bauer 
ketone 23 in 1 µg/ml of fraction 3.  Previously published studies conducted by our laboratory 
found that Bauer alkylamide 11 and ketone 23, at concentrations of 3.55 µM and 0.83 µM, 
respectively contributed to the activity of an earlier fraction prepared similar to the current 
fraction 3.  Therefore, 3.5 µM of chemically synthesized Bauer alkylamide 11 and 0.83 µM 
of Bauer ketone 23 were added to 1 µg/ml of fraction 3 to produce an enriched fraction 3.  
Echinacea angustifolia fraction 3, enriched fraction 3, and combinations of individual 
constituents and fraction 3, were evaluated after an eight hour treatment with the RAW264.7 
cells for PGE2 and NO production, showing significant PGE2 inhibition with all treatments 
and significant NO inhibition with the combination of chemically synthesized Bauer 
alkylamide 11 and ketone 23 and each constituent individually (Figure 2).  The enriched 
fraction 3 was found to have significantly greater PGE2 inhibition capabilities than the 
fraction by itself.  Cytotoxic effects were not identified with any of the five E. angustifolia 
fractions, or with the enriched fraction or combinations of fraction and constituents (data not 
shown). 
Gene Expression and Protein Studies with E. angustifolia Fraction and Constituents 
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Gene expression was analyzed with GeneChip® Mouse Genome 430A 2.0 Arrays in 
order to identify target genes and determine pathways leading to the inhibition of PGE2 
production in the RAW264.7 mouse macrophage cells with selected treatments from Figure 
2 treated for eight hours.  The media + DMSO control was compared to the media + DMSO 
+ LPS control in order to establish that the expected genes were differentially expressed.  
With a false discovery rate of 0.0001% there were 3,257 differentially expressed (DE) genes 
were identified between the controls, which corresponded with the DE genes identified by 
Hammer et al. (unpublished).  Of these 3,257 DE genes, 1,253 had increased expression 
levels (5.5% of total probe-sets) and 2,004 (8.9% of total probe-sets) had decreased 
expression levels, with 731 genes decreased at least 50% below the expression level of the 
media + DMSO control and 951 genes increased at least 50% above the expression level of 
media + DMSO control after LPS treatment, which represented 3.2% and 4.2% of the total 
probe-sets, respectively.  Genes that were increased by the LPS treatment were involved in 
the inflammatory response, cell cycle, cell signaling, and cell proliferation and those genes 
that were decreased were involved in the immune response, cell death, and cell motility. 
When searching for DE genes between the media + DMSO + LPS control, E. 
angustifolia fraction 3 + LPS, enriched fraction 3 + LPS, and the combination of Bauer 
alkylamide 11 + Bauer ketone 23 + LPS, no genes were identified with a FDR below 50%.  
The eight DE genes that were identified between LPS treated samples with FDRs between 
50% and 75% were analyzed by MetaOmGraph (20) indicating that none were genuine DE 
genes.  Figure 3A provides a visual representation of the general gene expression pattern 
with all five treatments through the use of hierarchical clustering.  Two clusters can be 
identified, one containing the media + DMSO control and the other consisting of all samples 
treated with LPS.  Figure 3B represents changes in gene expression level with the different 
treatment groups, consistent with the analysis showing the LPS effect with the controls, 
without any differences between each treatment + LPS.    
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In order to obtain a more thorough understanding of the effect of E. angustifolia 
fraction 3, enriched fraction 3, the combination of Bauer alkylamide 11 and Bauer ketone 23, 
and these constituents individually on gene expression, qRT-PCR was used to produce a time 
course for genes expected to be modulated by Echinacea.  Genes chosen for this analysis 
included COX-1, COX-2, TNF-α, iNOS, and GADPH.  These studies indicated that COX-2 
gene expression was not significantly different throughout the time course from 0.5 hr to 24 
hr (Figure 4B).  The only significant increase in COX-2 gene expression was with the LPS 
treated samples compared to the media + DMSO control.  TNF-α gene expression was 
significantly increased with treatment of the RAW264.7 cells with Bauer ketone 23 at the 0.5 
hr time point compared to the media + DMSO + LPS control (Figure 4C and 4E).  At the 1 
hr time point TNF-α gene expression was significantly decreased with treatment of Bauer 
alkylamide 11 (Figure 4C and 4E).  When gene expression analysis for TNF-α was carried 
out to 24 hr a significant decrease in gene expression was identified for E. angustifolia 
fraction 3 + LPS, enriched fraction 3 + LPS, combination of Bauer alkylamide 11 and Bauer 
ketone 23 + LPS as well as with each individual constituent + LPS compared to the media + 
DMSO + LPS control (Figure 4C and 4E).  Treatments were also carried out without LPS 
showing no significant difference in TNF-α gene expression compared to the media + 
DMSO control (p-values >0.08).  Lipopolysaccharide induced TNF-α protein production was 
also analyzed, indicating that each treatment + LPS, except for synthetic Bauer ketone 23 + 
LPS, were capable of significant inhibition (Figure 5).  A significant difference in iNOS 
gene expression was identified at the 24 hr time point, indicating an increase in iNOS mRNA 
with the enriched fraction 3 compared to the media + DMSO + LPS control (Figure 4D and 
4F).  The expected LPS induction of the RAW264.7 macrophage cells was identified with 
the increase of COX-2, TNF-α, and iNOS genes after treatment with the media + DMSO + 
LPS control compared to the media + DMSO control.  GADPH was selected as the house 
keeping gene for the experiments, indicating no change in mRNA levels with any of the 
153 
treatments during the time course from 0.5 hr to 24 hr (p-values >0.14).  COX-1 mRNA was 
shown to increase at the 24 hr time point after treatment with the E. angustifolia fraction 3, 
enriched fraction 3, Bauer alkylamide 11, and Bauer ketone 23 compared to the media + 
DMSO + LPS control (p-values <0.02), although the combination of Bauer alkylamide 11 
and Bauer ketone 23 did not significantly change the mRNA levels. 
  Protein levels of COX-1, COX-2, and α-tubulin were assessed after the treatment 
with the E. angustifolia fraction 3, enriched fraction 3, and the combination of synthetic 
Bauer alkylamide 11 and Bauer ketone 23 (Figure 5A & B), Bauer alkylamide 11(Figure 
6A & B), and Bauer ketone23 (Figure 7A & B).  From these analyses it was shown that 
there was a significant increase in COX-2 protein with fraction 3 at 1 µg/ml and 5 µg/ml, as 
well as with Bauer ketone 23 at 5 µM.  Interestingly, there was a significant decrease in 
COX-1 protein with the treatment of fraction 3 at 5 µg/ml, yet α-tubulin protein level 
remained unchanged.  Protein levels of lipopolysaccharide induced iNOS were also assessed 
after treatment with enriched fraction 3, the combination of Bauer alkylamide 11 and Bauer 
ketone 23, and these constituents individually, showing no significant differences between 
treatments (ranging from 97.7 ± 23.5% to 101.1 ± 21.7% of control) and media + DMSO + 
LPS control after a 24 hr treatment .   
Inhibition of Cyclooxygenase-2 Activity 
COX-2 activity was analyzed after treating the RAW264.7 macrophage cells for eight 
hours with E. angustifolia fraction 3 + LPS, enriched fraction 3 + LPS, the combination of 
Bauer alkylamide 11 and Bauer ketone 23 + LPS, and the synthetic constituents individually 
+ LPS.  No significant differences in COX-2 activity were identified between any of the 
treatments without LPS compared to the media + DMSO control.  When analyzing all LPS 
treated samples compared to the media + DMSO + LPS control the E. angustifolia fraction 3 
(31.6 ± 10% of control), enriched fraction 3 (29.6 ±7.3% of control), and the combination of 
synthetic compounds (45.2 ± 12.3% of control) potently inhibited COX-2 activity with p-
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values less than 0.001 and synthetic Bauer alkylamide 11 (74.3 ± 11.0% of control) and 
synthetic Bauer ketone 23 (65.3 ± 16.3% of control) individually significantly inhibited 
COX-2 activity with –p-values less than 0.05. 
Discussion 
A major finding in this study is that by enriching an E. angustifolia fraction (1 µg/ml) 
with Bauer alkylamide 11 (3.5 µM) and Bauer ketone 23 (0.83 µM) a more potent inhibition 
of the LPS induced inflammatory mediator, PGE2, was identified compared to that seen with 
the fraction alone after an eight hour treatment on the RAW264.7 macrophage cells.  From 
these results, it appears that Bauer alkylamide 11 and Bauer ketone 23 partially accounted for 
the PGE2 inhibitory capabilities of the fraction, but do not show evidence of additivity.  This 
finding indicates that it is possible to manipulate an Echinacea preparation to target a specific 
bioactivity after discovering constituents of importance as well as the concentration required 
to elicit the desired effect.  Having the ability to target specific bioactivities with Echinacea 
preparations would be very important in the development of botanical products that are used 
for specific medicinal purposes.  Results collected on the clinical efficacy of Echinacea to 
treat symptoms of the common cold or other upper respiratory infections have been 
ambiguous due to several confounding factors, including the use of different or undefined 
preparations of this botanical (21, 22). In order to characterize which constituents are 
necessary for particular medicinal outcomes and at what concentrations, more studies are 
needed to provide concrete evidence of in vivo effectiveness in both animals and humans, as 
well as bioavailability of these constituents both individually and as a complex mixture.  
Our studies set out to understand the mechanism of action leading to the inhibition of 
PGE2 production in the RAW264.7 cells that was previously identified with certain 
Echinacea fractions (10, 11).  Using microarray analysis and qRT-PCR it became apparent 
that our Echinacea treatments were not acting on the gene expression level for COX-2.  Also, 
western blot analysis led to the intriguing finding that E. angustifolia fraction 3 and Bauer 
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ketone 23 could increase COX-2 protein levels after an eight hour treatment, yet also have 
the ability to inhibit PGE2 production at that same time point.  These studies directed the way 
to another key observation, which is supported by previous literature (15) that the identified 
inhibition of LPS induced PGE2 production with E. angustifolia fraction 3, enriched fraction 
3, the combination of Bauer alkylamide 11 and Bauer ketone 23, and these constituents 
individually on the RAW264.7 cells, occurs in part through the inhibition of COX-2 activity.  
The discovery of COX-2 specific inhibitors has been the objective in the development of 
several drugs for relief of inflammatory symptoms.  Aspirin was one of the first COX 
inhibitors shown to act through acetylation of an active-site serine residue (23). Other COX 
inhibitors called nonsteroidal anti-inflammatory drugs (NSAIDS) act as competitive 
inhibitors of COX by reversibly engaging the binding site for arachidonic acid.  
Understanding the kinetics behind the inhibition of COX-2 activity with these Echinacea 
treatments is critical to understanding its possible usefulness as an anti-inflammatory agent.  
The results obtained from this study allow us to hypothesize a model for the inhibition of 
PGE2 production based on increased COX-2 protein levels and decreased COX-2 activity.  
One model that could explain these observations would be that these Echinacea alkylamides 
and ketones are directly inhibiting COX-2 activity by competing with arachidonic acid for 
the active site of this enzyme while at the same time blocking ubiquitination that would 
normally target the enzyme for degradation.  Therefore, we would observe a decrease in 
COX-2 activity, a decrease in PGE2 production, and an increase in COX-2 protein, with no 
change in gene expression, which is consistent with our findings.   
Tumor necrosis factor alpha has been shown to be a cytokine regulated through the 
cannabinoid receptors and therefore modulated through the binding of Echinacea 
alkylamides to the CB2 receptor.  Gertsch et al. performed a RT-PCR time-course 
experiment to understand how Echinaforce™ modulated TNF-α gene expression in human 
monocytes/macrophages (3).  The results from this study show that LPS induced TNF-α 
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mRNA decreases around 10 hours after treatment of the alkylamide rich preparation, with a 
steady decline until approximately 25 hours.  Other findings from this study indicate that it 
was the alkylamide constituents that acted on the CB2 receptors to modulate the TNF-α gene 
expression at a concentration as low as 0.5 µM (3).  Our qRT-PCR time-course was carried 
out to 24 hours showing a significant decrease in LPS induced TNF-α gene expression with 
the alkylamide rich E. angustifolia fraction 3, enriched fraction 3, combination of alkylamide 
and ketone and with the individual constituents, corresponding with the findings of Gertsch 
et al., although the concentration of alkylamide in our studies was slightly higher at 3.55 µM.  
Our studies indicate that these treatments, excluding Bauer ketone 23, also significantly 
inhibit TNF-α protein production.  Due to the similarity in our results it could be 
hypothesized that our Echinacea treatments are also acting through binding the cannabinoid 
receptors, with the exception of synthetic Bauer ketone 23 (0.83 µM) which also showed a 
significant decrease in TNF-α gene expression at the 24 hour time point.  An interesting 
finding from our studies was that Bauer ketone 23 (0.83 µM) did not significantly modulate 
TNF-α protein levels.  Egger et al. determined that ketones, analyzed at 3% (v/v) DMSO do 
not appear to mediate their immunomodulatory effects through the cannabinoid receptors (2) 
and therefore it is likely that Bauer ketone 23 acts through a different mechanism to inhibit 
the noted TNF-α gene expression.   
Lipopolysaccharide induced NO production was shown to be significantly inhibited 
by treatments of synthetic Bauer alkylamide 11 and ketone 23, Bauer alkylamide 11 
individually, and Bauer ketone 23 individually after a 24 hour incubation on the RAW264.7 
mouse macrophage cells.  From the gene expression data it was determined that the enriched 
fraction 3 showed a significant increase in iNOS mRNA compared to the media + DMSO + 
LPS control, although NO production was not increased.  Enriched fraction 3, Bauer 
alkylamide 11, and Bauer ketone 23 were shown to have no effect on LPS induce iNOS 
protein levels after a 24 hour incubation.  Previous studies on Echinacea extract treated 
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RAW264.7 cells incubated for 23 hours determined that the extracts were capable of NO 
inhibition, not through direct scavenging of the free radical, but through the inhibition of 
iNOS (13).  Chen et al. also demonstrated that alkylamides were capable of inhibiting LPS 
induced NO production after a 24 hour incubation in the RAW264.7 cell line, including 
Bauer alkylamide 11, with an ID50 of 23.9 µM (12).  Our prior studies had also indicated that 
Bauer ketones could significantly inhibit NO production at concentrations as low as 1 µM 
(10). The findings from the present study indicate that compounds from Echinacea target NO 
production and future studies will concentrate on the mechanism leading to the identified 
inhibition. 
The results acquired from this study provide evidence that through the manipulation 
of an Echinacea fraction with the addition of key anti-inflammatory constituents, it is 
possible to enhance the anti-inflammatory potential of this botanical.  It is also of interest to 
note that no additivity was identified with treatments that combined synthetic Bauer 
alkylamide 11 and Bauer ketone 23 in the PGE2 screening, although their addition to the E. 
angustifolia fraction proved to increase anti-inflammatory potential.  The results obtained 
from our COX-2 activity studies indicated that the E. angustifolia fraction, enriched fraction, 
combination of constituents and individual constituents were all capable of a significant 
inhibition of COX-2 enzyme activity, therefore accounting for the identified inhibition of 
PGE2 production.   
Abbreviations Used 
E. = Echinacea 
PI = Plant Introduction  
DMSO = Dimethyl Sulfoxide 
PGE2 = Prostaglandin E2 
NO = Nitric Oxide 
LPS = Lipopolysaccharide 
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GC-MS = Gas Chromatography Mass Spectrometry 
HPLC = High Performance Liquid Chromatography 
Safety 
LPS compounds are pyrogenic and should not be inhaled or allowed to enter the 
bloodstream.  
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Figure Legends 
Figure 1. A. Fraction 3 from a 2009 extract of Echinacea angustifolia (PI631293) 
significantly inhibited PGE2 production in RAW264.7 cells.  The black bars represent PGE2 
levels after induction with 1 µg/ml LPS and treatment with an Echinacea fraction or ethanol 
extract (n = 3).  All treatments + LPS were compared to media + DMSO + LPS control that 
was set at 100 % (4.3 ng/ml).  Treatments were also performed without LPS induction 
showing significant reduction in PGE2 production with fractions 2, 3, and 5 (p < 0.04).  The 
treatments without LPS were compared to the media + DMSO control set at 100 % (0.03 
ng/ml).  * and ** are representative of p<0.05 and p<0.001.  Each bar represents % of control 
± standard error.  Parallel cytotoxicity screens were conducted yielding no significant 
cytotoxicity with any of the fractions or the extract (data not shown).  B. Gas 
chromatography analysis of bioactive fraction 3 from E. angustifolia.  Total ion 
chromatograms of fractions 3 with peaks whose chemical identity was established by 
comparing their retention times and mass-spectra to authentic standards: Bauer alkylamide 
13 (1), Bauer alkylamide 12 (2), Bauer alkylamide 10 (3), Bauer alkylamide 11 (4), Bauer 
alkylamide 8/9 (5), and Bauer alkylamide 14 (6).  Quantification of Bauer alkylamide 11 
yielded a concentration of 0.05 µM. 
Figure 2.  Lipopolysaccharide induced PGE2 and NO production in RAW264.7 cells treated 
with E. angustifolia fraction, enhanced fraction, and chemically synthesized Bauer 
alkylamide 11 and ketones 23.   The black bars represent PGE2 levels and the white bars 
represent NO levels after induction with 1 µg/ml LPS and treatment (n = 3).  All treatments + 
LPS were compared to media + DMSO + LPS control that was set at 100 % PGE2 production 
(2.5 ng/ml) and NO production (18.8 ng/ml).  The treatments without LPS were compared to 
the media + DMSO control set at 100 % PGE2 production (0.05 ng/ml) and NO production 
(~0 ng/ml) identifying no significant differences with treatment for either endpoint.  
Quercetin was used as a positive control for both studies and showed significant inhibition of 
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PGE2 and NO production (p<0.0001). * and ** are representative of p<0.05 and p<0.001.  
Each bar represents % of control ± standard error.  Parallel cytotoxicity screens were 
conducted yielding no significant cytotoxicity with any of the treatments or combination of 
treatments (data not shown). 
Figure 3. A. Hierarchical cluster analysis of differentially expressed genes in RAW264.7 
mouse macrophages.  2,719 differentially expressed genes were identified comparing the 
media + DMSO control to the media + DMSO + LPS control with a FDR of 0.001%, with no 
differentially expressed genes identified between treatments with LPS.  On the heatmap the 
rows represent the genes and the columns represent the treatments.  The red color is 
indicative of low gene expression and green is indicative of high gene expression.  
Treatments are labeled as follows: M0 = Media + DMSO control, M1 = Media + DMSO + 
LPS control, FR = E. angustifolia fraction 3, EN = E. angustifolia fraction 3 enriched with 
synthetic Bauer alkylamide 11 and Bauer Ketone 23, and AK = combination of synthetic 
Bauer alkylamide 11 and Bauer ketone 23. B. Standardized log signal for the two clusters 
identified in the analysis represents changes in gene expression level with different treatment 
groups. The size of each cluster is given in parentheses on the right above the cluster graph. 
Figure 4. A.  Legend for qRT-PCR treatments. B.  Analysis of qRT-PCR time course for 
COX-2 gene expression. N=3 for each treatment. Standard errors ranged from 0.02 to 0.16 
TNF-α transcript log starting quantity for all treatments and time points.  C.  Analysis of 
qRT-PCR time course for TNF-α gene expression. N=3 for each treatment. Standard errors 
ranged from 0.03 to 0.16 TNF-α transcript log starting quantity for all treatments and time 
points.  * and ** are representative of p<0.05 and p<0.001.  D.  Analysis of qRT-PCR time 
course for iNOS gene expression. N=3 for each treatment. Standard errors ranged from 0.03 
to 0.24 for all treatments and time points.  * and ** are representative of p<0.05 and p<0.001.  
E.  qRT-PCR analysis at time points with significant treatment effects for TNF-α gene when 
compared to the media + DMSO + LPS control.   * and ** are representative of p<0.05 and 
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p<0.001.  Bars represent the mean ± standard error.  F.  qRT-PCR analysis at time point with 
significant treatment effect for iNOS gene when compared to the media + DMSO + LPS 
control.   * and ** are representative of p<0.05 and p<0.001.  Bars represent the mean ± 
standard error. 
Figure 5.  Lipopolysaccharide induced TNF-α production in RAW264.7 cells treated with E. 
angustifolia fraction, enhanced fraction, and chemically synthesized Bauer alkylamide 11 
and ketones 23.   The light grey bars represent TNF-α levels after treatment with Echinacea 
fraction, enriched fraction or compounds. The dark grey bars represent TNF-α levels after 
induction with 1 µg/ml LPS and treatment (n = 3).  All treatments + LPS were compared to 
media + DMSO + LPS control.  The treatments without LPS were compared to the media + 
DMSO control (p<0.0001). * and ** are representative of p<0.05 and p<0.001.  Each bar 
represents mean ± standard error.   
Figure 6.  A.  Analysis of LPS induced COX-1, COX-2, and α-tubulin protein levels in 
RAW264.7 cells with representative western blots for E. angustifolia fraction 3, enriched 
fraction 3, and the combination of Bauer alkylamide 11 and ketone 23. N=3 for each blot. B. 
Semi-quantitative representation of the blots from figure 6A.  Bars represent mean percent of 
media + DMSO + LPS control ± standard error. Lipopolysaccharide induced COX-2 protein 
from 24.3 ± 8.2% average for the media + DMSO control to 100 ± 20.6% average for the 
media + DMSO + LPS control.  There was no significant LPS affect for the media + DMSO 
control with COX-1 (96.9 ± 1.8% of control average) or α-tubulin (104.4 ± 3.4% of control 
average) on protein level compared to the media + DMSO + LPS control.  Quercetin was 
used as a positive control at 100 µM for the reduction of LPS induced COX-2 protein 41.3 ± 
16.9% of control.  Quercetin did not significantly affect LPS induced COX-1 (85.3 ± 3.2% of 
control average) or α-tubulin (109.6 ± 16.7 % of control average).  * and ** are 
representative of p<0.05 and p<0.001 when compared to media + DMSO + LPS control. 
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Figure 7.  A.  Analysis of LPS induced COX-1, COX-2, and α-tubulin protein levels in 
RAW264.7 cells with representative western blots for Bauer alkylamide 11.  N=3 for each 
blot. B. Semi-quantitative representation of the blots from figure 7A.  Bars represent mean 
percent of media + DMSO + LPS control ± standard error. Lipopolysaccharide induced 
COX-2 protein from 19.1 ± 6.2% average for the media + DMSO control to 100 ± 10.9% 
average for the media + DMSO + LPS control.  There was no significant LPS affect for the 
media + DMSO control with COX-1 (83.4 ± 3.0% of control average) or α-tubulin (94.7 ± 
2.1% of control average) on protein level compared to the media + DMSO + LPS control.  
Quercetin was used as a positive control at 100 µM for the reduction of LPS induced COX-2 
protein 71.4 ± 3.1% of control.  Quercetin did not significantly affect LPS induced COX-1 
(96.1 ± 6.5% of control average) or α-tubulin (98.0 ± 4.3 of control average).  * and ** are 
representative of p<0.05 and p<0.001 when compared to media + DMSO + LPS control. 
Figure 8.  A.  Analysis of LPS induced COX-1, COX-2, and α-tubulin protein levels in 
RAW264.7 cells with representative western blots for Bauer ketone 23 individually and in 
combination with E. angustifolia fraction 3.  N=3 for each blot. B. Semi-quantitative 
representation of the blots from figure 8A.  Bars represent mean percent of media + DMSO + 
LPS control ± standard error. Lipopolysaccharide induced COX-2 protein from 4.8 ± 2.8% 
average for the media + DMSO control to 100 ± 12.0% average for the media + DMSO + 
LPS control.  There was no significant LPS affect for the media + DMSO control with COX-
1 (95.4 ± 3.3% of control average) or α-tubulin (103.9 ± 7.3% of control average) on protein 
level compared to the media + DMSO + LPS control.  Quercetin was used as a positive 
control at 100 µM for the reduction of LPS induced COX-2 protein 53.0 ± 15.7% of control.  
Quercetin did not significantly affect LPS induced COX-1 (95.5 ± 2.2% of control average) 
or α-tubulin (91.8 ± 9.7 of control average).  * and ** are representative of p<0.05 and 
p<0.001 when compared to media + DMSO + LPS control. 
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Figure 9.  Lipopolysaccharide induced COX-2 activity in RAW264.7 cells treated with E. 
angustifolia fraction, enhanced fraction, and chemically synthesized Bauer alkylamide 11 
and ketones 23.   The black bars represent COX-2 activity levels after induction with 1 µg/ml 
LPS and treatment (n = 3).  All treatments + LPS were compared to media + DMSO + LPS 
control that was set at 100 % COX-2 activity (5.8 nmol/min/ml).  The treatments without 
LPS were compared to the media + DMSO control set at 100 % COX-2 activity (2.4 
nmol/min/ml) identifying no significant differences.  Quercetin was used as a positive control 
for both studies and showed significant inhibition of COX-2 activity (p<0.0001). * and ** 
are representative of p<0.05 and p<0.001.  Each bar represents % of control ± standard error.   
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Table 1.  Primers used for qRT-PCR analysis   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Primer 
Oligonucleotide Sequence 
 (5'-3') 
COX-1 S CCTCACCAGTCAATCCCTGT 
 AS GTAGCCCGTGCGAGTACAAT 
COX-2 S TTGGGGAGACCATGGTAGAG 
 AS GCTCGGCTTCCAGTATTGAG 
TNF-α S AGGAGGGAGAACAGAAACTC 
 AS AATGAGAAGAGGCTGAGACA 
iNOS S  GTCTTGGTGAAAGTGGTGTT 
 AS   GTGCTTGCCTTATACTGGTC 
GAPDH S CAATGTGTCCGTCGTGGAT 
 AS AGCCCAAGATGCCCTTCAG 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
%
 
o
f C
o
n
tr
o
l
Media
+
DMSO
Enrichment of fraction 3 Synthetic Bauer alkylamide11 
and Bauer ketone 
Quercetin
*
**
*
**
**
-
-
-
1
3.5
0.83
-
3.55
-
1
3.5
-
-
-
0.83
1
-
-
-
3.55
0.83
10 µM1
-
0.83
*
E. angustifolia fraction 3 (µg/ml)
Bauer alkylamide 11 (µM)
Bauer ketone 23 (µM)
-
-
-
1µg/ml LPS induced PGE2
1µg/ml LPS induced NO
**
**
*
*
*
**
Fraction 3Media
a
b
ab
ab ab
abac
170 
Figure 3. 
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Figure 4. 
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Figure 5. 
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CHAPTER 6: GENERAL CONCLUSIONS 
Importance of Botanical Research 
For centuries plant preparations have been used medicinally to treat a wide variety of 
human diseases and ailments.  Approximately 400 years ago Indian tribes used Echinacea 
angustifolia, Echinacea purpurea, and Echinacea pallida plants to treat anything from horse 
saddle sores to rheumatism (1).  Echinacea is a plant that has found its way to modern use, 
commonly taken for the treatment of the common cold and other upper respiratory infections.  
The popularity of this botanical has been consistent throughout the last decade with estimated 
annual sales in the multi-million dollar range (2).  The importance of research regarding the 
safety and efficacy of the botanical Echinacea cannot be understated, due to the large 
quantity of people that consume such preparations.  Research on this botanical has provided 
evidence that Echinacea has anti-viral, anti-oxidant, anti-microbial, anti-tumorigenic, and 
anti-inflammatory properties (3-5).  Many of these bioactivities have been attributed to 
certain classes of constituents of Echinacea, with a strong focus on the major class of 
lipophilic compounds, alkylamides.  
Goals of the Studies Presented in this Dissertation 
The overarching goal of the studies presented in this dissertation was to strengthen 
the knowledge and understanding of the anti-inflammatory potential of the botanical 
Echinacea.  Our research set out to identify Echinacea constituents that are key modulators 
of the immune system through the use of a mouse macrophage model system and determine 
the mechanistic basis for the identified modulation. 
Advancing the Field of Echinacea Research 
The research conducted in this dissertation advances the field of Echinacea botanical 
research by identifying Echinacea species that have the strongest potential for use as anti-
inflammatory products and establishes a basis to examine alkylamides and ketones at 
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concentrations relevant to those found in the plant for their ability to interfere with the 
inflammatory response.  All bioactivity studies conducted with Echinacea treatments were 
paralleled with screens for cytotoxicity, therefore also examining the safety of this botanical.  
Our studies were the first to credit ketones with the ability to inhibit inflammatory endpoints 
in vitro.  Further, this research leads to a proposed mechanism for the inhibition of PGE2 
production by selected Echinacea angustifolia treatments. 
Summary of Research conducted in this Dissertation and Major Findings 
Our research used the well established RAW264.7 mouse macrophage cell line.  
Lipopolysaccharide, a common endotoxin, was applied to the cells to mimic the initiation of 
an in vitro inflammatory response.  Through the activation of the arachidonic cascade, a key 
lipid mediator of inflammation, prostaglandin E2 (PGE2), was produced.   To initiate our 
studies for this dissertation on the anti-inflammatory properties of Echinacea, root material 
from six of the nine species of Echinacea were Soxhlet ethanol extracted and analyzed for 
their ability to modulate PGE2 production.  It was determined that E. angustifolia, E. pallida, 
E. sanguinea, and E. simulata significantly inhibited the production of PGE2 at a 
concentration of 15 µg/ml.  These findings were interesting in that E. purpurea was 
incapable of inhibiting this inflammatory endpoint at 15 µg/ml, but is consistently found in 
commercial preparations of this botanical supplement.  Examination of the known classes of 
constituents through HPLC analysis indicated that the amount of alkylamides, caffeic acid 
derivatives, and ketones vary significantly among the bioactive Echinacea species and 
therefore provide a rational for thorough investigation of each class of constituent 
individually to better understand the species data.  Parallel cytotoxicity screens established 
that high concentrations of Echinacea extracts, >100 µg/ml were required to cause 
macrophage cell death, indicating the safety of this herb and discounting cytotoxicity as a 
factor leading to PGE2 inhibition.  It is of importance to note that our studies revealed little 
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variability in bioactivity results between repeat extractions or harvest years, allowing for 
consistency between replications and studies.  Another key finding from this study was that 
alkylamides were consistent inhibitors of PGE2, although not at the low concentrations 
identified in the species.  This data led to the hypothesis that no single compound can 
account for the PGE2 inhibition noted with the Echinacea extracts and therefore the anti-
inflammatory alkylamides must be acting either synergistically or additively with each other 
or other compounds.  Finally, these initial studies indicated that the Echinacea alkylamides 
were not cytotoxic to the RAW264.7 macrophage cells, again providing evidence of safety 
for the use of this botanical.    
In order to identify which Echinacea constituents were key contributors to the 
inhibition of PGE2 production seen with the Echinacea extracts, semi-preparative reverse-
phased HPLC fractionation was applied to E. angustifolia, E. pallida, E. purpurea, and E. 
tennesseensis extracts.  This method allowed for the separation of compounds according to 
their hydrophobic properties, with caffeic acid derivatives eluting in the first fractions and 
alkylamides and ketones following in the middle and later fractions.  The fractionation 
studies were used to test the hypothesis that alkylamides acted in a synergistic or additive 
manner with other compounds to elicit their in vitro anti-inflammatory properties.  Through 
the fractionation of E. pallida, it was determined that ketones were an important class of 
constituents capable of inhibiting PGE2 and nitric oxide (NO) production in the RAW264.7 
mouse macrophage model.  For these studies NO was another endpoint chosen for the study 
of the anti-inflammatory properties of Echinacea, due to its important role during 
inflammation. NO was screened after 24 hr treatments with Echinacea fractions or 
constituents, which allowed us to follow the inflammatory response induced by LPS out to a 
later time point.  The analysis of the ketones provided evidence that Bauer ketone 23 and 24 
were of importance for the identified PGE2 inhibitory capabilities of E. pallida.  These 
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studies were the first to look for anti-inflammatory potential with the ketones of Echinacea 
and identify this class of compounds as inflammatory modulators.  As found with the extracts 
and alkylamides, significant cytotoxicity was not identified for any of the Bauer ketones 
screened.  It was determined through the fractionation of all four species that fractions 
containing caffeic acid derivatives were unable to inhibit PGE2, even at concentrations 
greater than 100 µg/ml.  In our search for compounds that act synergistically or additively we 
tried combinations of constituents found in second round fractions of E. angustifolia, Bauer 
alkylamide 10 and 11.  At the concentrations identified to be present in the second round 
fraction, the combination of Bauer alkylamide 10 and 11 was unable to inhibit PGE2, 
although the individual constituents at the same concentrations were significantly inhibitory.  
The most significant findings from the fractionation studies were that synthetic Bauer 
alkylamide 11 at a concentration of 3.55 µM and Bauer ketone 23 at a concentration of 0.83 
µM, which were concentrations corresponding to what was found in the fractions, were able 
to partially explain the inhibition of PGE2 identified with their respective third round E. 
angustifolia fractions.  The results from this study provided no evidence of additivity or 
synergy between the compounds for the inhibition of PGE2 or NO production and indicated 
that other, unidentified constituents play a key role in the anti-inflammatory activity of 
Echinacea.  It was interesting to find constituents that could modulate a bioactivity at the 
concentrations found in the plant preparation.  
From the discovery of the importance of Bauer alkylamide 11 and Bauer ketone 23 
for the inhibition of the inflammatory mediator PGE2 and the understanding of the 
concentrations that were effective for this outcome, we re-fractionated an E. angustifolia 
extract to produce an alkylamide rich first round fraction with similar chemical composition 
and PGE2 inhibition capabilities as we had found in our earlier studies.  Upon repeating the 
fractionation protocol used previously, we found a fraction capable of significant PGE2 
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inhibition, although to a lesser extent than what was observed in our initial fractionation 
studies.  GC-MS analysis identified that Bauer alkylamide 11 was present at a concentration 
of 0.05 µM and Bauer ketone 23 was not detected in the newly prepared E. angustifolia 
fraction.  We then hypothesized that enrichment of the E. angustifolia fraction with synthetic 
Bauer alkylamide 11 to a concentration of 3.55 µM and Bauer ketone 23 to a concentration 
of 0.83 µM would increase the anti-inflammatory potential compared to the fraction alone.  
The hypothesis was correct, with the enriched fraction showing the ability to inhibit PGE2 to 
a more significant extent than the unmodified fraction.  Therefore this study provided 
evidence that it is indeed possible to manipulate an Echinacea fraction to act on a specific 
bioactivity when constituents and concentrations of importance have already been 
determined, which could pave the way for medicinal applications that can target specific 
symptoms.  Mechanistic studies were then undertaken to understand how treatments of E. 
angustifolia fraction, enriched fraction, combination of synthetic Bauer alkylamide 11 and 
ketone 23, and these constituents individually inhibit PGE2 production.  Because LPS 
induced PGE2 is produced through the arachidonic acid cascade by the action of the COX-2 
enzyme, COX-2 gene expression, protein expression, and activity were studied after 
treatments in the mouse macrophage cell line.  It was determined that LPS induced COX-2 
gene expression was not affected by treatment over a 24 hr time course, but protein levels 
were increased significantly with the treatment of E. angustifolia fraction 3 + LPS and Bauer 
ketone 23 + LPS at 8 hours, consistent with the time point for the PGE2 data in the 
RAW264.7 macrophages.  The results from the LPS induced COX-2 activity and PGE2 
studies indicate that all treatments of Echinacea fraction, enriched fraction, and constituents 
inhibit the enzymatic activity and PGE2 production.  These findings have led to the proposal 
of a model as to how the treatments inhibit PGE2 production, yet show an increase in COX-2 
protein levels (Figure 1). 
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 To fully understand the model being proposed it is important to understand how our 
cell line responds to LPS under ordinary conditions.  During a normal response in the 
RAW264.7 mouse macrophage cells to lipopolysaccharide, arachidonic acid (AA) is released 
from the phospholipid membrane by phospholipase A2.  Meanwhile LPS binds to 
lipopolysaccharide binding protein (LBP) and toll like receptor 4 (TLR4) activating the NF-
kB signal transduction cascade leading to the expression of COX-2 mRNA, which is then 
translated into the COX-2 enzyme that converts AA to prostaglandin G2 (PGG2).  PGG2 is 
then converted to an eicosanoid, possibly PGE2.   It has previously been demonstrated that 
COX-2 is degraded by the ubiquitin (Ub) proteasome system (6).  COX-2 is 
polyubiquitinated by Ub ligases, which allows the enzyme to be recognized by the 26S 
proteosome and rapidly degraded.  Ubiquitination occurs on lysine residues of target proteins 
where an isopeptide bond is created between the lysine and the C-terminal glycine of 
ubiquitin (7).  The model described in Figure 1 indicates that LPS stimulates the production 
of COX-2 enzyme and AA is released from the phospholipid membrane, but AA is unable to 
bind to the active site of COX-2.  It is proposed in the model that the inability of AA to bind 
to the enzyme could be due to the competitive or non-competitive binding of Echinacea 
fraction or constituent, which blocks AA.  Alternatively, the Echinacea product in the model 
could be directly binding to AA making it too large to enter the active site of the enzyme.  
This would cause an inhibition of enzyme activity, a decrease in the amount of AA allowed 
to bind to the COX-2 enzyme, and therefore an inhibition of PGE2 production.  It is also 
proposed in Figure 1 that the Echinacea fraction or ketone interfere with ubiquitination of 
the COX-2 enzyme, either by directly blocking ubiquitination sites, by interfering with the 
ubiquitin ligase, or by causing a conformation change of the enzyme which makes the 
ubiquitination sites inaccessible after binding to the active site.  Due to the proposed 
interference of ubiquitination in the model the COX-2 protein levels would increase because  
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Normal Induction of PGE2 Production by Lipopolysaccharide: 
 
 
 
 
 
 
 
 
 
 
Model for the Inhibition of PGE2 Production and Increase in Protein Levels of COX-2 After 
Echinacea Treatment: 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Model for the inhibition of PGE2 production. Top diagram illustrates normal 
circumstances. Bottom diagram illustrates Bauer ketone 23 treated circumstances, which could 
also be replaced with the Echinacea angustifolia fraction 3. Ub = Ubiquitin.  Red bar represents 
an inhibition caused by the Echinacea constituent or fraction.  Not drawn to scale. 
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they would not be targeted for degradation. 
Overall Strengths of the Studies in this Dissertation 
One of the major strengths of the studies presented was the quality of plant material 
used for the studies.  Our plant material was produced by the USDA North Central Regional 
Plant Introduction Station, with great care to maintain disease free plants that were grown, 
handled, and collected under strict protocols providing material that showed consistency in 
biological assays.  Most studies reported in the literature focus on the three medicinal species 
namely E. purpurea, E. angustifolia, and E. pallida.  Due to the resources available to us, our 
studies were able to examine several additional species of Echinacea for their anti-
inflammatory potential including E. tennesseensis, E. simulata, and E. sanguinea. 
Due to the fact that many of the compounds of Echinacea are not commercially 
available for purchase other researchers must rely on isolation of constituents through 
extraction and fractionation methods and therefore cannot study pure constituents and their 
ability to modulate bioactivities.  Our studies utilized pure chemically synthesized 
alkylamides and ketones of Echinacea, which allowed us to thoroughly investigate the roles 
these constituents play in modulating the biological endpoints chosen without interference of 
other compounds.  The synthetic compounds were available for producing standard curves 
for GC-MS quantification that allowed for the identification of compounds in extracts and 
fractions at concentrations present in the plants.  Because of this we were able to compare 
and combine individual constituents at concentrations present in the fractions and look for 
synergy or additivity.  We also had access to synthetic isomers and analogs of the known 
alkylamides that could be produced naturally in the plant, to look at the effect of adding an 
extra carbon or subtracting a double bond from Bauer alkylamide 12 and assaying PGE2 
production.  It was determined that through the addition of an extra carbon to the fatty acid 
like tail of Bauer alkylamide 12 (Bauer alkylamide 12A) a significant reduction in PGE2 
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production was achievable at a lower concentration than identified with Bauer alkylamide 12 
(8).  Evidence that all synthetic constituents produced were in the same conformation as 
those present in the Echinacea plant was attained through NMR and GC-MS analyses. 
Another strength of our approach was that we attempted to identify the lowest 
concentrations of extract, fraction, or pure constituent possible that were capable of 
significant inhibition of PGE2 or NO production.  This allowed us to use concentrations of 
constituents that were consistent with what was determined to be present in selected 
Echinacea fractions by GC-MS analysis.  Much of the data available in the literature uses 
very high quantities of extract or constituent to modulate specific bioactivities, which may 
not be relevant to what is actually found in Echinacea plant preparations. 
We used the RAW264.7 mouse macrophage cell model for all bioactivity assays. This 
cell model is strongly established in the literature for inflammatory studies and provided an 
excellent screening tool for identifying Echinacea extracts, fractions, and compounds with 
anti-inflammatory potential.  
Limitations of the Studies 
 One of the major weaknesses was the use of one cell line for all studies.  Although the 
RAW264.7 mouse macrophage cell line was a good choice for identifying Echinacea 
products with anti-inflammatory properties, it does not predict how these products might act 
in vivo.  We focused on only one cell type in the inflammatory reaction therefore simplifying 
our results by not accounting for the other interactions that occur between cells.  To further 
the knowledge of identified bioactive constituents from Echinacea, other cell lines or animal 
models would be necessary for studies looking at inflammatory endpoints.  Without knowing 
the bioavailability status of the constituents when treated to the RAW264.7 cells, it is hard to 
draw concrete conclusions as to what concentrations of constituents are necessary to elicit the 
desired effect.  More studies on bioavailability are necessary to better understand 
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physiologically relevant concentrations of Echinacea extracts and constituents.  Literature 
related to bioavailability studies with Echinacea extracts and constituents can be found in 
Chapter 2 of this dissertation. 
 Prostaglandin E2 and nitric oxide production were the two inflammatory endpoints 
chosen for screening Echinacea products for anti-inflammatory activity in our studies.  We 
realize that other endpoints would be necessary to fully understand the inflammatory 
response of the RAW264.7 and that our conclusions are limited by relying on two 
inflammatory endpoints.  Ongoing studies are utilizing multiplex technology to also examine 
a panel of 32 cytokines/chemokines, which will give a broader look at the inflammatory 
response and allow the studies presented in this dissertation to integrate with studies on the 
effect of Echinacea products on influenza. 
Researchers studying the botanical Echinacea have limited access to chemically 
synthesized commercially available Echinacea constituents.  For our studies we were able to 
use synthetic alkylamides and ketones to delve into the particular roles of these constituents 
in the modulation of PGE2 and NO production, and attempt to delineate their mechanisms of 
action.  We did not have available to us all of the alkylamides or ketones present in the plant, 
not to mention that there are several unknown compounds that have not been identified in the 
complex mixture of an Echinacea extract or fraction.  Therefore, a limitation would be that 
with all of our studies there could be other, either unknown or unavailable constituents, 
present that are able to explain the bioactivities that were analyzed in this dissertation.  In 
order to obtain the strongest data possible we worked diligently to isolate compounds present 
in the greatest quantity from the most bioactive Echinacea species extracts and target those 
compounds for synthesis. 
A difficulty that we have encountered with our studies was that of stability.  Our 
studies determined that over time, E. angustifolia fractions that were previously capable of 
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significant PGE2 inhibition lost their ability to inhibit this endpoint (8).  We had also 
determined that the concentrations of major alkylamides and ketones in the fraction were not 
changing, indicating an important role for unidentified constituents.  To address issues of 
instability we aliquoted Echinacea samples into several glass vials in order to reduce the 
number of freeze-thaw cycles when performing bioactivity assays.  Also, to assure stability 
of Echinacea fractions and synthetic constituents we froze samples at -80 °C under argon 
gas. 
A limitation of the studies conducted in this dissertation that must be acknowledged is 
that all of our studies were conducted on the root material from Echinacea, therefore it is 
possible that preparations from aerial parts of the Echinacea plant could produce 
significantly different data than what we have observed, although several of the constituents 
found in the root material are also present in the aerial parts (9).  Another limitation was that 
a Soxhlet method of extraction was used to prepare all species extracts, including those used 
for fractionation.  Due to the aggressive nature of this extraction procedure, which includes 
high heating temperatures, it is possible that certain compounds were destroyed or altered to 
a non-natural state.  These non-natural compounds could have had an effect on our bioassays, 
perhaps accounting for the inability of Bauer alkylamide 11 to explain a majority of the PGE2 
inhibition capabilities identified with the third round E. angustifolia fraction 3E40, where 
alkylamide 11 made up approximately 96% of the fraction by dry weight.  In order to 
circumvent the possibility of potentially creating non-natural compounds, perhaps a more 
gentle method of extraction could be utilized.   
The method of bioactivity-guided fractionation allows for the separation of 
constituents in Echinacea extracts to identify which compounds may be important for noted 
bioactivity.  This method provides a limitation in that when fractionation and therefore 
separation of constituents occurs, these divisions could potentially separate constituents that 
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must be present together to illicit a specific response.  For example because we used semi-
preparative reverse-phased HPLC for fractionation which separates constituents in the extract 
based on hydrophobic properties, perhaps the phenolics that come out in the earlier fractions  
and the alkylamides which come out in later fractions could act as stronger inhibitors of 
PGE2/NO/TNF-α production had they not been separated in different fractions.  
Follow-up Studies  
The initial results we obtained from our Echinacea species extract data indicate that 
E. sanguinea was the most active species measured via the inhibition of PGE2 production.   It 
would be interesting to examine this alkylamide rich species further to identify key 
constituents leading to the noted bioactivity through fractionation studies.    
From our qRT-PCR time course studies it was determined that E. angustifolia 
fraction 3, enriched fraction 3, the combination of Bauer alkylamide 11 and Bauer ketone 23, 
and these constituents individually coincubated with LPS significantly inhibited TNF-α gene 
expression at 24 hours compared to the media + DMSO + LPS control in the RAW264.7 
cells.  The literature on TNF-α and Echinacea suggests that alkylamides bind cannabinoid 
receptor 2 to mediate the modulation of TNF-α at nanomolar concentrations, through the 
activation of cAMP, p38/MAPK, JNK, and NF-κB signaling (10).  It would be interesting to 
use qRT-PCR to examine treatments listed above after using a cannabinoid receptor 2 
antagonists (SR144528) to determine if this receptor plays a role in the TNF-α modulation 
we identified.  Cannabinoid receptor 2 has been identified in the RAW264.7 mouse 
macrophage cells induced with 100ng/ml LPS and cannabinoid receptor 1 was not detected 
(11).  Pathways important for the inhibition of TNF-α gene expression could be analyzed 
using specific synthetic inhibitors such as, PD98059 for MAPK/MEKK, U0126 for MEK1/2, 
SB203580 and SB202190 for p38/MAPK, SP600125 for JNK, and parthenolide for NF-κB.  
Our studies showed that the Echinacea treatments inhibited gene expression of TNF-α after a 
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24 hr treatment and therefore this time point would be a relevant starting point for conducting 
studies with receptor and signaling inhibitors.  The microarray study conducted in this 
dissertation examined gene expression after an 8 hr incubation of Echinacea angustifolia 
samples with the RAW264.7 cells, consistent with the time point where PGE2 production 
was analyzed.  From our qRT-PCR studies it would appear that the more informative time 
point may be 24 hr treatments for the microarray. Therefore, we would propose that future 
microarray studies dealing with Echinacea treatments in the RAW264.7 cell model be 
carried out after a 24 hr treatment.  Information gathered from microarray study at the 24 hr 
time point would also be relevant for the elucidation of pathways important for the inhibition 
of NO and TNF-α. 
We determined that the combination of synthetic Bauer alkylamide 11 and Bauer 
ketone 23, as well as these constituents individually were capable of significant inhibition of 
nitric oxide production, whereas the E. angustifolia fraction and enriched fraction were not. 
We also determined that the enriched fraction was increasing the mRNA levels of iNOS, 
whereas the fraction and constituents had no effect.  Also, the iNOS western blot data 
indicates that the enriched fraction, combined constituents, nor the constituents individually 
affected the protein levels.  To better understand how these Echinacea treatments are 
inhibiting NO production we would propose looking at iNOS activity levels in the 
RAW264.7 cells after treatment with LPS.  Nitric oxide is produced through the action of 
nitric oxide synthases through the conversation of L-arginine to L-citruline (12).  Nitric oxide 
acts as a signaling molecule and a free radical that can react with other free radicals to form 
more potent radicals like peroxynitrite and other lipid peroxides and has been shown to be 
involved in the inflammatory response of macrophages.  We would propose parallel studies 
to analyze the effect of Echinacea treatments on arginase enzyme, which converts L-arginine 
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into L-ornithine leading the way to the production of polyamines and L-proline that is 
involved in cell growth and wound healing.    
Previously in this chapter a model was proposed to explain the action of Echinacea 
treatments to inhibit COX-2 activity and therefore PGE2 production, as well as to explain the 
induction in COX-2 protein identified after treatments of E. angustifolia fraction or Bauer 
ketone 23 to the LPS induced RAW264.7 cells.  The active site of the COX-2 enzyme 
contains specific residues, specifically Arg-120, Tyr-355, and Glu-524 (13).  Predictive 
computer modeling of the COX-2 enzyme could provide information as to whether 
compounds of Echinacea have the potential to bind to the active site of this enzyme stably 
and therefore compete with arachidonic acid for the binding site (Insight® II version 97.0).  
This modeling could also show possible ubiquitination sites and predict whether Echinacea 
compounds could block these sites.  After verification of possible interactions of the 
Echinacea constituents with the COX-2 enzyme, biological assays could examine the 
proposed competition between arachidonic acid and Echinacea fractions/constituents for the 
active site of COX-2 through competitive binding assays. To assess ubiquitination status of 
COX-2 enzyme we propose using recombinant COX-2 protein and co-transfect the 
RAW264.7 mouse macrophage cells with Flag-COX-2 and His-Xpress-Ub.  Flag-COX-2-Ub 
conjugates could be pulled down with Flag-beads and detected by western blot analysis using 
anti-Xpress antibody.  In general, isolation of the COX isoforms, which are integral 
membrane proteins, have been successful using microsomal preparations from insect cells 
expressing recombinant protein using detergent solubilization followed by purification to 
yield an apo-enzyme that can be reconstituted with hematin (14).  Successful His tagging 
methods have lead to the purification of active native COX enzymes. 
Overall Conclusions 
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The data presented in this dissertation advances the knowledge and understanding of 
the anti-inflammatory potential of the botanical Echinacea and due to the simplicity of the 
model chosen for these studies can be used as an initial study to guide future research and 
development of Echinacea products for immune modulation.  All together, these studies 
draw attention to the complex nature of studying botanical supplements and the care that 
must be taken to identify key components relevant to specific bioactivities.  The endpoints 
chosen for screening, PGE2 and NO, play broad roles in the inflammatory response for many 
disease states and therefore our research does not target a specific disease but remains in 
context with how Echinacea is utilized by consumers for the treatment of cold or upper 
respiratory tract infections. 
As stated in chapter one of this dissertation the hypothesis that drove the direction of 
this research was that Echinacea extracts, fractions, and pure constituents, such as 
alkylamides and ketones, are capable of inhibiting prostaglandin E2 production through the 
inhibition of the NF-kB signal transduction pathway, which therefore inhibits the expression 
of COX-2 in a RAW264.7 mouse macrophage model.  Our mechanistic studies disproved 
this hypothesis, indicating that the identified inhibition of PGE2 production after treatment 
with Echinacea fractions and selected constituents in LPS induced RAW264.7 cells was due 
to an inhibition of COX-2 activity, not acting at the gene expression level.  Therefore it is 
unlikely that NF-κB signaling events are disrupted by Echinacea products to inhibit PGE2.  
Initially we proposed that the NO inhibition caused by the Echinacea products was also due 
to the inhibition of NF-kB signal transduction leading to an inhibition of iNOS gene 
expression, but it appears that from our qRT-PCR data that this is most likely not the case.  
We determined that the combination of Bauer alkylamide 11 and Bauer ketone 23, as well as 
each constituent individually was able to significantly inhibit NO production, but there was 
no effect on iNOS gene expression over a 24 hr time course, or iNOS protein levels at an 8 hr 
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time point.   Therefore, iNOS activity may be the target of these treatments and follow-up 
studies addressing this issue will need to be conducted.   
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